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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the National Board of Occupational
Safety and Health (NBOSH). In most cases a scientific basis is written on request from
the NBOSH. The Criteria Group shall not propose a numerical occupational exposure
limit value but, as far as possible, give a dose-response/dose-effect relationship and the
critical effect of occupational exposure.
In searching of the literature several data bases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group. In some cases criteria
documents are produced within the Criteria Group, often in collaboration with DECOS or
US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to NBOSH.
This is the 20th volume which is published and it contains consensus reports approved
by the Criteria Group during the period July 1998 to June 1999. Previously published
consensus reports are listed in the Appendix (p 111).
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1Consensus Report for Cyanamide
September 30, 1998
Physical and chemical data. Uses
CAS No.: 420-04-2
Synonyms: amidocyanogen, carbimide, hydrogen cyanamide,
carbodiimide
Formula: CH2N2
Structure: H2NC=N
Molecular weight: 42.04
Melting point: 45 – 46 ° C
Boiling point: 127 ° C
Density: 1.28 g/ml
Flash point: 141 ° C
Conversion factors: 1 ppm = 1.72 mg/m3
1 mg/m3 = 0.58 ppm
Cyanamide at room temperature is a crystalline substance that absorbs moisture
from the air and forms a damp solid or a solution. No odor threshold has been
reported. Cyanamide is soluble in water (78 g/100 ml), alcohol and ether, but its
solubility in benzene is low.
Cyanamide is used in chemical syntheses, in fertilizers, and as a biocide. It is also
used in ore refining and in the wood processing and rubber industries. Cyanamide
can also be formed by hydrolysis of calcium cyanamide, a substance which has
similar uses. Cyanamide and its salts have also been used medicinally in treatment
of alcoholics, since cyanamide inhibits aldehyde dehydrogenase. It is no longer
registered as a medicine. No information on air concentrations was found in the
literature.
Uptake, biotransformation, excretion
Cyanamide can be absorbed via the digestive tract and skin. It is metabolized to
acetyl cyanamide, mostly in the liver, by acetyl-S-CoA-dependent N-acetyl-
transferase (26). It may also be metabolized in a reaction induced by catalase (8). In
one study, six volunteers were given cyanamide orally (0.25 mg/kg body weight):
40% of the dose was excreted in urine as acetylcyanamide during the next 48 hours,
most of this within the first 12 hours. A 1-ml dose of a 1% cyanamide solution
(0.25 mg/kg) was applied to skin (4 x 4 cm) and left for 6 hours: 7.7% of the dose
was excreted in urine as acetylcyanamide (17).
2Most cyanamide is excreted in urine. When animals were given 14C-labeled
cyanamide (8 mg/kg intraperitoneally for rats, 1.6 mg/kg intravenously and orally
for dogs and rabbits) nearly all the radioactivity was detected in urine, and the
primary metabolite was found to be N-acetylcyanamide (11, 26). In a study with
rats and dogs, the highest plasma concentration was reached in the rats 30 minutes
after oral administration of 4 mg/kg. After intravenous administration of 1.4 mg/kg,
the half time in plasma was 30 to 61 minutes for both species (21). Indications of
non-linear metabolism have been observed in rats under steady-state conditions
(0.005 – 32 mg/kg i.p. at 45-minute intervals). Clearance and first passage
metabolism were not constant between the doses, probably because the biotrans-
formation capacity of the liver had been saturated (23).
Toxic effects
Human data
The effects of cyanamide on the liver have been studied in conjunction with
cyanamide treatment of alcoholics. One study describes liver biopsies from 37
patients who had been treated with cyanamide for from 2 months to 7 years, with
daily doses ranging from 45 to 180 mg. In addition to the liver changes seen with
alcoholism, there were structural changes such as fibrosis and changes in connec-
tive tissue in all biopsies, as well as a particular type of inclusions in hepatocytes
(Lafora-like inclusion bodies consisting of lipid vesicles, glycogen and traces of
degenerated organelles) (19). Elevated blood levels of liver enzymes (ALAT,
ASAT) induced by cyanamide were also detected in this study. The histological
picture resembled that of cirrhosis, and the authors concluded that the longer the
treatment, the greater the changes. Other studies have also shown that cyanamide
used to treat alcoholism induces inclusion bodies in hepatic cells (2, 19, 30, 31,
32).
Two cases of skin sensitization from occupational contact with cyanamide have
been described (5, 6). One man who was sensitized by working for 1.5 years with
medicines that contained cyanamide had a positive reaction to the substance in a
patch test (0.1% in water; 48 hours) (6). Sensitization to cyanamide was reported to
be rare. The other case report describes sensitization in a chemist whose work
included some contact with cyanamide. He had a positive reaction to a 0.01%
cyanamide solution in a patch test (5). Seven cases of cyanamide-induced skin
eruptions are reported in a study from 1977. The patients had been treated with oral
doses of a 1% cyanamide solution, 7 ml daily for from 1 to 4 months (14). After 10
days to 3 months of the treatment, all of them had skin disorders: 6 had scaling
dermatitis and one had lichen planus-like eruptions. The authors concluded that this
type of reaction may have been a common but ignored problem. One case report
describes granulocytopenia and skin sensitization in a man who was treated with
100 mg cyanamide during a 3-week period (1). The symptoms disappeared after
the treatment was broken off.
3There is a study on endocrine function (thyroidea, testes) in 21 persons who
worked in a calcium cyanamide production plant and 9 controls (18). One of the
reasons it was undertaken was that testicular atrophy had been observed in male rats
experimentally exposed to cyanamide (28). N-Acetylcyanamide content in urine at
the end of the workday was used as a measure of exposure, and clearly showed
exposure in the 21 workers. There were no observed differences in endocrine
function (testosterone, follicle-stimulating hormone, luteinizing hormone) between
exposed persons and controls.
Animal data
The LD50 for rats has been calculated to be 125 mg/kg body weight for oral admini-
stration (3) and 56 mg/kg for intravenous administration (13). Cyanamide causes
skin irritation (13) and severe eye irritation in rabbits (100 mg dropped in the eye)
(7).
In several in vivo studies, cyanamide has been shown to inhibit alcohol
dehydrogenase activity. Cyanamide treatment (2 mg/kg, i.p. 1 hour) of rats
inhibited alcohol dehydrogenase and increased the toxicity of alcohol (24).
Intraperitoneal doses of 0.35 mg/kg repeated at 45-minute intervals suppressed
alcohol dehydrogenase activity completely (23). Elevated acetaldehyde levels
following alcohol exposure were seen in rats pre-treated with cyanamide
(0.7 mg/kg, p. o.) 45 minutes before the exposure. Elevated alcohol levels in blood
have also been related to pre-treatment with cyanamide (10 mg/kg, p.o.) (12, 25).
Reduced body weight and elevated levels of monoamines in the brain were
reported in rats after oral or intravenous administration of cyanamide (8 mg/kg,
20 weeks or more) (22). Catalase activity in various organs of rats has been shown
to diminish at dose levels greater than 1.3 mg/kg (i.p., maximum after 1 hour) (9).
Doses exceeding 10 mg/kg ( i.p., 4 hours) increased the level of circulating ketone
bodies in rats (10).
Mutagenicity
In a study with Salmonella typhimurium (strains TA98, TA100, TA1535, TA1537,
TA1538) and E coli, cyanamide caused no increase in mutation frequency, either
with or without metabolic activation (4). Cyanamide was not clastogenic in a micro-
nucleus test with mice (16). Elevated frequencies of mitotic gene conversion and
non-disjunction were seen in Aspergillus nidulans (29). No increase of DNA string
breaks was seen in hepatocytes exposed to cyanamide in vitro (27).
Carcinogenicity
Cancer incidence and mortality were mapped in a cohort of 790 workers in a plant
producing calcium carbide. No increase in cancer was seen among the 117 workers
who had worked with cyanamide/dicyandiamide production for at least 18 months
during 1953 – 1970 (15). Exposures are not reported. The National Cancer Institute
in the United States has tested calcium cyanamide (which hydrolyzes to cyanamide)
4for carcinogenic effect in a two-year study (20) with rats and mice. No carcinogenic
effect was observed.
Teratogenicity
In a two-generation reproduction/fertility study, male rats were given cyanamide in
oral doses of 2 to 25 mg/kg daily for 70 days before mating, and females for 15
days prior to or during gestation. The females in the highest dose group (25 mg/kg)
had lower body weights, fewer corpora lutea, fewer implanted embryos and smaller
litters. Males in the highest dose group had bilateral testicular atrophy and lower
fertility. There were no observed effects on the F1 generation. The NOEL in this
study was 7 mg/kg (28).
Table 1. Effects of cyanamide on experimental animals.
Exposure
mg/kg
Time Species Effect Ref.
125 p.o. Rat LD50 3
56 i.v. Rat LD50 13
25 p.o. daily for 70 days (prior to
mating)
Rat (males) Testicular atrophy, reduced fertility 28
25 p.o. daily for 15 days (before or
during gestation)
Rat (females) Lower body weight, fewer corpora
lutea and implanted embryos,
smaller litters
28
10 i.p. 4 hours Rat Elevated levels of ketone bodies 10
 8 p.o. 20 weeks Rat Lower body weight, elevated levels
of monoamines in brain
22
 2 i.p. 1 hour Rat Inhibited alcohol dehydrogenase
activity, increased alcohol toxicity
24
1.3 i.p. 1 hour Rat Inhibited catalase activity 9
0.7 p.o. 45 minutes Rat Elevated acetaldehyde levels 12, 25
0.35 p.o. 45-minute intervals Rat Suppressed alcohol dehydrogenase
activity
23
 (p.o = oral; i.v. = intravenous; i.p. = intraperitoneal)
5Dose-effect/dose-response relationships
There are no data on which to base a dose-effect or dose-response relationship for
occupational exposure to cyanamide. The dose-response and dose-effect relation-
ships observed in animal experiments are summarized in Table 1.
Conclusions
Cyanamide inhibits alcohol dehydrogenase when used medicinally. There are no
data on which to base a critical effect for occupational exposure. Cyanamide can be
skin sensitizing to humans and has been shown to irritate the eyes of rabbits.
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7Consensus Report for Phosphorus
Chlorides
September 30, 1998
This report treats phosphorus trichloride, phosphorus pentachloride and phosphoryl
chloride.
Chemical and physical data. Uses
phosphorus trichloride
CAS No: 7719-12-2
Synonyms: phosphorus(III)chloride, trichlorophosphine
Formula: PCl3
Molecular weight: 137.33
Boiling point: 76 ° C
Melting point: - 112° C
Vapor pressure: 12.7 kPa (20 ° C)
Conversion factors: 1 ppm = 5.70 mg/m3 (20° C)
1 mg/m3 = 0.175 ppm (20 ° C)
phosphorus pentachloride
CAS No.: 10026-13-8
Synonyms: phosphorus(V)perchloride, pentachlorophosphorane
Formula: PCl5
Molecular weight: 208.24
Boiling point: sublimates at 160° C *
Melting point: 167 ° C (three-phase equilibrium) *
Conversion factors: 1 ppm = 8.64 mg/m3 (20° C)
1 mg/m3 = 0.116 ppm (20 ° C)
_______________________
* From Reference 14. Other sources give other boiling and melting points.
phosphoryl chloride
CAS No: 10025-87-3
Synonyms: phosphoryl trichloride, trichlorophosphine oxide,
phosphorus oxychloride, phosphorus oxytrichloride
Formula: POCl3
Molecular weight: 153.33
Boiling point: 105.5° C
Melting point: 1 ° C
Vapor pressure: 3.6 kPa (20 ° C)
Conversion factors: 1 ppm = 6.36 mg/m3 (20° C)
1 mg/m3 = 0.157 ppm (20 ° C)
8Phosphorus trichloride at room temperature is a clear liquid that steams in damp air:
it hydrolyzes, emitting heat, to phosphorous acid and hydrochloric acid.
Phosphorus pentachloride at room temperature is a steaming, yellowish or white to
greenish-white solid. It hydrolyzes initially to hydrochloric acid and phosphoryl
chloride, and in a second step the phosphoryl chloride (a clear, steaming liquid)
hydrolyzes, producing heat, phosphoric acid and more hydrochloric acid.
Phosphorus trichloride, phosphorus pentachloride and phosphoryl chloride all three
have a sharp, penetrating odor (1, 2, 3, 12, 13, 17, 20).
Phosphorus trichloride is used mostly as an intermediate in the production of
pesticides, surfactants, softeners, gasoline additives and pigments. Phosphorus
pentachloride is used as a thickener. Phosphoryl chloride is used in the production of
softeners and gasoline additives and also in the production of hydraulic fluids and fire
retardants. All three substances are used as chlorinators and catalysts (1, 2, 3).
Uptake, biotransformation, excretion
No information was found in the literature.
Toxic effects
Human data
Vapor/dust (including hydrolysis products) of all three substances are irritating/cor-
rosive to eyes and respiratory passages, but information on exposure levels is
usually not given (5, 10, 11, 19, 22, 26, 27, 29). Phosphorus trichloride and
phosphorus pentachloride are reported to be strongly irritating to mucous
membranes (4, 29). Phosphoryl chloride has been reported to strongly affect both
the upper and lower respiratory passages and to be more likely to have delayed
effects on respiratory passages than phosphorus trichloride (10, 26, 29). Exposure
to phosphorus trichloride and its hydrolysis products has also resulted in skin
irritation (17, 27). Occupational exposure to phosphorus chlorides has been
reported to etch the teeth (21), but the type of exposure was not described.
Effects other than local irritation/ulceration have also been reported to result from
exposure to phosphorus chlorides. One study (27) reports nausea, vomiting,
headache and transient elevation of lactate dehydrogenase levels in serum in several
persons acutely exposed to phosphorus trichloride and its hydrolysis products.
Another study (5) reports dizziness and severe headache in a person who had
inhaled phosphorus pentachloride vapor for a few seconds. Brief exposure (in some
cases only a few seconds) to phosphoryl chloride vapor has caused dizziness,
nausea, vomiting and effects on the heart (5, 10, 11). In a few cases, enlarged liver,
albuminuria and anemia have also been reported after exposure to phosphoryl
chloride vapor (22), but it is not clear whether these effects were the result of the
exposure.
Only a few studies report both exposure levels and the symptoms of exposed
persons. One study (Dadej, 1962; reviewed in Reference 17) describes effects on
some people who were exposed to phosphorus trichloride and its hydrolysis
9products by an explosion. Three workers who were exposed for from a few
seconds up to half a minute or so, and who died within 24 hours, had severe skin
burns, ulcerated eyes, inflamed bronchi and pulmonary edema. Ulcerated eyes,
respiratory passages and skin were also seen in one surviving worker who was
exposed for several seconds. Concentrations during the first 120 seconds were
roughly estimated to have been about 36,800 mg/m3 phosphorus trichloride,
116,300 mg/m3 hydrochloric acid, and 62,500 mg/m3 phosphorous acid.
A report from NIOSH (25) states that, of 37 workers exposed to phosphorus
trichloride and phosphoryl chloride, about 65% (24/37) suffered acute respiratory
symptoms such as breathing difficulty or chest tightness at least once a month. Only
5% (1/22) of non-exposed persons reported these symptoms. Lung function tests,
however, revealed no significant differences between the two groups. Air concen-
trations were measured with personal monitors for two days, and were below the
detection limits for phosphorus trichloride and phosphoryl chloride in nearly all
cases. There was one exposure to 5.7 mg/m3 phosphorus trichloride (1 hour) and
one to 4.2 mg/m3 phosphoryl chloride (25 minutes). A significant difference
between exposed and unexposed workers is also reported in a follow-up medical
study made two years later (16). Half (13 of 26 persons) of the exposed workers
had periods of acute breathing difficulty, tightness in the chest and breathlessness
(5 of them regarded the symptoms as work-related), whereas none of the un-
exposed workers (11 persons) reported these symptoms.
Two studies from Italy (23, 24) contain exposure data and describe respectively
effects on 23 workers exposed to phosphorus trichloride and 20 workers exposed
to phosphorus oxychloride. Air concentrations varied considerably in both cases.
They were reported to be 10 – 20 mg/m3 most of the time, but could occasionally
exceed 150 mg/m3 (phosphorus trichloride) or 70 mg/m3 (phosphorus oxy-
chloride). The reports contain no information on hydrolysis products. Photophobia,
stinging in eyes and throat, chest tightness, coughing and rapid breathing were
reported in a few subjects within 2 to 6 hours of exposure, and some of them
subsequently developed bronchitis. In other cases it took 4 or 5 days or up to 8
weeks for symptoms to appear, and then in the form of slight throat irritation,
conjunctivitis, coughing, shortness of breath and asthmatic bronchitis. Emphysema
was also mentioned. The studies have the form of multiple case reports, and there is
no collation or analysis of the findings. The diagnoses are based only on clinical
observations and x-rays: there is no mention of medical history or smoking habits,
for example. All this gives rise to some uncertainty in assessing the results, and it is
therefore impossible to draw any definite conclusions from these studies.
A sketchily reported Russian study (21) with volunteers gives irritation
thresholds of 4 mg/m3 for phosphorus trichloride, 10 mg/m3 for phosphorus
pentachloride and 1 mg/m3 for phosphoryl chloride. Since no details on the results
or the design of the experiment are given, however, the information can not be
satisfactorily assessed.
Skin burns have been reported in persons splashed with phosphorus trichloride
or phosphorus pentachloride (concentrations not given) (9, 19).
10
Animal data
The LC50 values for exposure to vapor/aerosol of phosphorus trichloride reported in
different studies range from 226 to > 2582 mg/m3. Reported LC50 values for
phosphoryl chloride range from 71 to 330 mg/m3 (18, 21, 28). The reported LC50
value for phosphorus pentachloride is 205 mg/m3 (21). The LD50 values for oral
administration to rats are 18 – 550 mg/kg for phosphorus trichloride, 600 mg/kg for
phosphorus pentachloride, and 380 mg/kg for phosphoryl chloride (17, 18, 21).
No LD50 information was found for skin application, but an LDLo of 1260 mg/kg
has been reported for application of phosphorus trichloride to the skin of rabbits
(24 hours) (18). Phosphorus trichloride applied to the skin of rabbits is reported to
cause burns (one reference reports that the substance was undiluted) (17, 18).
Phosphorus pentachloride (concentration not reported) and phosphoryl chloride
(pure substance) have also been reported to cause burns when applied to the skin of
rabbits (17, 18). Application of phosphorus trichloride (concentration not reported)
or phosphoryl chloride (pure substance) in liquid form has also been shown to
cause severe damage to the eyes of experimental animals (17, 18).
During 4-hour exposures made to determine the LC50 for phosphorus trichloride
and phosphoryl chloride, experimental animals (rats and guinea pigs) showed
agitation, indications of irritation, porphyrin secretion around the eyes and labored
breathing (28). The exposure to phosphorus trichloride also caused severe erosion
of the nostrils and paws as well as kidney damage (nephrosis). The exposure to
phosphoryl chloride caused irritation in the trachea, bronchi and lungs. The deaths
occurred within 10 days after exposure to phosphorus trichloride and within
48 hours after exposure to phosphoryl chloride. The study reports that about 40%
of the phosphorus trichloride and 15% of the phosphoryl chloride were hydrolyzed
(28).
Effects on eyes and respiratory passages were reported in a study in which
rabbits and cats (one of each per group) were exposed by inhalation to concen-
trations of phosphorus trichloride ranging from 4 mg/m3 to 3870 mg/m3 for 3 to
10 hours (6). There was a large difference in sensitivity between the two species.
Sneezing, coughing, salivation, nasal secretion and reduced respiratory rates were
seen in the cats at exposure as low as 4 – 5 mg/m3, and effects on the eyes were
noted at air concentrations of 13 – 20 mg/m3 or above. Histological examination
(cats) revealed liquid in the lungs (13 – 20 mg/m3). Exposed rabbits – two animals
exposed to air concentrations of 13 – 20 mg/m3 and 13 – 27 mg/m3 respectively –
became somewhat restless, had greatly reduced respiration rates, slight symptoms
of irritation and/or slight nasal secretion (see Table 1).
A Russian study (21) reports that the threshold value for irritation of respiratory
passages (rats) was 5 mg/m3 for phosphorus trichloride, 8 mg/m3 for phosphorus
pentachloride and 1 mg/m3 for phosphoryl chloride. The study also reports that the
effect was more pronounced for phosphorus trichloride (clouding of the cornea,
sores around the mouth and nose, pronounced irritation of respiratory passages)
than for the other phosphorus chlorides. The same study reports that “dystrophic
changes,” particularly in the liver, kidneys and nervous system, were observed after
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single exposures to high (not reported) air concentrations of phosphorus chlorides,
and that exposure to 10 mg/m3 for 4 hours caused a reduction of pH in blood and
urine. Pronounced morphological changes, most notably in respiratory passages,
kidneys, liver, bone tissue (osteoporosis) and brain (degenerative changes in nerve
cells), as well as cytogenetic effects (see below), were also observed after 4 months
of exposure to 1.34 mg/m3 phosphoryl chloride, and irritation of mucous mem-
branes in airways and elevated kidney weights were noted at 0.48 mg/m3. Since the
report gives no details on the design of the experiment, controls etc., this informa-
tion can not be evaluated.
Mutagenicity, carcinogenicity, reproduction toxicity
No mutagenic effects were observed when phosphorus trichloride was tested on
bacteria in vitro (15). A Russian study (21), which can not be adequately assessed
(see above), reports mutagenic and cytostatic effects in rats (bone marrow) after
chronic exposure to 1.34 mg/m3 phosphoryl chloride but no significant changes
after exposure to 0.48 mg/m3. Phosphoryl chloride (air concentration not given)
was also reported to affect the motility of sperm but to have no effect on spermato-
genesis.
Dose-effect/dose-response relationships
There are few reliable measurements of air concentrations of these phosphorus
chlorides in work environments. Two Italian studies report symptoms of eye
irritation with exposure to phosphorus trichloride and airway irritation with
exposure to phosphoryl chloride. Air concentrations varied, but in both cases
were reported to be around 10 – 20 mg/m3 most of the time.
Effects on experimental animals exposed by inhalation to phosphorus trichloride
are summarized in Table 1.
Dose-dependent effects on respiratory passages were observed in cats at air
concentrations of 4 – 5 mg/m3 phosphorus trichloride or higher, and dose-
dependent effects on eyes at air concentrations of 13 – 20 mg/m3 or higher.
Conclusions
The critical effect of exposure to phosphorus trichloride, phosphorus pentachloride
and phosphoryl chloride is irritation of respiratory passages. Due to their chemical
characteristics, these three substances can also irritate/ulcerate eyes and skin.
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Table 1. Effects on experimental animals exposed by inhalation to phosphorus
trichloride.
Exposure
(mg/m3)
Species Effects Ref.
930 – 1070
4 hours
cat, rabbit
(one of each)
Cat: agitation, salivation, red noses, dyspnea,
corneal and nasal ulceration, pleurisy, reddened
trachea, death after 36 hours.
Rabbit: sneezing, agitation, conjunctivitis,
secretions from eyes and nose.
6
530 – 1090
6.5 hours
cat
(one animal)
Salivation, dyspnea, death after 390 minutes,
corneal ulceration, emphysema, swollen epiglottis.
6
586
4 hours
rat LC50 28
330
6 hours
cat, rabbit
(one of each)
Cat: agitation, coughing, sneezing, salivation,
conjunctivitis, rhinitis, dyspnea, red nose, ulcerated
cornea and nose, emphysema, swollen epiglottis.
Rabbit: agitation, nasal secretion, rhinitis, reduced
respiratory rate, dyspnea, red nose, ulcerated cornea.
6
282
4 hours
guinea pig LC50 28
226 rodents LC50 21
40 – 90
7 hours
cat, rabbit
(one of each)
Cat: sneezing, secretion, cough, dyspnea,
conjunctivitis, red nose.
Rabbit: marked decline in respiratory rate, but few
other symptoms.
6
13 – 27
6 hours
cat, rabbit
(one of each)
Cat: salivation, dyspnea.
Rabbit: slight irritation, nasal secretion, reduced
respiratory rate.
6
13 – 20
6 hours
cat, rabbit
(one of each)
Cat: salivation, nasal secretion, cough, dyspnea,
conjunctivitis, liquid accumulation in lungs.
Rabbit: slight restlessness, marked drop in
respiratory rate.
6
4 – 5
3 hours
cat
(one animal)
Sneezing, coughing, salivation, nasal secretion,
reduced respiratory rate.
6
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Consensus Report for Glutaraldehyde
September 30, 1998
This report is based primarily on a criteria document produced jointly by the Nordic
Expert Group and the Dutch Expert Committee (3).
Chemical and physical data. Uses
CAS No.: 111-30-8
Name: glutaraldehyde
Synonyms: glutaral, pentanedial,
glutardialdehyde, 1,5-pentanedial
Formula: CHO-(CH2)3-CHO
Molecular weight: 100.13
Boiling point: 188 ° C
Freezing point: - 14 ° C
Vapor pressure: 0.00016 kPa (20% solution)
0.002 kPa (50% solution)
Saturation concentration: 6.6 mg/m3 (1.6 ppm) (20% solution)
82 mg/m3 (20 ppm) (50% solution)
Distribution coefficient: log Po/w = 0.01
Conversion factors: 1 mg/m3 = 0.25 ppm
1 ppm = 4.0 mg/m3
Glutaraldehyde at room temperature is a colorless, oily liquid with a sharp odor.
The reported odor threshold is 0.04 ppm (2, 3). Glutaraldehyde is soluble in water,
ethanol, benzene, ether and other organic solvents. It can react violently with strong
oxidants. An aqueous solution of glutaraldehyde has a pH of 3 – 4.
Glutaraldehyde is marketed in aqueous solutions of 1%, 2%, 25% or 50%. The
solutions may contain alkalis added to raise their pH to 7.5 – 8.5 (activated solu-
tions). Glutaraldehyde has a wide range of uses: as a disinfectant and sterilizer in
hospitals, in embalming, as a fixative in electron microscopy, as a slimicide in the
paper industry etc.
Glutaraldehyde was monitored in hospitals in England: concentrations ranged
from 0.003 to 0.17 mg/m3 (19). In Denmark, concentrations of 0.25 to 0.5 mg/m3
were measured in surgery wards (28). In a Swedish study, the highest concentra-
tion – 0.57 mg/m3 – was associated with sterilization of gastroscopes. The average
of 16 measurements made around this task was 0.05 mg/m3 (25).
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Uptake, biotransformation, excretion
In an in vitro study, skin from rats, mice, rabbits, guinea pigs and humans was
exposed to a 1,5-14C-labeled glutaraldehyde solution for 6 hours. Concentrations
were 0.75% or 7.5%. Between 0.5 and 0.7% of the solution was absorbed
through/into the skin (11). Human stratum corneum and epidermis were exposed in
vitro to 450 m l of a 10% glutaraldehyde solution for 1 hour. Penetration through the
stratum corneum ranged from 3.3% (skin from the back) to 12% (skin from the
stomach), with large individual variations. Penetration through epidermis was about
4% of the applied amount (27). When glutaraldehyde (0.75 or 7.5%) was left on
the skin for 24 hours, the amount absorbed was calculated to be 4 – 9% for rats,
and 33 – 53% for rabbits (3, 23).
Biotransformation of glutaraldehyde involves oxidation, decarboxylation and
hydroxylation. Oxidation to glutaric acid, bonding to coenzyme A and breakdown
to acetate yields the end product carbon dioxide. In hepatic and renal tissue of rats in
vitro, glutaraldehyde is oxidated (probably in the mitochondria) to CO2 (26). Doses
of 0.2 ml of a 0.075 or 0.75% solution of 14C-labeled gutaraldehyde were injected
into the caudal vein of rats, and up to 80% of the radioactivity was found in CO2
during the next 4 hours. Within 3 days 90% of the radioactivity had left the body
(3, 23).
Toxic effects
Human data
Glutaraldehyde solutions can cause skin irritation, the severity of which depends on
the strength of the solution and the duration of the contact. Inhalation of low levels
of glutaraldehyde – less than 0.8 mg/m3 – has been reported to cause irritation of
nose and throat as well as nausea and headache (4). A special effect is the bleeding
in mucous membranes of the intestine that may be caused by endoscopes sterilized
in glutaraldehyde (8).
Of 167 nurses in endoscopy units, 65% had complaints of eye irritation, skin
irritation, headaches, coughing and nasal congestion. In those cases in which
measurements of glutaraldehyde concentrations are reported, they are below 0.2
ppm (0.8 mg/m3) (5). There are several reported cases of sensitization caused by
glutaraldehyde (3). Repeated or prolonged contact with glutaraldehyde or
disinfectants containing glutaraldehyde has caused dryness, redness, eczema,
cracking and sensitization of the skin (3). In a multi-center study of patients patch-
tested at dermatology clinics in Germany over a 5-year period (1990 – 1994), it is
reported that the number of patients sensitized to glutaraldehyde increased markedly
during the study period (29). In a follow-up report (30) covering the years 1992 –
1995, 1194 women working in health care were tested: 10% had a positive
response, compared with 2.6% of about 4000 patients who did not work in health
care. Dental nurses were found to have the highest risk of skin sensitization (30).
Skin tests were given to 109 volunteers, using a 0.5% glutaraldehyde solution for
both induction and provocation. One of the 109 subjects had a clear reaction, and 16
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developed mild local erythema (redness) (1). In another study with 102 persons,
0.1% glutaraldehyde in vaseline was used for induction and 0.5 % in vaseline for
provocation. No sensitization was observed. When the induction dose was 5.0%,
7 of 30 persons became sensitized to glutaraldehyde (21).
There are several case reports of severe asthma attacks suffered by asthmatics
exposed to glutaraldehyde (3, 6, 7, 14, 32). There are also descriptions of six cases
of glutaraldehyde-induced asthma in non-asthmatics, four of whom were not atopic
(14).
Animal data
An alkaline 2% glutaraldehyde solution applied to the skin of rabbits caused
“moderate” skin irritation. When a 24% glutaraldehyde solution was applied to
rabbit skin it caused edema, followed by necrosis and scarring (3, 34). A drop of
2% acid glutaraldehyde solution placed in the conjunctival sac of rabbit eyes caused
severe damage to the conjunctiva (edema and inflammation). A 2% alkaline solution
applied to the eyes of rabbits caused opacity of the cornea and irritation of the iris,
and was judged to be severely irritating to the eyes (3, 24).
Glutaraldehyde in gas form caused eye irritation at a concentration of 0.2 ppm.
Mice were exposed to concentrations ranging from 1.6 to 36.7 ppm and the RD50
(a measure of airway irritation) was calculated to be 13.9 ppm. The LC50 for
glutaraldehyde was estimated to be 24 – 40 ppm (3).
Solutions of 0.3, 1.0 and 3.0% glutaraldehyde were tested in a skin sensitization
study with guinea pigs. A 10% solution was used as provocation. Each group
consisted of six animals. There was no difference between the lowest dose group
(0.3% solution) and controls (index 0.4). In the group receiving the 1.0% solution
the index was 1.1 and in the high-dose group 2.7. In a positive control group that
received DNFB (1-fluoro-2,4-dinitrobenzene) the index was 5.9. The maximum
non-irritating concentration was reported to be 3%, since the 10% solution
produced some irritation. The result was the same when the same test, using the
same concentrations, was given to mice, but here the lowest dose group was also
significantly different from the vehicle-control group (33).
A modified Magnusson-Kligman test was given to 30 guinea pigs using a 10%
solution of glutaraldehyde, and 72% of the animals were sensitized. Glutaraldehyde
was concluded to be a potent allergen. Cross-sensitization was shown between
glyoxal, formaldehyde and glutaraldehyde (10). In another type of test, the mouse
ear swelling test, a 1% solution was used for induction and a 10% solution for
provocation, and 67% of the animals were sensitized (12). With a local lymph node
assay, it was shown that glutaraldehyde had greater potential than formaldehyde for
inducing skin sensitization (18). Sensitization of respiratory passages was tested
with guinea pigs, using 13.9 ppm as induction and 4.4 ppm as provocation. No
indications of sensitization were observed (3).
Rats were given 0, 10, 20 or 40 mM glutaraldehyde by intranasal instillation. No
damage was observed at 0 and 10 mM. The two higher doses caused inflammation,
hyperplasia  and squamous metaplasia in epithelium, and increased cell prolifera-
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tion. The damage resembled that observed in rats after inhalation of carcinogenic
concentrations of formaldehyde (31).
In a two-week study, groups of rats and mice (5 of each sex per group) were
exposed to 0, 0.16, 0.5, 1.6, 5 or 16 ppm glutaraldehyde for 6 hours/day,
5 days/week. All the rats in the two highest dose groups and all the mice in the
three highest dose groups died during the exposure period. Deaths were caused by
respiratory arrest. Rats exposed to 1.6 ppm grew more slowly, and all of them had
necroses in nasal epithelium. Two males and all the females in this group also had
squamous metaplasia. At 0.5 ppm there was nasal hyperplasia in three males and
squamous metaplasia in two males and one female (26). In a 13-week follow-up
study, groups of rats and mice (10 animals of each sex per group) were exposed to
0, 62.5, 125, 250, 500 or 1000 ppb glutaraldehyde. Slower growth was noted in
the males in the highest dose group, in the females in the two highest groups, and in
the mice in the four highest groups. For rats, the NOAEL for damage to respiratory
passages was determined be 125 ppb, whereas inflammation was observed in the
noses of the mice at 62.5 ppb (15, 26).
Mice were exposed to 0.3, 1.0 or 2.6 ppm glutaraldehyde, 6 hours/day for up to
two weeks, and histopathological damage to respiratory epithelium was observed in
all exposure groups. Inhalation of 1.0 ppm for 14 days caused an elevated incidence
of squamous metaplasia and necrosis in nasal epithelium. No damage was observed
in the lungs (37).
Mutagenicity, carcinogenicity, teratogenicity
Glutaraldehyde has been shown to be genotoxic in vitro, and to induce mutations in
both bacteria and mammalian cells. It has also caused sister chromatid exchanges
and chromosome aberrations in mammalian cells in vitro. However, glutaraldehyde
yielded negative results when it was tested in vivo, in both the micronucleus test
and a test for chromosome aberrations in bone marrow (3, 13, 16, 22, 26, 36).
No elevation in the incidence of malignant tumors was observed in a mortality
study of 186 occupationally exposed workers in a factory producing glutaral-
dehyde. There were 4 deaths due to cancer (6.1 expected), one each lympho-
sarcoma, stomach, lung and brain (35).
A cancer study with rats and mice is being made by the NTP, and results have not
yet been reported.
Spontaneous abortions and birth defects were studied among hospital personnel
exposed to glutaraldehyde disinfectants. No elevation in risk was observed (17).
In a study with mice, the animals were given a 2% glutaraldehyde solution by
gavage on days 6 – 15 of gestation. Doses were 16, 20, 24, 40, 50 or 100 mg/kg
body weight. The animals were sacrificed on day 18. Fetal weights in the lowest
dose group were lower than those in controls. In the highest dose group there was a
marked increase of deformities. The deformities were thus seen only at doses that
were highly toxic to the mothers (20).
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In a similar study, rats were given glutaraldehyde by gavage in doses of 25, 50,
or 100 mg/kg body weight on days 6 – 15 of gestation. Maternal toxicity was seen
in the highest dose group but morphological examinations of the fetuses revealed no
teratogenic effects (9).
Dose-response/dose-effect relationships
Available data on human exposures do not provide a sufficient basis for estimates of
a dose-response or dose-effect relationship. Data from inhalation studies with rats
and mice are summarized in Tables 1 (rats) and 2 (mice).
Conclusions
There are little data that can be used as a scientific basis for an occupational
exposure limit for glutaraldehyde. The critical effect is irritation of eyes and mucous
membranes, which can occur at exposure levels below 0.2 ppm. Exposure to
0.0625 ppm (the lowest tested dose) can cause inflammatory changes in the nasal
mucosa of mice.
Glutaraldehyde is definitely sensitizing to skin. It exacerbates asthma in
asthmatics and may cause asthma in non-asthmatics.
Table 1. Effects noted in rats exposed to glutaraldehyde by inhalation
Exposure Effect Ref.
ppm time
24 - 120 4 hours LC50  3
1.6 6 h/d, 5 d/w, 2 weeks Retarded growth 26
1.0 6 h/d, 5 d/w, 13 weeks Lower weight gain 26
0.5 6 h/d, 5 d/w, 13 weeks Squamous metaplasia in nose 26
0.25 6 h/d, 5 d/w, 13 weeks Inflammation in nose 26
0.125 6 h/d, 5 d/w, 13 weeks NOAEL for damage to respiratory passages 26
Table 2. Effects noted in mice exposed to glutaraldehyde by inhalation
Exposure Effect Ref.
ppm time
2.6 15 minutes RD50 37
1.6 6 h/d, 5 d/w, 2 weeks 10/10 animals died 26
1.0 6 h/d, 5 d/w, 13 weeks 20/20 animals died 26
1.0 14 days Squamous metaplasia, epithelial necrosis 37
0.3 4 days Damage to epithelium in respiratory passages 37
0.25 6 h/d, 5 d/w, 13 weeks Retarded growth 26
0.125 6 h/d, 5 d/w, 13 weeks Retarded growth 26
0.0625 6 h/d, 5 d/w, 13 weeks Inflammation in nose 26
20
References
 1. Ballantyne B, Berman B. Dermal sensitizing potential of glutaraldehyde: A review and recent
observations. J Toxicol Cut Ocular Toxicol 1984;3:251-262.
 2. Beauchamp R O, St Clair M B G, Fennell T R, Clarke D O, Morgan K T, Kari F W. A
critical review of the toxicology of glutaraldehyde. CRC Crit Rev Toxicol 1992;22:143-174.
 3. Beije B, Lundberg P. DECOS and NEG basis for an occupational standard. Glutaraldehyde.
Arbete och Hälsa 1997;20:1-30.
 4. Burge P S. Occupational risk of glutaraldehyde. Br Med J 1989;299:342.
 5. Calder I M, Wright L P, Grimstone D. Glutaraldehyde allergy in endoscopy units. Lancet
1992;339:433.
 6. Chan-Yeung M, McMurren T, Catonio-Begley F, Lam S. Occupational asthma in a
technologist exposed to glutaraldehyde. J Allergy Clin Immunol 1993;91:974-978.
 7. Corrado O J, Osman J, Davies R J. Asthma and rhinitis after exposure to glutaraldehyde in
endoscopy units. Human Toxicol 1986;5:325-327.
 8. Dolcé P, Gourdeau M, April N, Bernard P-M. Outbreak of glutaraldehyde-induced
proctocolitis. Am J Infect Control 1995;23:34-39.
 9. Ema M, Itami T, Kawasaki H. Teratological assessment of glutaraldehyde in rats by gastric
intubation. Toxicol Lett 1992;63:147-153.
10. Foussereau J, Cavelier C, Zissu D. L’allergie de contact professionelle aux antiseptiques
aldéhydés en milieu hospitalier. Arch Mal Prof 1992;53:325-338.
11. Frants S W, Beskitt J L, Tallant M J, Futrell J W, Ballantyne B. Glutaraldehyde: Species
comparisons of in vitro skin penetration. J Toxicol Cut Ocular Toxicol 1993;12:349-361.
12. Gad S C, Dunn B J, Dobbs D W, Reilly C, Walsh R D. Development and validation of an
alternative sensitization test: The mouse ear swelling test (MEST). Toxicol Appl Pharmacol
1986;84:93-114.
13. Galloway S M, Armstrong M J, Reuben C et al. Chromosome aberrations and sister
chromatid exchanges in Chinese hamster ovary cells: Evaluation of 108 chemicals. Environ
Mol Mutgen 1987;10 suppl 10:1-175.
14. Gannon P F G, Bright P, Campbell M, O’Hickey S P, Burge P S. Occupational asthma due
to glutaraldehyde and formaldehyde in endoscopy and x-ray departments. Thorax 1995;50:156-
159.
15. Gross E A, Mellick P W, Kari F W, Miller F J, Morgan K T. Histopathology and cell
replication responses in the respiratory tract of rats and mice exposed by inhalation to
glutaraldehyde for up to 13 weeks. Fund Appl Toxicol 1994;23:348-362.
16. Haworth S, Lawlor T, Mortelmans K, Speck W, Zeiger E. Salmonella mutagenicity test
results for 250 chemicals. Environ Mutagen 1983;5 suppl 1:3-142.
17. Hemminki K, Kyyrönen P, Lindbohm M-L. Spontaneous abortions and malformations in the
offspring of nurses exposed to anaesthetic gases, cytostatic drugs, and other potential hazards
in hospitals, based on registered information of outcome. J Epidemiol Commun Health
1985;39:141-147.
18. Hilton J, Dearman R J, Harvey P, Evans P, Basketter D A, Kimber I. Estimation of relative
skin sensitizing potency using the local lymph node assay: A comparison of formaldehyde
with glutaraldehyde. Am J Contact Dermat 1998;9:29-33.
19. Leinster P, Baum J M, Baxter P J. An assessment of exposure to glutaraldehyde in hospitals:
Typical exposure levels and recommended control measures. Br J Ind Med 1993;50:107-111.
20. Marks T A, Worthy W C, Staples R E. Influence of formaldehyde and Sonacide® (potentiated
acid glutaraldehyde) on embryo and fetal development in mice. Teratology 1980;22:51-58.
21. Marzulli F N, Maibach H I. The use of graded concentrations in studying sensitizers:
Experimental contact sensitization in man. Food Cosmet Toxicol 1974;12:219-227.
21
22. McGregor D, Brown A, Cattanach P et al. Responses of the L5178Y tk+/tk- mouse
lymphoma cell forward mutation assay: III. 72 coded chemicals. Environ Mol Mutagen
1988;12:85-154.
23. McKelvey J A, Garman R H, Anuszkiewicz C M, Tallant M J, Ballantyne B. Percutaneous
pharmacokinetics and material balance studies with glutaraldehyde. J Toxicol Cut Ocular
Toxicol 1992;11:341-367.
24. Miner N A, McDowell J W, Willcockson G W, Bruckner N I, Stark R L, Whitmore E J.
Antimicrobial and other properties of a new stabilized alkaline glutaraldehyde disinfectant/
sterilizer. Am J Hosp Pharm 1977;34:376-382.
25. Norbäck D. Skin and respiratory symptoms from exposure to alkaline glutaraldehyde in
medical services. Scand J Work Environ Health 1988;14:366-371.
26. NTP. Technical Report on Toxicity Studies of Glutaraldehyde (CAS No. 111-30-8)
Administered by Inhalation to F344/N Rats and B6C3F1 Mice. Research Triangle Park:
National Toxicology Program, 1993. (Toxicity Report No. 25)
27. Reifenrath W G, Prystowsky S D, Nonomura J H, Robinson T B. Topical glutaraldehyde –
percutaneous penetration and skin irritation. Arch Dermatol Res 1985:277:242-244.
28. Rietz B. Determination of three aldehydes in the air of working environments. Anal Lett
1985;18:2369-2379.
29. Schnuch A, Geier J, Uter W, Frosch P J. Patch testing with preservatives, antimicrobials and
industrial biocides. Results from a multicentre study. Br J Dermatol 1998;138:467-476.
30. Schnuch A, Uter W, Geier J, Frosch P J, Rustemeyer T . Contact allergies in healthcare
workers. Results from the IVDK. Acta Derm Venereol 1998;78:358-363.
31. St Clair M B G, Gross E A, Morgan K T. Pathology and cell proliferation induced by intra-
nasal instillation of aldehydes in the rat: Comparison of glutaraldehyde and formaldehyde.
Toxicol Pathol 1990;18:353-361.
32. Stenton S C, Beach J R, Dennis J H, Keaney N P, Hendrick D J. Glutaradehyde, asthma and
work – a cautionary tale. Occup Med 1994;44:95-98.
33. Stern M L, Holsapple M P, McCay J A, Munson A E. Contact hypersensitivity response to
glutaraldehyde in guinea pigs and mice. Toxicol Ind Health 1989;5:31-43.
34. Stonehill A A, Krop S, Borick P M. Buffered glutaraldehyde, a new chemical sterilizing
solution. Am J Hosp Pharm 1983;20:458-465.
35. Teta M J, Avashia B H, Cawley T J, Yamin A T. Absences of sensitizations and cancer
increases among glutaraldehyde workers. Toxic Subst Mechanisms 1995;14:293-305.
36. Vergnes J S, Ballantyne B. Glutaraldehyde (50% aqueous solution): Assessment of genotoxic
potential in vivo. Toxicologist 1993;14:328.
37. Zissu D, Gagnaire F, Bonnet P. Nasal and pulmonary toxicity of glutaraldehyde in mice.
Toxicol Lett 1994;71:53-62.
22
Consensus Report for Methyl Tert-Butyl
Ether
September 30, 1998
This report is an update of the Consensus Report of November 26, 1987 (38).
Chemical and physical characteristics.* Uses
CAS No.: 1634-04-4
Synonyms: methyl tertiary butyl ether,
methyl t-butyl ether,
2-methoxy-2-methyl propane,
tert.-butyl methylether,
methyl-1,1-dimethylether,
MTBE
Formula: CH3-O-C(CH3)3
Molecular weight: 88.15
Density: 0.7404 (20 ° C)
Boiling point: 55.2 ° C
Vapor pressure: 32.67 kPa (245 mm Hg) (25 ° C)
Autoignition temperature: 224 ° C
Distribution coefficient: log Poctanol/water = 1.04 (25 ° C)
Solubility: 4.8 g/100 g water
Saturation concentration: 320,000 ppm (25 ° C)
Conversion factors: 1 ppm = 3.60 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.278 ppm (20 ° C, 10l.3 kPa)
_______________________
* from References 16, 18 and 33
Methyl tert-butyl ether (MTBE) is an aliphatic, branched ether. At room temperature
it is a clear, flammable liquid with a characteristic odor and a low odor threshold
(0.05 – 0.2 ppm) (28, 57). Peroxide formation on exposure to ultraviolet light is
lower for MTBE than for linear ethers (25, 43).
MTBE is produced from methanol and isobutene, and on a very large scale (1).
World production in 1994 was 20.6 million metric tons (24). Sweden produced
36,500 tons and imported 33,000 tons in 1996 (59).
Nearly all MTBE is used as an additive (oxygenator) in unleaded gasoline. MTBE
raises the octane of gasoline and improves combustion, thus reducing emissions of
carbon monoxide, benzene etc. (28, 67). MTBE is also used in chromatography as
an eluent (37, 50) and in medicine to dissolve gallstones in situ (31, 34).
Since MTBE is extremely volatile, most exposure occurs via inhalation, and
particularly in conjunction with production and distribution. A study from Finland
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reports MTBE exposures of 0.8 to 63 ppm (10 – 40 minutes) for tank truck drivers
delivering gasoline (27). A summary of exposure measurements made in the United
States (28) gives MTBE exposures for distribution of pure MTBE (peaks of 14 –
1000 ppm) and MTBE in gasoline (peaks of 2 – 100 ppm for < 30 minutes), for
filling station personnel (0.3 – 6 ppm; peaks of > 10 ppm for 1 – 2 minutes; 6 to
8-hour median values 0.1 – 1 ppm) and for professional drivers and garage
mechanics (< 1 ppm, 4 hours). The general public is exposed mostly while putting
gasoline in their cars (3 – 10 ppm, 2 minutes) and driving (0.002 – 0.02 ppm per
hour) (36). Drinking water may be a further source of exposure: in some parts of
the United States low concentrations of MTBE (ng/liter) have been detected in
groundwater following leakage from gasoline storage tanks (28).
It has been estimated that uptake of MTBE by people who are occupationally
exposed to gasoline or MTBE in air is 0.1 to 1.0 mg/kg body weight/day, and that
uptake for people not occupationally exposed (uptake from the general environment)
is 0.0004 to 0.006 mg/kg body weight/day (14). These estimates are based on a
collation of analyses and occupational exposure data collected in the United States.
Uptake, biotransformation, distribution, excretion
Uptake
In studies with volunteers, uptake of MTBE has been reported to be 32 to 42% of
amount inhaled with exposures to concentrations ranging from 5 ppm to 75 ppm for
two to four hours of rest or light physical labor (0 – 50 W) (52, 55). There are no
quantitative data on human uptake via skin or digestive tract.
In rats, uptake from the digestive tract is rapid and complete, whereas skin uptake
is limited (44). Absorption via the lungs is also rapid, and MTBE concentrations in
blood reach a plateau about 2 hours after the start of exposure to low levels (400
ppm) as well as high ones (8000 ppm).
Biotransformation
MTBE is metabolized by oxidative dealkylation to tert-butyl alcohol (TBA) and
formaldehyde. TBA and MTBE have been detected in human blood and urine (17,
46, 52, 55, 57). In addition, a -hydroxyisobutyric acid and 2-methyl-1,2-
propanediol have been identified in the urine of persons exposed by inhalation to 50
ppm  1,2-13C-labeled MTBE for two hours (n = 4) (53) and after oral intake of 5
mg/kg 13C-labeled TBA (n = 1) (7).
Rat liver microsomes biotransform MTBE to TBA (13) and the TBA to formal-
dehyde (20). TBA was found in the blood of rats exposed to 14C-labeled MTBE
(44). Four other metabolites have been found in urine, and two of them have been
identified as a -hydroxyisobutyric acid (70% of total excreted radioactivity) and 2-
methyl-1,2-propanediol (14%). The three main metabolites found in the urine of
rats after 6 hours of exposure to 2000 ppm 2-13C-labeled MTBE were a -hydroxyi-
sobutyric acid, 2-methyl-1,2-propanediol and an unidentified conjugate of TBA (7).
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Fig 1. Proposed metabolism pathways for MTBE (rats) (28).
Low concentrations of TBA, TBA conjugate (possibly a glucuronide) and acetone
were also found. Rats exposed to 14C-labeled TBA excreted the isotope in acetone
and carbon dioxide (5). Figure 1 shows the proposed pathways for metabolism of
MTBE in rats.
MTBE activates UDP-glucuronosyltransferase and the cytochrome P-450 system
(isoenzymes 2B1, 2A6 and 2E1) in liver microsomes from both rats and humans
(13, 30, 63, 66). Hong et al. (29) measured the metabolic activity (formation of
TBA) in microsomes in various organs in male rats and found much higher activity
in nasal mucosa than in liver.
Distribution
The olive oil/blood distribution coefficient for MTBE is 7 to 10, which indicates that
the substance, like many other solvents, has a greater affinity for fatty tissue than
for blood (12, 51). For TBA, distribution coefficients are 0.27 for oil/water and
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0.36 for oil/blood, indicating that in the body this metabolite tends to stay in body
fluids.
When volunteers were exposed to MTBE in a closed chamber (5 – 75 ppm, 2 – 4
hours, 0 – 50 W), concentrations of MTBE in blood rose rapidly at first and leveled
out toward the end of the exposure period (17, 52, 55, 57). As soon as exposure
was terminated blood levels of MTBE began to drop rapidly, and two to three hours
later concentrations were down to about 1/10 of maximum levels. In contrast, the
concentration of TBA in blood increased slowly and reached a plateau after expo-
sure was ended (52, 55, 57). TBA in blood began to drop two to four hours after
termination of exposure, and then dropped more slowly than MTBE: 24 hours after
the exposure blood levels of TBA were about a third of peak levels. Concentrations
of MTBE and TBA in blood were proportional to exposure levels, which suggests
linear kinetics, i.e. metabolism is not saturated at the tested concentrations (up to
75 ppm for humans) (52, 55).
MTBE and TBA in the blood of rats also exhibited linear kinetics after inhalation
of 50, 100 or 300 ppm MTBE for 2 weeks (63).
Excretion
In the 24 hours following the volunteers’ exposure in the chamber, 32 to 58% of
the MTBE taken up was eliminated unchanged in exhaled air (52, 55) and about 1%
as MTBE or TBA in urine (15, 52, 55, 57).
Excretion of 14C-labeled MTBE by rats was rapid and independent of sex or
method of administration. Most of the radioactivity was excreted within 3 hours via
lungs and within 24 hours via urine (44). After intravenous administration of 14C-
labeled MTBE (40 mg/kg body weight), 60% of the radioactivity was eliminated via
lungs, 35% in urine and 2% in feces, and 0.4% remained in tissues. With increas-
ing doses of MTBE the proportion in urine decreased and the proportion in exhaled
air increased (this was seen primarily with inhalation exposures, but also with oral
doses). The shift in excretion pathways suggests that one or more of the stages in
metabolism of the substance tends to become saturated at high exposures
(8000 ppm and 400 mg/kg).
In another study, mice were give MTBE by intraperitoneal injection (50, 100 or
500 mg/kg), and 23 to 69% of the dose was eliminated unchanged in exhaled air –
most of this (90%) within three hours (70).
Toxic effects
Human data
Healthy volunteers were exposed to MTBE under controlled conditions in a
chamber: levels were chosen to approximate non-occupational exposure while
putting gasoline in a vehicle (0 – 1.7 ppm) (17, 57) and occupational exposure (0 –
75 ppm) (52, 54, 55, 60).
Prah et al (57) exposed healthy men and women (n = 37) to pure air or to
1.4 ppm MTBE for 1 hour (resting). Before and after the exposures, the subjects
filled in questionnaires and were given objective tests: eye exams (redness, ”tear
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film breakup time”) and analysis for inflammation markers in nasal lavage fluid and
tears. The only significant result observed was a difference in the assessments of air
quality: the women reported that the air smelled better under control conditions than
during the MTBE exposure.
A corresponding study was made by Cain et al (17): 43 healthy volunteers were
exposed to pure air or to air containing 1.7 ppm MTBE or 7.1 ppm VOC (a mixture
of 17 organic chemicals) for 1 hour (resting). They made subjective assessments
(eye or throat irritation, headache, feelings of grogginess or light-headedness, air
quality etc.) and took a computerized performance test, and objective examinations
(described above for the previous study) were made before and after the exposures.
No acute effects could be related to the MTBE exposure, although the subjects did
notice the difference in the odors.
In a Swedish study, ten healthy men were exposed to 5, 25 or 50 ppm MTBE for
2 hours (light physical work; 50 W) (54). Subjective assessments (odor, breathing
difficulty, headache, fatigue, nausea, dizziness, grogginess or irritation of eyes,
nose or throat) and objective examinations of the eyes (redness, ”tear film breakup
time”, damage to conjunctival epithelia, blinking frequency) and nasal mucosa
(nasal congestion and inflammation markers in nasal lavage fluid) were made before
and after the exposures. Estimates of the odor were significantly higher when the
subjects first entered the chamber, but declined as exposure progressed. A slight
nasal swelling was noted after the exposures, but the effect was not dose-related
and probably not related to the exposure to MTBE.
In a Finnish study, 13 subjects were exposed to 0, 25 or 75 ppm MTBE for 4
hours (resting) (60). Symptoms and other effects were assessed, and reaction times
and balance were tested during the exposures (after 1 and 3 hours) and 1 hour
afterward. The frequency of symptoms increased with level and duration of expo-
sure. At the highest level (75 ppm) and after 3 hours of exposure, there was a
significant increase in reports of minor symptoms such as grogginess, and also to a
lesser extent irritation of mucous membranes. Most of the symptoms had dis-
appeared when assessments were made one hour after exposure was terminated.
Six of the 13 persons reported MTBE-related symptoms. No effects related to the
exposures were noted in the tests of balance and reaction time.
In the United States, several field studies and epidemiological studies have been
made in which subjective assessments of effects were compared with exposures (4,
26, 28, 45, 46, 68). In Fairbanks, Alaska, 18 persons exposed to gasoline were
given blood tests and filled in questionnaires: the reported frequencies of the
following symptoms: headache, eye irritation, irritation of nose and throat,
coughing, nausea, dizziness, disorientation, ranged from 33 to 72% (46). Measured
MTBE  levels were 0.02 m M in blood and 0.1 ppm in air (8-hour average). A
follow-up study was made three months later, when MTBE was not added to
gasoline. At that time the frequencies of the symptoms ranged from 0 to 7% among
those exposed to the gasoline (n = 28). Measured MTBE levels on that occasion
were 0.003 m M in blood and 0.04 ppm in air (8-hour average). Other studies (4,
26, 28, 45, 46, 48) have found no connection between MTBE exposure and
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subjective assessments of acute symptoms. The Fairbanks study has been criticized
on the grounds that a number of external factors – odor, increase in gasoline price,
winter climate, media coverage etc. – may have influenced the persons reporting the
symptoms (24, 28, 67).
Vojdani et al (69) compared 32 unexposed subjects with 60 persons who had
been exposed to water containing MTBE (0.0036 – 0.27 m g/liter) and benzene
(0.00064 – 0.045 m g/liter) for 5 to 8 years (the analysis method is not described).
The proportion of apoptosis (programmed cell death) observed in the lymphocytes
of exposed persons (in vitro) was significantly higher than that in the controls. Cell
cycle progressions were determined, and the persons who had elevated apoptosis
had more cells in the DNA synthesis or mitosis phase than in the resting phase
(compared with controls). It is not clear how this applies to risk assessment, but
according to the authors these cellular deviations may be due to exposure to MTBE
or benzene or their metabolites or to a synergistic effect of MTBE and benzene.
MTBE is sometimes used to dissolve gallstones. It is introduced into the
gallbladder via a catheter, and the procedure is repeated as often as necessary. Acute
effects – nausea, vomiting, drowsiness, mild inflammation of intestinal mucosa,
etc. – have been reported. Accidental leakage has occurred during a few treatments,
and has resulted in lethargy, hemolysis, low blood pressure, kidney failure and
stomach ulcers (31, 34, 56, 65).
Animal data
The acute toxicity of MTBE is low to moderate. For mice, the LD50 is 4000 mg/kg
(37) and the LC50 for inhalation exposure (15 minutes) has been determined to be
39,000 ppm (40).
Rats were given oral doses of MTBE daily for 14 days (357, 714, 1071 or
1428 mg/kg body weight) or 90 days (100, 300, 900 or 1200 mg/kg) (61).
Anesthesia was observed at doses of 1200 mg/kg and above, and lasted for
2 hours, but then disappeared entirely. Diarrhea was common in all treatment
groups, but there were no deaths. Animals in the 14-day study had reduced lung
weights and the females had lower urea and creatinine levels in their blood, whereas
cholesterol was elevated in both sexes. In the 90-day study there was an increase of
cholesterol in blood, but blood urea (females) and creatinine (males) dropped.
Organs were unchanged, except for accumulation of a 2u-globulin in the kidneys of
males in the high-dose group (1200 mg/kg), which is a known and specific effect in
male rats.
In a long-term study, rats were exposed for 24 months and mice for 18 months to
0, 400, 3000 or 8000 ppm MTBE (6 hours/day, 5 days/week) (11). Toxicity was
observed at the two higher dose levels. At 8000 ppm there were clinical indications
of effects on the central nervous system (eyelid tics, reduced activity, ataxia and
deterioration of reflex movements). The rats showed these effects for up to a week
after the start of exposure, but in the mice the effects continued throughout the
study. In addition, there were changes in body weights and organ weights in both
species, and the males had shorter life spans. No exposure-related hematologic
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changes were observed, but there were lowered corticosterone levels in the male
rats exposed to 8000 ppm. Liver and kidney weights were higher in rats exposed to
3000 and 8000 ppm, but this was not accompanied by any histopathological
changes.
The occurrence of neurotoxicity was examined in rats after exposure to MTBE
concentrations of 0, 800, 4000 or 8000 ppm for 6 hours or 13 weeks (23). In the
6-hour study, there were indications of an acute reversible effect on the central
nervous system (ataxia, changes in respiratory rate and movement patterns, and loss
of gripping strength in hind legs) for up to an hour after the exposure to 8000 ppm
and to a lesser extent after the 4000 ppm exposure as well. In the 13-week study,
examinations were made 42 to 50 hours after the last exposure day and no effects
on the nervous system were observed.
In a 13-week inhalation study (0, 800, 4000 or 8000 ppm) increases in liver,
adrenal and kidney weights were noted in rats (both sexes) at the two higher
exposure levels (35). At the highest level the rats had lower body weights and poor
coordination (the first 4 weeks), and the males also had slight histopathological
changes in spleen, kidneys and lymph nodes.
In another inhalation study (0, 400, 1500 or 3000 ppm MTBE, 6 hours/day,
10 days) male rats in the highest exposure group had elevated concentrations of
a 2u -globulin (58). Necrosis and protein droplet accumulation were observed in
renal collecting ducts at 1500 ppm.
Mice were exposed to MTBE concentrations of 83, 280, 830, 2800 or 8300 ppm
for 1 hour (64). In all but the highest dose group, respiratory rates dropped initially
but normalized after five to ten minutes of exposure. At 8300 ppm the respiratory
rate was lower during the entire exposure and did not return to normal until 15
minutes after the exposure was ended. The authors attribute this to both effects on
the respiratory passages and ”sensory irritation” (3). Analysis of cells in
bronchoalveolar lavage fluid showed no changes in this group.
To examine the question of whether MTBE causes tissue damage when used to
treat gallstones, MTBE was injected (2 ml/kg body weight) into etherized rats,
either through the vena cava to the central circulatory system  (n = 13), through a
peripheral vein (n = 10), or into the hepatic parenchyma (n = 22) (2). The study
demonstrated that MTBE is locally cytotoxic to tissues and causes severe and often
fatal lung damage when injected into the vena cava.
Mutagenicity, carcinogenicity, teratogenicity
Animal data
In a genotoxicity study, rats were exposed to 800, 4000 or 8000 ppm MTBE 6
hours/day for 5 days and mice to 400, 3000 or 8000 ppm MTBE 6 hours/day for 2
days (41). In another study, mice were given injections of MTBE in single doses of
0.25, 0.5, 1, 1.5 or 1.75 g/kg body weight (32). Samples of bone marrow were
taken from the femurs 6, 24 or 48 hours after the exposures (41) or 24 hours after
the injections (32). No changes were noted in either chromosome aberrations in
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bone marrow of the rats or number of micronuclei in the mice. MTBE did not
induce DNA repair in liver cells of mice (41) or rats (exposures not given) (21). No
mutagenicity was observed in the sex-linked recessive lethal test with Drosophila
after administration of 0.01 – 0.3% MTBE in food (41).
MTBE was negative (i.e. no point mutations) in Ames tests (21, 32). It caused no
gene mutations in V79 cells from Chinese hamsters, either with or without the
addition of liver fraction (S9 mix); however, the survival of the cells was lower in
the presence of the S9 mix (21). In one of the studies (32) some toxicity was
observed at the highest dose (7400 m g MTBE).
The study above was repeated (21), and this time the mutagenicity of MTBE was
tested with the addition of formaldehyde dehydrogenase and its cofactor NAD+
(39). A linear increase of mutation frequency and a reduction of cell proliferation
were observed without the enzyme system, but when the system was added the
effect was reduced. The authors regard this as an indication that the metabolite
formaldehyde may affect the mutagenicity of MTBE.
In an inhalation study, rats were exposed  for 24 months and mice for 18 months
to 0, 400, 3000 or 8000 ppm MTBE (6 hours/day, 5 days/week). The two higher
concentrations had toxic effects (11). At 8000 ppm there was an increase in the
number of hepatocellular adenomas in the female mice. This observation was
followed up with another study, with exposures for 5 or 28 days at the same levels,
and a significant increase of cell proliferation in the livers of female mice was seen
after 5 days of exposure, but not after 28 days. The authors regard this as an
indication that MTBE induces mitogenesis. Male rats were killed before the end of
the study (8000 ppm – week 82; 3000 ppm – week 97) because so many of them
were dying of advanced nephrosis. At the end of the study an elevated prevalence of
chronic nephropathy was observed in male rats in all exposure groups and in
females  in the two higher groups. The nephropathy was associated with secondary
organ damage to cell growth in the parathyroid and a mineralization of tissues.
Kidney tumors (renal tubular cell tumors) were seen in males in the two higher
exposure groups. The authors (11) suggest that this may be associated with the
accumulation of a protein in the epithelium of the renal tubules (observed after as
little as 4 weeks of exposure) and may be an effect similar to or analogous to a 2u-
globulin (42). The high mortality of both mice and rats indicates, according to the
authors, that at the highest exposure level (8000 ppm) the maximum tolerable dose
had been exceeded.
In a long-term study, rats were given MTBE in oral doses of 0, 250 or 1000
mg/kg body weight, 4 days/week for 104 weeks (6). Survival after 80 weeks of
exposure was higher in the high-dose group than in the controls or the low-dose
group (males), though there were more testicular (Leydig cell) tumors in this group
(controls 8%, low-dose group 8%, high-dose group 34%, calculated from the
number of rats still living week 96, when the first tumor was discovered). Leydig
cell tumors are quite common in control material (42), which suggests that the
reported increase (6) may be random. For females there was a dose-related increase
in mortality from week 32 onward. Increases of leukemia and lymphoma were seen
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in females (combined leukemia and lymphoma: controls 3%, low-dose group 12%,
high-dose group 25%, calculated from the number of living rats week 56, when the
first leukemia was discovered). The authors point out that some fluctuation was
expected, since up to 10% of their historical controls (females) had developed
neoplasias, but the increase in the high-dose group was significant in comparison
with these earlier controls as well. Despite the fact that the combined incidence of
these two tumor types (leukemia and lymphoma) was significantly elevated, the
results for the neoplasias were not presented separately (42).
No DNA–protein cross-links or RNA-formaldehyde adducts were observed in
mouse liver cells in vitro after incubation with MTBE (19). However, incubation
with formaldehyde yielded a concentration-dependent increase in the number of
cross-links and adducts. According to the authors, this shows that the formation of
formaldehyde from MTBE is slower than other endogenic metabolism, and
indicates that metabolism of MTBE to formaldehyde does not make a critical
contribution to MTBE’s carcinogenicity in mice.
No treatment-related teratogenicity was observed in rabbits exposed to MTBE, up to
8000 ppm, for 6 hours/day on days 6 to 18 of gestation (9).
Mice exposed to 4000 or 8000 ppm MTBE for 6 hours/day on days 6 to 15 of
gestation  showed reduced activity, suppressed reflexes and changes in gestation;
the effects were not seen at exposure to 0 or 1000 ppm (9).
Mice and rats were exposed to MTBE for 6 hours/day on days 6 to 15 of gesta-
tion (0, 250, 1000 or 2500 ppm): no toxic effects were observed in the mothers or
in the fetuses, or on reproduction (22).
No reproduction toxicity was observed in two generations of rats after 10 weeks
of exposure to MTBE in concentrations of 0, 400, 3000 or 8000 ppm (8).
In a one-generation study, rats were exposed to 300, 1300 or 3400 ppm MTBE –
males for 12 weeks before mating, and females for 3 weeks (10). Exposures
continued during gestation and nursing, and two litters were born. No effects on
reproduction were observed. The only observed effect was a widened renal pelvis
in the females exposed to 300 and 3400 ppm.
Moser et al (49) exposed female mice to air containing 7800 ppm MTBE or
2000 ppm gasoline (containing no MTBE) for 3 or 21 days (6 hours/day, 5 days/
week). Elevated liver weights and reduced uterus weights were observed in all
exposure groups. When mice were given the substances by gavage (1800 mg/kg
MTBE or gasoline, 3 days) the metabolism of estrogen in isolated hepatocytes
increased. The authors suggest that the increase of estrogen metabolism in the liver
and reduction of uterus weight may indicate an endocrine modulation in both
MTBE-induced and gasoline-induced liver carcinogenesis. In a follow-up study it
was observed that exposure to MTBE (8000 ppm, 3 or 21 days, 4 or 8 months,
female mice) elicits a response in some cells and tissues of the endocrine system,
and that these effects are not activated through the estrogen receptor (47).
Female mice 12 days of age were initiated with either N-nitrosodiethylamine
(7.1 ml DEN/kg body weight) or a saline solution, and exposed to 0 or 8000 ppm
MTBE for 16 or 32 weeks (48). Elevated liver weights and increased microsomal
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cytochrome P-450 activity in liver were seen, but no toxicity was observed. The
MTBE exposure did not increase the size or volume fraction of liver foci compared
with DEN-initiated controls. According to the authors, the absence of tumor forma-
tion in the DEN-initiated female mice exposed to MTBE was unexpected, and
indicates that MTBE does not produce liver tumors by the same mechanism as
gasoline.The genotoxicity, mutagenicity and carcinogenicity of MTBE in
experimental animals have also been assessed with a predictive (structure-activity)
computer program, which gave no indications of genotoxic, mutagenic or
carcinogenic activity (62, 71).
Dose-effect/dose-response relationships
Human data
No clear dose-effect relationship has been found in epidemiological studies. In
experimental studies, no effect has been observed at concentrations below 50 ppm
(questionnaires and objective measures of eye and nose irritation) (17, 54, 57).
After 3 hours of exposure to 75 ppm (n = 13) there was a significant increase of
minor symptoms such as grogginess and irritated mucous membranes (60).
Animal data
The estimated NOAEL for rats is 1000 ppm, and the LOAEL is 1500 ppm, since
effects on kidneys are seen at that level. Mice had reduced respiratory rates for the
first 5 to 10 minutes of exposure to 83 ppm, and this level was therefore taken to be
the LOAEL for mice. Dose-effect relationships observed in inhalation studies with
animals are summarized in Table 1.
Conclusions
The critical effect of occupational exposure to MTBE is judged to be irritation of
mucous membranes.
In a study with volunteers, grogginess and irritation of mucous membranes were
reported at exposure to 75 ppm. In another study, no irritation or other effect was
seen at 50 ppm.
Liver tumors have been observed in female mice, and renal and testicular tumors
in male rats, after exposure to high concentrations of MTBE.
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Table 1. Dose-effect relationships observed in experimental animals exposed to
MTBE by inhalation (6 hours/day, 5 days/week)
Species, exposure Observed effects Ref.
Rabbit
1000 ppm
   days 6-18 of gestation
No observed effects. 9
4000 ppm
   days 6-18 of gestation
Lower body weights and food consumption. 9
8000 ppm
   days 6-18 of gestation
Lower body weights and relative liver weights, lower food
consumption.
9
Rat
250 ppm
   days 6-15 of gestation
No observed effects. 22
400 ppm
   10 days or 4 weeks
No observed effects. 11, 58
400 ppm
   10 weeks or
   24 months
No observed effects 8, 11
800 ppm
   6 hours or 13 weeks
No observed neurotoxic effects 23
800 ppm
   13 weeks
No observed effects 35
1000 ppm
   days 6-15 of gestation
No observed effects 22
1500 ppm
   10 days
Necrosis and protein droplet accumulation in renal
collecting ducts (males).
58
2500 ppm
   days 6-15 of gestation
No observed effects. 22
3000 ppm
   10 days
Necrosis and protein droplet accumulation in renal
collecting ducts, increased a 2u-globulin concentration in
kidneys (males).
58
3000 ppm
   4 weeks
Cell proliferation in kidneys on days 5 and 28 (males) 11
3000 ppm
   10 weeks
F1: reduced activity, depressed reflexes, elevated liver
weights; no histopathological changes.
8
3000 ppm
   24 months
Renal tumors (males); elevated kidney and liver weights
(both sexes)
11
4000 ppm
   6 hours
CNS effects (ataxia, changes in respiratory rate and
movement patterns, reduced grip strength in hind legs) for
up to 1 hour after exposure
23
2500 ppm
   days 6-15 of gestation
No observed effects 22
3000 ppm
   10 days
Necrosis and protein droplet accumulation in renal
collecting ducts, increased a 2u-globulin concentration in
kidneys (males)
58
3000 ppm
   4 weeks
Cell proliferation in kidneys on days 5 and 28 (males) 11
3000 ppm
   10 weeks
F1: reduced  activity, depressed reflexes, elevated liver
weights; no histopathological changes.
 8
3000 ppm
   24 months
Renal tumors (males) and elevated kidney and liver weights
(both sexes).
11
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Table 1. Continued
Species, exposure Observed effects Ref.
4000 ppm
   6 hours
CNS effects (ataxia, changes in respiratory rate and
movement patterns, reduced grip strength in hind legs) for
up to 1 hour after exposure.
23
4000 ppm
   13 weeks
No observed neurotoxic effects. 23
4000 ppm
   13 weeks
Elevated liver, adrenal and kidney weights 35
8000 ppm
   6 hours
CNS effects (ataxia, changes in respiratory rate and
movement patterns, reduced grip strength in hind legs) for
up to 1 hour after exposure.
23
8000 ppm
   13 weeks
No observed neurotoxic effects. 23
8000 ppm
   10 weeks
F1: lower body weights, reduced activity, depressed
reflexes, ataxia and elevated liver weights, but no
histopathological findings.
F2: elevated mortality 4 days after birth
 8
8000 ppm
   13 weeks
Lower body weights, poor coordination (first 4 weeks);
elevated liver, adrenal and kidney weights. Slight
histopathological changes in spleen, kidneys and lymph
nodes (males).
35
8000 ppm
   4 weeks
Cell proliferation in kidneys on day 28 (males). Weight
loss.
11
8000 ppm
   24 months
Renal tumors, elevated mortality and reduced body weights
(males). CNS effects during first week of exposure.
Elevated kidney and liver weights (both sexes).
11
Mouse
83 ppm
   1 hour
Temporary reduction in respiratory rate (13%). 64
250 ppm
   days 6-15 of gestation
No observed effects. 22
280 ppm
   1 hour
Temporary reduction in respiratory rate (17%). 64
400 ppm
   4 weeks or 18 months
No observed effects. 11
830 ppm
   1 hour
Temporary reduction in respiratory rate (28%). 64
1000 ppm
   days 6-15 of gestation
No observed effects.  9
2500 ppm
  days 6-15 of gestation
No observed effects. 22
2800 ppm
   1 hour
Temporary reduction in respiratory rate (35%). 64
3000 ppm
   4 weeks
No observed effects. 11
3000 ppm
   18 months
Elevated kidney weights (males) and liver weights, reduced
brain weights.
11
4000  ppm
   days 6-15 of gestation
Reduced activity, suppressed reflexes. Effects on gestation
(fetal body weight/litter, skeletal anomalies).
9
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Table 1. Continued
Species, exposure Observed effects Ref.
8000 ppm
   days 6-15 of gestation
Reduced body weights,  activity and food consumption;
suppressed reflexes. Effects on gestation (post-implantation
damage, fewer males born, fetal body weight/litter, skeletal
anomalies).
9
8000 ppm
   4 weeks
Cell proliferation in livers (females) on day 5, disappeared
by day 28.
11
8000 ppm
   18 months
Hepatic adenomas (females); elevated kidney weights
(males), elevated mortality (males). Elevated liver weight,
reduced body, brain and spleen weights, CNS effects during
first week of exposure (both sexes).
11
8300 ppm
   1 hour
Reduction in respiratory rate (52%); normal again 15
minutes after termination of exposure.
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Chemical and physical data. Uses
dimethyl adipate
CAS No.: 627-93-0
Synonyms: dimethyl hexanedioate, methyl adipate
Formula: C8H14O4
Structure: CH3-O-CO-CH2-CH2-CH2-CH2-CO-O-CH3
Molecular weight: 174.22
Boiling point: 231 ° C
Melting point: 10.3 ° C
Vapor pressure: 0.0016 kPa (20 ° C)
Conversion factors: 1 ppm = 7.23 mg/m3 (20 ° C)
1 mg/m3 = 0.138 ppm (20 ° C)
dimethyl glutarate
CAS No.: 1119-40-0
Synonyms: dimethyl pentanedioate, methyl glutarate
Formula: C7H12O4
Structure: CH3-O-CO-CH2-CH2-CH2-CO-O-CH3
Molecular weight: 160.17
Boiling point: 214 ° C
Melting point: - 42.5 ° C
Vapor pressure: 0.0061 kPa (20 ° C)
Conversion factors: 1 ppm = 6.65 mg/m3 (20 ° C)
1 mg/m3 = 0.150 ppm (20 ° C)
dimethyl succinate
CAS No.: 106-65-0
Synonyms: dimethyl butanedioate, methyl succinate
Formula: C6H10O4
Structure: CH3-O-CO-CH2-CH2-CO-O-CH3
Molecular weight: 146.14
Boiling point: 196.4 ° C
Melting point: 19 ° C
Vapor pressure: 0.0167 kPa (20 ° C)
Conversion factors: 1 ppm = 6.06 mg/m3 (20 ° C)
1 mg/m3 = 0.165 ppm (20 ° C)
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Dimethyl adipate (DMA), dimethyl glutarate (DMG) and dimethyl succinate (DMS)
usually occur together. The mixtures are a clear liquid (1). DMA, DMG and DMS
are soluble in substances such as ethanol and ether (13). Solubility in water has
been reported to be 29.9 g/l (20 ° C) for DMA and 131 g/l (25 ° C) for DMS (7).
Product information leaflets state that the water solubility of mixtures containing >
55% DMG, >15% DMS and > 10% DMA is 5 to 5.5% by weight (20 ° C), and that
the vapor pressure is 0.013 kPa.
Mixtures of DMA, DMG and DMS are used as solvents. The mixtures are used
industrially in paints and coatings, and also for paint removal and for cleaning
polyurethane foam and unsaturated polyester resin (22).
DMS is also used in the cosmetics and food processing industries. It occurs, for
example, as a flavoring in ice cream, candy, bakery products and drinks (2).
Uptake, biotransformation, excretion
There is little information in the literature on oral uptake of either DMA, DMG or
DMS. In one study with rats (16), it was shown that DMS was rapidly absorbed in
the digestive tract. There are no quantitative data on skin uptake for any of the three
esters.
Nearly all of inhaled DMA, DMG and DMS is deposited in the upper respiratory
passages. In one study (19), rats were exposed (one-way air flow) for 40 minutes
to 50 –100 mg/m3 DMA, DMG and DMS vapors, either separately or mixed, or to
250 – 320 mg/m3 DMG vapor. It was found that deposition in the upper respiratory
passages exceeded 97% in all cases – much the same for all three substances, both
sexes, and all air concentrations tested.
DMA, DMG and DMS are metabolized by hydrolysis and can form monomethyl
esters, dicarboxylic acids and methanol; this has been demonstrated in vitro with
homogenates, nasal explants and isolated cells (5, 19, 22, 29, 30). In rats, the
esters are efficiently hydrolyzed by carboxylesterase, mostly in the airways
(especially in olfactory epithelium) and liver (4, 5, 19, 22, 30). There is some
difference between males and females. In a comparative study, the efficiency of
hydrolysis to monomethyl esters was tested with low (“subsaturating”) substrate
concentrations of DMA, DMG and DMS in homogenates of olfactory epithelium
from female or male rats. Hydrolysis was equally effective in homogenates from
both sexes when DMG was used as substrate, whereas DMA was hydrolyzed more
effectively by the olfactory epithelium homogenate from females and DMS by that
from males. A structure-activity relationship was also observed in the hydrolysis
reactions: DMA > DMG > DMS (5).
The activity of carboxylesterase in olfactory epithelium from humans (hydrolysis
of DBE in 3/6 samples) was reported in an abstract to be 100 to 1000 times lower
than that of rats (9). (DBE = dibasic esters, i.e. DMA, DMG and DMS.)
Glutaric acid (a metabolite of DMG) is one of the body’s natural components. It
is formed in metabolism of the amino acid lysine (8). Malic acid (a metabolite of
DMS) also occurs naturally in the body’s general metabolism. It is a component, for
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example, of the energy-producing Krebs cycle, which yields the end products
carbon dioxide and water (8, 14, 29). Increased synthesis of proinsulin and
increased insulin secretion have been shown to follow administration of DMS, and
are ascribed primarily to an influx of malic acid to the Krebs cycle in the pancreatic
islets (isles of Langerhans) (15, 17, 18, 30).
Toxic effects
Human data
Product information leaflets from suppliers/manufacturers report that temporary
effects on vision (foggy vision) may occur after exposure to mixtures of DMG,
DMS and DMA. No air concentrations are given, but it is stated that the problem
had occurred at exposure to “high” concentrations of vapor or after direct contact
with the eyes (product mixtures containing > 55% DMG, > 15% DMS and > 10%
DMA). The product information leaflets also warn that inhalation of “high”
concentrations of the vapors can irritate respiratory passages.
Animal data
The LD50 for rats given DMA by intraperitoneal injection is reported in one study
(21) to be 1.9 g/kg.
Mice were exposed by inhalation to various concentrations of DMA, DMG and
DMS, either separately or in mixtures, and their respiratory rates were measured
(mixture 1: 63% DMG, 25% DMS, 12% DMA; mixture 2: 57% DMG, 23% DMS,
20% DMA). The data were used to calculate the concentration that caused a 50%
decrease in respiratory rate (RD50), which is a measure of the irritation potential of a
substance. The RD50 was reported to be 890 mg/m3 for DMG, 910 mg/m3 for
DMA, 1600 mg/m3 for DMS, 590 mg/m3 for mixture 1 and 610 mg/m3 for mixture
2. DMS appeared to be the least potent of the three esters but was reported to have
the steepest dose-response curve (20).
In an inhalation study (12), male rats were exposed to a vapor-aerosol DBE mixture
(90% aerosol) generated from a liquid that was 66% DMG, 17% DMS and 17%
DMA. The animals were exposed for 4 hours to an average aerosol concentration of
5900 mg/m3 and sacrificed at intervals of 1 to 42 days after the exposure. Damage
(degeneration, inflammation, necrosis), which was largely reversible within 6 weeks,
was seen in nasal mucosa exposed to air flow. Severe necrosis was noted in olfactory
epithelial cells in the anterior portion of the nasal cavity, for example (these cells did
not recover within 6 weeks), whereas the damage further back was lighter and more
limited. The cells that were most sensitive and affected first were the sustenacular cells
(which support the olfactory epithelium).
In another inhalation study, male and female rats were exposed to DBE vapors
generated from a liquid mixture of 67% DMG, 17% DMS and 17% DMA, 6 hours/
day, 5 days/week for up to 13 weeks. Concentrations were 390, 76 or 20 mg/m3.
After seven weeks, animals in the two higher dose groups (both sexes) showed
dose-dependent degeneration (minimal to mild) of olfactory epithelium in the nasal
cavities. After 13 weeks of exposure, minimal to moderate degenerative changes
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were observed in the nasal cavities (olfactory epithelium) of females at all dose
levels and males at the two higher dose levels. The damage was characterized by
initial cell death and loss of sustenacular and sensory cells. After an exposure-free
period of 6 weeks there were indications that the damaged tissue was regenerating.
At the highest dose level there were negative effects on weight gain and lower liver
weights in the females (reversible changes) (10).
In a reproduction study (1), female rats were exposed for 6 hours/day during
gestation to 990 mg/m3 vapor/aerosol (about 40/60), or to 380 or 150 mg/m3 vapor
of a DBE mixture (65% DMG, 18% DMS, 17% DMA). Somewhat reduced abso-
lute liver weights were observed in all dose groups (trend, not significant). Animals
in the two higher dose groups had reduced food intake during the first 6 days and
reduced growth. In another reproduction study, male and female rats (parent
generation) were exposed 6 hours/day before, during and after gestation (a total of
about 22 weeks) to 1000 mg/m3 vapor/aerosol or 400 or 160 mg/m3 vapor
generated from an identical DBE mixture (65% DMG, 18% DMS, 17% DMA) (11).
From week 7 onward, both males and females in the highest dose group gained
weight more slowly. When the animals were killed, however, significantly lower
body weights were noted only in females in the highest dose group. Some organ
weights were also significantly different in the high-dose group, especially among
the females. Liver weights were significantly lower in males (relative liver weights
only) and females in both the high and medium dose groups. Histopathological
examination of nasal tissue revealed squamous cell metaplasias, especially in
olfactory epithelia. Their prevalence and severity increased with dose, and females
were more sensitive than males.
A dose-dependent cytotoxicity, expressed as increased leakage of acidic phospha-
tases, was observed when olfactory and respiratory epithelia from female rats were
incubated with DMA, DMG or DMS (10 – 100 mM). All three substances were
observed to have significant effects on the olfactory epithelium at concentrations of
25 mM and above, whereas effects on respiratory epithelium were not seen below
50 mM. The toxicity of DMA, DMG and DMS was shown to be dependent on a
carboxylesterase-mediated activation. Liberation of acidic phosphatases was
reduced when the animals were pre-treated with a carboxylesterase inhibitor (22).
No significant elevation of acidic phosphatases was observed when nasal explants
from rats were incubated with the metabolite methanol (100 mM) (22), but the
monomethyl esters and dicarboxylic acids produced by metabolism of DBE were
reported in another in vitro study (23) to stimulate liberation of acidic phosphatases
(in tests with 25 or 50 mM). A ranking of the monoesters for cytotoxic potency
yielded the result monomethyl adipate > monomethyl glutarate > monomethyl
succinate (23).
In a subsequent study (24), olfactory and respiratory epithelia from female rats
were examined under optical and electron microscopes after incubation with 10, 25
or 50 mM DMA. At the lowest dose level mild degenerative changes were noted in
the respiratory epithelium and more pronounced degenerative changes in the
sustenacular cells in olfactory epithelium. The two higher dose levels caused severe
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necrotic changes in both respiratory and olfactory epithelia. Respiratory epithelium
from animals that had been pre-treated with a carboxylesterase inhibitor showed less
severe damage after exposure to 50 mM DMA, but the changes in olfactory epithe-
lium from treated and untreated animals were the same.
A report from the chemical industry (25) describes several laboratory experiments
with a mixture of 63% DMG, 20% DMS and 17% DMA. Rabbits were exposed via
inhalation (about 15 or 60 ppm vapor for 4 hours), skin (50 or 200 m l) or eyes
(10 m l) and effects on eyes were examined. In one of the inhalation experiments
(15 ppm, 60 ppm) there was a dose-dependent increase in the incidence of slight
conjunctival irritation (slight chemosis: mild reddening). In another inhalation
experiment (60 ppm) there was also a single case of moderate irritation of the iris
with very slight corneal clouding. Putting the mixture directly into the eyes of the
rabbits produced indications of slightly stronger irritation (including slight
cloudiness of the cornea). In addition to these effects on the eyes, rabbits exposed
to 60 ppm in one of these inhalation experiments showed a slight but significant
(p < 0.05) increase in the depth of the anterior chamber of the eye 4 hours after
exposure, but not on the following day. A slight but significant increase in depth of
the anterior chamber was also observed 2 hours after treatment in the animals that
had the mixture applied to their skins (200 m l).
When fasting rats were given oral doses of 294 mg DMS (1,4-14C labeled) there
was a rapid rise in insulin and a drop in glucose concentration in plasma (16).
Another study reports a marked increase of plasma insulin within 2 minutes, but no
significant effect on blood glucose, when fasting rats were given DMS intra-
venously (146 mg/kg body weight) (26). Increased liberation of insulin has also
been observed in several in vitro studies when pancreatic islets from rats were
incubated with 10 mM DMS (3, 6, 15, 17).
Mutagenicity, carcinogenicity, effects on reproduction
DMS, either with or without addition of metabolizing systems, has shown no muta-
genic activity in studies with several strains of Salmonella typhimurium (2, 28). It is
reported in an abstract (27) that mutagenicity/chromosome damage did not occur in
tests using a mixture of DMG, DMS and DMA, either in bacteria in vitro or with
inhalation exposure of mice (micronucleus test). However, it was also reported that,
when high concentrations of the mixture were used, chromosome aberrations could
be demonstrated in human lymphocytes in vitro – especially lymphocytes from
women (significant at concentrations of 3.3 mg/ml and above) (27).
In a reproduction study (1), pregnant rats were exposed to a DBE mixture (65%
DMG, 18% DMS, 17% DMA) 6 hours/day on days 7 to 16 of gestation. Concen-
trations were 990 mg/m3 (vapor/aerosol, about 40/60), 380 or 150 mg/m3 (vapor).
No exposure-related effects on reproduction were observed (weight, malforma-
tions, number of corpora lutea, implantations, resorptions, living young). In
another reproduction study (11), male and female rats were exposed to the same
mixture (65% DMG, 18% DMS, 17% DMA) before, during and after gestation, a
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total of about 22 weeks. Concentrations were 1000 mg/m3 (vapor/aerosol), 400 or
160 mg/m3 (vapor). Animals in the parent generation were exposed 6 hours/day,
5 days/week before the breeding period (14 weeks), and thereafter 6 hours/day,
7 days/week during breeding, gestation (days 1 – 19) and nursing (days 4 – 21).
Body weights were significantly lower in pups in the high-dose group (p < 0.05) at
birth and at 21 days of age, and the mothers in this dose group also had lower body
weights. No other exposure-related effects (visible aberrations, deviations in organ
weights) were observed in fetuses/pups in any group, nor were there any observed
effects on other studied reproduction parameters (including fertility, length of
gestation, number of living fetuses, litter size, milk production).
In a study (21) in which DMA was given to rats by intraperitoneal injection on
days 5, 10 and 15 of gestation (64, 192, 384 or 640 mg/kg) there was a significant
increase of aberrations (including hemangiomas, skeletal anomalies) at the two
highest dose levels. No such effects were noted at the lowest dose level. This study
contains no information regarding effects on the mothers.
Table 1. Effects on experimental animals exposed by inhalation to DMA,
DMG and DMS, separately or in mixtures.
Exposure Species Effect Ref.
5900 mg/m3, 4 hours
66% DMG, 17% DMS, 17% DMA
Rat Damage to various kinds of cells in nasal
mucosa
 12
1600 mg/m3
DMS
Mouse 50% reduction in respiratory rate  20
1000 mg/m3
6 h/d, 5-7 d/w, 22 weeks
before, during and after gestation
65% DMG, 18% DMS, 17% DMA
Rat Somewhat lower weight gain, increased
relative lung and brain weights, lower
absolute spleen weight, lower absolute
and relative liver weight, minimal to
moderate squamous cell metaplasia in
olfactory and respiratory epithelia.
Pups: lower body weight.
 11
990 mg/m3
6 h/d, days 7-16 of gestation
65% DMG, 18% DMS, 17% DMA
Rat Somewhat lower absolute liver weight,
reduced growth
Fetuses: no exposure-related effects
  1
910 mg/m3
DMA
Mouse 50% decrease in respiratory rate  20
890 mg/m3
DMG
Mouse 50% decrease in respiratory rate  20
610 mg/m3
57% DMG, 23% DMS, 20% DMA
Mouse 50% decrease in respiratory rate  20
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Table 1. Continued
Exposure Species Effect Ref.
590 mg/m3
63% DMG, 25% DMS, 12% DMA
Mouse 50% decrease in respiratory rate  20
400 mg/m3
5-7 d/w, 22 weeks
before, during and after gestation
65% DMG, 18% DMS, 17% DMA
Rat Lower relative and absolute liver
weights, minimal to moderate squamous
cell metaplasia in olfactory epithelium
 11
390 mg/m3
6 h/d, 5 d/w, up to 13 weeks
67% DMG, 17% DMS, 17% DMA
Rat Minimal to moderate degeneration of
olfactory epithelium, lower weight gain,
lower liver weight
 10
380 mg/m3,
6 h/d, days 7-16 of gestation
65% DMG, 18% DMS, 17% DMA
Rat Somewhat lower absolute liver weight,
lower growth
Pups: no exposure-related effects
  1
160 mg/m3
6 h/d, 5-7 d/w, 22 weeks
before, during and after gestation
65% DMG, 18% DMS, 17% DMA
Rat Minimal to mild squamous cell
metaplasia in olfactory epithelium
 11
76 mg/m3
6 h/d, 5 d/w, up to 13 weeks
67% DMG 17% DMS, 17% DMA
Rat Minimal to mild degeneration of
olfactory epithelium
 10
20 mg/m3
6 h/d, 5 d/w, up to 13 weeks
67% DMG, 17% DMS, 17% DMA
Rat Minimal degeneration of olfactory
epithelium
 10
Dose-effect/dose-response relationships
There are no data from which to derive a dose-effect or dose-response relationship
for humans.
Effects on experimental animals exposed to DMA, DMG and/or DMS are
summarized in Table 1. Dose-dependent effects on olfactory epithelium have been
observed in rats exposed to a mixture of DMA, DMG and DMS in air
concentrations of 20 mg/m3 and higher.
Conclusions
There are no data from which to determine a critical effect of occupational exposure
to DMA, DMG and DMS. Judging from animal experiments, degeneration of
olfactory epithelium is the critical effect of exposure to mixtures of the three
substances.
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1,1,1-Trifluoroethane and
1,1,1,2,2-Pentafluoroethane
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Chemical and physical data. Uses
1,1,1-trifluoroethane
CAS No.: 420-46-2
Synonyms: methylfluoroform, HFC143a,
FC143a, R143a
Formula: CH3CF3
Molecular weight: 84.04
Boiling point: - 47.5 ° C
Melting point: - 111.3 ° C
Vapor pressure: 1267 kPa (25 ° C)
Conversion factors. 1 ppm = 3.49 mg/m3 (20 ° C)
1 mg/m3 = 0.287 ppm (20 ° C)
1,1,1,2,2-pentafluoroethane
CAS No.: 354-33-6
Synonyms: pentafluoroethane, HFC125,
FC125, HFA125, R125
Formula: CHF2CF3
Molecular weight: 120.02
Boiling point: - 48.5 ° C
Melting point: - 103 ° C
Vapor pressure: 1381 kPa (25 ° C)
Conversion factors: 1 ppm = 4.98 mg/m3 (20 ° C)
1 mg/m3 = 0.20 ppm (20 ° C)
1,1,1-Trifluoroethane at room temperature is a gas. It is combustible at air
concentrations of about 70,000 ppm or higher (2). It is reported to be soluble in
ethanol and chloroform (7). 1,1,1,2,2-Pentafluoroethane at room temperature is a
colorless, non-combustible gas with low solubility in water (0.97 g/liter) (4, 6).
Both substances are used in coolants/refrigerants. 1,1,1,2,2-Pentafluoroethane is
also used in fire extinguishers. In 1977, 77 tons of 1,1,1-trifluoroethane (in 5
products) and 104 tons of 1,1,1,2,2-pentafluoroethane (in 16 products) were used
in Sweden (product register, National Chemicals Inspectorate).
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Uptake, biotransformation, excretion
No studies on the metabolism of 1,1,1-trifluoroethane were found.
The metabolism of 1,1,1,2,2-pentafluoroethane has been studied in experiments
with rats. In one study, rats were exposed to up to 50,000 ppm pentafluoroethane
6 hours/day, 5 days/week for 4 or 13 weeks, and it is reported that no increase of
fluoride concentration was found in either plasma or urine (6). In another study (5)
rats were exposed to 9700 ppm pentafluoroethane for 6 hours, and it was found that
the concentration of trifluoroacetic acid in urine was extremely low during the 12
hours immediately following the exposure (40 times lower than after exposure to
11,000 ppm halothane). Slight trifluoracetylation of protein was demonstrated in
liver homogenates from the exposed animals (using immunochemical methods).
These data suggest that metabolism of 1,1,1,2,2-pentafluoroethane by rats is
extremely limited. To the extent that metabolism does occur, it is effected by the
P450 system: the pentafluoroethane is probably transformed via a pentafluoroethyl
radical to pentafluoroethanol, which may subsequently eliminate hydrogen fluoride
and form trifluoroacetyl fluoride. The trifluoroacetyl fluoride may be hydrolyzed,
creating trifluoroacetic acid and more hydrogen fluoride. Trifluoroacetyl fluoride
can also eliminate fluoride and bind to protein (1, 3, 5).
The reported oil/gas distribution coefficient in vitro for 1,1,1,2,2-pentafluoro-
ethane is 7.3 (9). The reported octanol/water distribution coefficient for 1,1,1,2,2-
pentafluoroethane is 1.48 (4).
Toxicity
Human data
There is no information regarding effects of human health attributed to exposure to
either 1,1,1-trifluoroethane or 1,1,1,2,2-pentafluoroethane.
Animal data
Rats exposed for 4 hours to 540,000 or 97,000 ppm 1,1,1-trifluoroethane had
temporary, dose-dependent weight loss, but there were no deaths. Oxygen
concentration in the exposures was about 20% (2). Dogs were given intravenous
injections of adrenaline and exposed to 1,1,1-trifluoroethane for 10 minutes: a
tendency to cardiac arrhythmia was noted at an air concentration of 300,000 ppm
but not at 250,000 ppm or lower (2).
Rats exposed for 4 hours to 800,000 ppm 1,1,1,2,2-pentafluoroethane (20%
oxygen by volume) developed ataxia and labored breathing, and their reaction to
noise was impaired, but there were no deaths (6). When mice were exposed for six
hours to 600,000 ppm (same oxygen concentration), observed effects included low
activity, tremor and weight loss (6). When dogs were given intravenous injections
of adrenaline and exposed to 1,1,1,2,2-pentafluoroethane for 10 minutes, they
showed a tendency to cardiac arrhythmia at air concentrations of 100,000 ppm or
higher, but none of the dogs showed a positive response to an exposure of
75,000 ppm under the same conditions (6). Rats exposed to 50,000 ppm
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1,1,1,2,2-pentafluoroethane 6 hours/day during gestation had an unsteady gait
during the exposures. Rabbits exposed to 50,000 ppm 1,1,1,2,2-pentafluoroethane
6 hours/day during gestation had somewhat slower weight gain and lower feed
intake during the first few days of the exposure (6).
Rats were exposed to 1,1,1-trifluoroethane concentrations of 40,000, 10,000 or
2000 ppm 6 hours/day, 5 days/week for 4 weeks or 90 days. Exposures were either
“nose only” (4 weeks) or whole-body (4 weeks or 90 days). Clinical signs, body
weights, organ weights, hematology, biochemical blood analyses, urine analyses,
tissue morphology, b -oxidation activity in the liver and effects on the eyes were
studied. No treatment-related effects were seen in the animals after whole-body
exposure. Males that had been exposed “nose only” for 4 weeks, however, had
recurring weight loss (no change in food intake) and degenerative changes in testes
at all dose levels. The authors regarded this as a result of stress caused mostly by
extreme temperature conditions. No significant changes were noted in female rats
after “nose only” exposures (2).
In another study (6), rats were given whole-body exposures to 50,000, 15,000
or 5000 ppm 1,1,1,2,2- pentafluoroethane 6 hours/day, 5 days/week for 4 or 13
weeks, and sacrificed at termination of exposure or at intervals for up to 4 weeks
afterward. Clinical signs, body weights, organ weights, hematology, biochemical
blood analyses, urine analyses, tissue morphology, b -oxidation activity in the liver
and effects on eyes were studied. No treatment-related effects are reported.
Mutagenicity, carcinogenicity, effects on reproduction
One study (8) reports that 1,1,1-trifluoroethane had mutagenic effects on two of
four strains of Salmonella typhimurium when tested in vitro, both with and without
metabolic activation. Another study (2) reports that mutagenic effects could not be
observed when the substance was tested, either with or without addition of
metabolizing systems, on a total of six strains of Salmonella typhimurium and two
strains of E coli. In cell transformation tests on mammalian cells in vitro, 1,1,1-
trifluoroethane had no observed mutagenic effect (8). There was no significant
increase in chromosome aberrations when human lymphocytes were exposed to the
substance in vitro (2). Further, there was no significant increase of micronuclei in
bone marrow cells of mice that had been exposed to 40,000, 10,000 or 2000 ppm
1,1,1-trifluoroethane 6 hours/day for two days (2).
No mutagenic effect was observed when 1,1,1,2,2-pentafluoroethane was tested
in vitro, either with or without metabolic activation, on various strains of
Salmonella typhimurium and one strain of E coli (6, 8). In tests on mammalian cells
in vitro there was a statistically significant (p < 0.01) increase of cells with chromo-
some aberrations at cytotoxic doses and prolonged exposure times, but not at other
doses/exposure times (6). The occurrence of chromosome aberrations did not
increase when 1,1,1,2,2,-pentafluoroethane was tested on human lymphocytes in
vitro (6). Nor was there a significantly higher frequency of micronuclei in the bone
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marrow cells of mice exposed for 6 hours to 600,000, 120,000 or 24,000 ppm
1,1,1,2,2-pentafluoroethane (6).
In one study, a 3% solution of 1,1,1-trifluoroethane in corn oil was given to rats
(36 of each sex) by gavage in doses of 300 mg/kg body weight, 5 days/week for
52 weeks. The animals were killed on week 125, and routine histopathological
examinations of lungs, liver, spleen, kidneys and brain were made, and other
organs were also examined if they looked abnormal. Males had significantly lower
body weights from week 28 to week 88. No other exposure-related effects were
observed: there was no significant increase of cancer incidence in any organ, for
example (8). Shortcomings in the design of the experiment (limited histopatho-
logical examinations, brief exposure time, single dose level) make it difficult to
draw any definite conclusions from this study.
In a reproduction study (2), rats and rabbits were exposed to 40,000, 10,000
or 2,000 ppm 1,1,1-trifluoroethane 6 hours/day on days 6 – 15 (rats) or 6 – 18
(rabbits) of gestation. A slight but significant increase of visceral and skeletal
anomalies (due to retarded development) was observed in the rats, and a slight
increase of skeletal aberrations in the rabbits, but, considering the unusually low
incidence in the control groups and the lack of a clear dose-response relationship,
the effects were judged to be unrelated to the exposures. No significant differences
were reported for other reproduction parameters (pre- and post-implantation losses,
embryo/fetus deaths, fetus weights), and it was concluded that 1,1,1-trifluoroethane
was neither teratogenic nor fetotoxic. No effects on the mothers were observed.
In another reproduction study (6), rats and rabbits were exposed to 50,000,
15,000 or 5000 ppm 1,1,1,2,2-pentafluoroethane for 6 hours/day on days 6 – 15
(rats) or 6 – 18 (rabbits) of gestation. Pre- and post-implantation losses,
embryo/fetus death, deformities/anomalies and fetal weights were registered.
Transient effects on the mothers (rat: ataxia; rabbit; initial slow weight gain) were
observed at 50,000 ppm, but no statistically significant difference in any of the
studied reproduction parameters was found in any dose group.
Dose-effect/dose-response relationships
There are no data from which to derive a dose-effect or dose-response relationship
for occupational exposure to either of these two substances. Effects on experimental
animals are summarized in Tables 1 and 2.
Conclusions
There are no data on human exposures that would serve to define a critical effect for
occupational exposure to either 1,1,1-trifluoroethane or 1,1,1,2,2-pentafluoro-
ethane. In animal studies, no effects that can be ascribed with certainty to either
substance have been reported at exposures to air concentrations below 50,000 ppm.
Effects such as tendencies to irregular heartbeat have been reported at higher
experimental exposures.
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Table 1. Effects of inhalation exposure to 1,1,1-trifluoroethane observed in
experimental animals (from Reference 2)
Exposure Species Effects
300,000 ppm, 10 minutes (+ adrenaline i.v.) Dog Cardiac arrhythmia
97,000 ppm, 4 hours Rat Temporary weight loss
40,000 ppm, 6 h/d 5 d/w, up to 90 days Rat No exposure-related effects
40,000 ppm, 6 h/d during gestation Rat, rabbit No exposure-related effects
40,000 ppm, 6 h/d, 2 days (micronucleus test) Mouse No exposure-related effects
Table 2. Effects of inhalation exposure to 1,1,1,2,2-pentafluoroethane observed in
experimental animals (from Reference 6)
Exposure Species Effects
800,000 ppm, 4 hours Rat Mild ataxia, breathing difficulty,
reduced reaction to noise
600,000 ppm, 6 hours (micronucleus test) Mouse Tremor, low activity, weight loss, no
significant increase of micronuclei in
bone marrow
100,000 ppm, 10 minutes (+ adrenaline i.v.) Dog Cardiac arrhythmia
50,000 ppm, 6 h/d, 5 d/w up to 13 weeks Rat No exposure-related effects.
50,000 ppm, 6 h/d during gestation Rat, rabbit Rat: Mild ataxia, no exposure-related
effects on young.
Rabbit: initial retardation in weight
gain, no exposure-related effects on
young.
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Calcium Hydroxide
February 24, 1999
Chemical and physical data. Occurrence
calcium oxide
CAS No.: 1305-78-8
Synonyms: unslaked lime, caustic lime,
quicklime, lime*
Formula: CaO
Molecular weight: 56.08
Density: 3.25 – 3.38 g/cm3
Boiling point: 2850 ° C
Melting point: 2614 ° C
Vapor pressure: extremely low
Solubility: disintegrates on contact with water
calcium hydroxide
CAS No.: 1305-62-0
Synonyms: slaked lime, hydrated lime, lime*
Formula: Ca(OH)2
Molecular weight: 74.10
Density: 2.24 g/cm3
Disintegration point: disintegrates, releasing water, at 580 ° C
Vapor pressure: extremely low
Solubility: 1.7 g/liter water
–––––––––––––––––––––––––
*  lime   may refer to either calcium oxide or calcium hydroxide.
Calcium oxide is produced by heating limestone (calcium carbonate) to 950 – 1000
° C in a process called calcining:
CaCO3 + heat  fi  CaO + CO2
Calcium oxide is a white, amorphous substance that crystallizes with the same
structure as sodium chloride. Most of it is used in chemical processing. Calcium
oxide is used as a slag-forming substance and for production of sodium hydroxide,
cement, glass, paper pulp, paper and sugar. Other areas of use are purification of
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drinking water and sewage, ore enrichment and refining, and as an earth stabilizer
in laying foundations for buildings. Commercial grade calcium oxide is usually
about 90 to 95% calcium oxide. The usual impurities are water, calcium carbonate
and iron.
Cement is produced by grinding limestone with clay or sand to a fine powder and
heating the powder, which becomes a gravel-like material. During this process the
calcium oxide reacts with the silicon oxide, forming calcium silicate, the most
important component of Portland cement. The material is then ground to powder
again, usually with a little gypsum. Addition of water forms calcium silicate hydrate
and calcium hydroxide.
Calcium hydroxide is formed when calcium oxide and water are mixed:
CaO + H2O fi  Ca(OH)2 + heat
This results in the creation of a dry, fine white powder. The process is called
slaking. A surplus of water creates solutions of calcium hydroxide, called
limewater. Calcium hydroxide is cheap, and is widely used to neutralize acid lakes
and farmland. Sugar refining is another area of use.
Mortar is a plastic mixture of calcium hydroxide, sand and water. During the
hardening process the calcium hydroxide reacts with the CO2 in the air:
Ca(OH)2 + CO2 fi  CaCO2 + H2O
The quartz in the sand also reacts with the calcium hydroxide, forming silicate,
which gives the mortar additional strength.
Other areas of use are in lubricants and pesticides. Commercially available
calcium hydroxide is usually 90 to 95% calcium hydroxide. The usual impurities are
water, calcium carbonate and iron. Calcium hydroxide is widely used in dentistry
for root canal treatments, since its high pH (around 12) neutralizes the acid
environment in the tooth and thus has a bactericidal effect. It also has the ability to
induce re-mineralization of demineralized dentin (5, 6). Calcium hydroxide is
sometimes chewed in various mixtures that may contain tobacco, areca nut or other
additives. These mixtures, called pan masala or betel quid, are quite popular in India
and the Far East.
The concentration of dust (which consisted mostly of calcium oxide) was
measured at a Swedish plant producing paper pulp. The geometric mean for total
dust at the monitoring stations was 1.2 (0.1 – 7.7) mg/m3 before the ventilation
system was upgraded and 0.1 (0.1 – 0.2) mg/m3 afterward. The two monitoring
stations closest to the kiln showed the greatest decrease, and the personal monitors
showed that the geometric mean for total dust concentration had dropped from 1.2
(0.4 - 5.8) mg/m3 to 0.2 (0.1 - 0.6) mg/m3 (25). Personal monitors were also used
to measure the average exposure to calcium oxide at a American sugar refinery.
Average exposures were 12.9 mg/m3 around the lime kiln and 4.3 mg/m3 during
handling after the substance had been powdered (15). An unpublished NIOSH
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report gives data from an American metal industry where calcium oxide was used as
a lubricant in wire drawing: air concentrations ranged from 0.8 to 5.8 mg/m3 for
calcium oxide and from 0.4 to 2.4 mg/m3 for the fraction in respirable form (9).
Uptake, biotransformation, excretion
Calcium oxide and calcium hydroxide react with skin and mucous membranes on
contact  by splitting fat and proteins. This facilitates continued penetration into the
tissues by the remaining alkalis. Calcium oxide damages mucous membranes and
damp skin by generating heat and dehydrating the tissues as the particles react with
the moisture in the skin, and by the alkalinity of the calcium hydroxide that is
formed in this process (1, 2).
Toxic effects
General effects
Effects on humans:
It is difficult to separate the effects of the two substances, since calcium oxide
immediately becomes calcium hydroxide on contact with moisture. Calcium oxide,
however, is considerably more irritating than calcium hydroxide. Symptoms
involving the skin, eyes and respiratory passages are the predominant effects, and
are described below. When the substances are ingested they cause irritation and
smarting, and may also cause corrosive damage to the lining of the mouth, throat
and esophagus. Stomach cramps, vomiting and in severe cases systemic effects can
occur (11, 12). Chronic exposure to calcium hydroxide can result in inflammatory
and ulcerous changes in the mouth as well as damage to the digestive tract (18).
Effects in experimental test systems:
The LD50 for calcium hydroxide in water given orally to rats is 7.3 (4.8 – 11.1)
g/kg (23). In one study reviewed, male rats were given water containing 50 or
350 mg calcium hydroxide/liter. After two months the animals had become restless
and aggressive, and their food intake was lower. After three months they had lost
weight and had lower hemoglobin values and lower counts of red and white blood
cells. Examination of the dead animals showed inflammation and damage in the
stomach, small intestine, kidneys and liver (18). Two odontological root-treatment
preparations containing up to 25% calcium hydroxide were applied to rat phrenic
nerves in vitro. Nerve impulses were blocked within 30 –100 seconds. Exposures
of 1.5 and 5 minutes yielded proportional degrees of reversibility, but 30 minutes of
exposure resulted in blocking that did not abate during an observation period of a
further 30 minutes (4). Another dental compound containing calcium hydroxide as
the active component was tested on human cells in vitro: it caused degenerative
changes in the cells and changes in various cell components within about a minute
(20).
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Eyes
Effects on humans:
Exposure to calcium oxide dust and to dust or solutions of calcium hydroxide have
similar effects on humans. These strongly irritating and corrosive substances can
cause severe damage, particularly to the cornea, resulting in permanent reduction of
visual acuity. The severity of the effect is determined by the concentration of the
substance, its pH and the exposure time. The hydroxyl ion is considered to be
primarily responsible for the damage, which increases steeply between pH 11 and
12. Calcium hydroxide penetrates the epithelium of the cornea more slowly than
other alkalis, which may explain why it causes less severe damage.
Slight erosion of the cornea produces a very superficial clouding of Bowman’s
membrane, which is just below the epithelium. This damage occurs immediately in
humans and is particularly common when the epithelium has been damaged and the
underlying tissue exposed. More prolonged or intense exposure results in more
severe damage, with clouding and penetration even deeper into the supporting tissue
(stroma) of the cornea. This occurs immediately at pH 12 or higher, and removes
substance from the cornea. Penetration of this extent can also damage the deepest
layer (endothelium). With severe corrosive damage the cornea becomes numb for
several days. When the damage is less severe, the calcium ion plays a critical role in
the clouding of the cornea: a thin layer of calcified material is formed in Bowman’s
membrane. With more severe damage there may be plaque formation. This type of
clouding occurs sporadically in people. In the most severe type of damage, the
stroma is completely and permanently eroded. Calcium hydroxide seldom penetrates
into the eye far enough to damage the lens and iris, although glaucoma has been
reported after severe damage. In a few of the cases it appeared after a few hours,
and in others after six to twelve weeks. Simply rinsing the eye after exposure may
not remove all the calcium hydroxide. Mechanical cleaning may also be necessary
(7).
Effects in experimental test systems, effects on animals:
When the epithelium was removed from the corneas of rabbits, it was found that
with up to 10 minutes of exposure and up to pH 11, damage to the stroma from
alkalis was moderate and reversible. The degree of damage became much more
severe when the pH was increased from 11 to 12, and at higher pH there is
extensive breakdown of corneal tissue. In some species there is an immediate and
severe clouding of the corneal stroma (7). After rabbits were exposed to a paste of
calcium hydroxide for 1 minute, there was a gradual reduction of mucopoly-
saccharides in the cornea, most pronounced after 24 hours and still not normalized
after 3 months (18). In another study with rabbits, 0.01, 0.03 or 0.10 ml of a
100% calcium hydroxide solution was dropped into one eye and the animals were
observed for three weeks. The exposures to the two higher doses had to be
terminated after 7 and 14 days because of the severity of the irritation. Furthermore,
it was apparent that the damage would be permanent. At the lowest concentration
there was some irritation remaining after 3 weeks (8).
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Skin
Effects on humans:
Calcium oxide is strongly irritating and corrosive to skin, and can cause open sores.
Sores can also result from exposure to wet cement, which contains calcium
hydroxide. Three factors contribute to the development of cement burns: alkalinity
(a pH around 12), the mechanical abrasion of the particles in the cement, and the
duration of contact with the skin. Two to three hours of exposure can cause severe
skin damage. A burning sensation may arise, sometimes not until several hours
after the contact, and the damage seems to continue even after the area is rinsed.
This may be due to the difficulty of getting rid of all the alkali (17, 27). A cement
burn often leaves a scar when it heals. In a survey at two cement factories in
Australia, it was found that 5 of 117 employees had an occupation-related, non-
allergic dermatitis (26).
Effects on animals:
No relevant data were found.
Respiratory passages
Effects on humans:
Calcium oxide is strongly irritating and corrosive to respiratory passages.
Inflammation of respiratory passages and ulceration and perforation of the nasal
septum, as well as pneumonia, have resulted from inhalation of calcium oxide dust.
In an undated publication from the health department in Pennsylvania, it was stated
that exposure caused severe nasal irritation at 25 mg/m3 but not at 9 – 10 mg/m3 (2).
In the previously mentioned Swedish study, fifteen Swedish pulp mill workers
exposed to calcium oxide were found to have lower nasal clearance than unexposed
controls matched for age, sex and smoking habits (25). The exposed workers
showed a significant improvement in nasal clearance after the total dust concentra-
tions in the workplace had been reduced from 1.2 mg/m3 to 0.1 mg/m3, and the
difference between exposed and unexposed workers disappeared. The improvement
was regarded as due mostly to the reduction in dust exposure, although the possi-
bility that it may have been at least partly due to the simultaneous reduction of
temperature in the work environment (42 ° C to 28 ° C) could not be ruled out. There
was no observed difference in lung function between the two groups. Air flow
through the nose, measured as PEF (Peak Expiratory Flow), was somewhat lower
among exposed workers both before and after the plant had been renovated. Nasal
inflammation tended to be more common among the exposed workers before the
dust concentration was reduced, but there was no statistically significant difference
between the groups with regard to symptoms or inflammation markers in nasal
lavage fluid. These results should be interpreted with caution, considering the size
of the studied group.
An unpublished report from NIOSH states that irritation of nose and throat was a
widespread complaint in an industry where measured concentrations of calcium
oxide were 0.4 to 5.8 mg/m3 (9). Studies of cement workers have revealed no
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elevation in risk of lung diseases (13, 16). Atrophy of mucous membranes in nose
and throat was a common observation among workers in a Polish cement plant
(19).
Exposure to calcium hydroxide can trigger symptoms of acute irritation,
coughing, pain and possibly chemical burns of mucous membranes. Massive
exposure can result in pulmonary edema and shock (18). There are no data on the
relationship between symptoms and exposure levels of calcium hydroxide.
Effects on animals
No relevant data were found.
Teratogenicity, mutagenicity, carcinogenicity
Effects on humans
A study of the most common form of cancer among the inhabitants of Papua New
Guinea, squamous cell carcinoma in the mouth, showed that the placement of
calcium hydroxide and the tumor location were in good agreement (the same side of
the mouth in 106 of 162 cases) among betel nut chewers (24).
Studies of cement plant workers revealed elevated risk of cancer in the stomach
(16) and caecum (13). Elevated incidences of cancers in lungs, bronchi, trachea,
and bladder have been observed among masons (21). These findings might
possibly be explained by exposure to quartz and/or chromium.
Effects in experimental test systems, effects on animals:
Calcium hydroxide at a concentration of 800 m g/ml showed no cytotoxic effects on
human cells. At 50 - 800 m g/ml there were 20 to 40% more cells after five days of
cultivation (compared with untreated cells), and at 100 m g/ml DNA synthesis was
23% higher. No genotoxicity, measured as DNA string breaks, was seen at
3 mg/ml, the highest tested concentration (14). Hamsters exposed to 4 mg calcium
hydroxide 5 days/week for up to 14 months showed both hyperplasia and papillary
formations in oral mucosa (3). Similar results are reported from other studies, e.g.
atypical epithelium in the cheek pouches of hamsters after exposure to calcium
hydroxide (10). When calcium hydroxide was applied to mucous membranes in the
mouths of rats, it caused various degrees of hyperplasia in all of them and thick-
ening of the mucous membrane (hyperkeratosis) in most of them. However, no
malignancy was seen during the 12-month follow-up period (22).
Dose-response/dose-effect relationships
It is difficult to determine the smallest dose that has a definite effect on skin and
eyes. Exposure of skin or mucous membranes often results in ulceration. The
corrosive damage and penetration into the skin are considerably worse if the pH is
above 11. Skin exposed to cement for two or three hours can develop severe
chemical burns. Reduced nasal clearance was found in workers exposed to dust
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consisting primarily of calcium oxide, where the geometric average for total dust
was 1.2 mg/m3 (25). The available literature supplies no further basis for deter-
mining a dose-response relationship for either calcium oxide or calcium hydroxide.
Conclusions
Direct contact with calcium oxide dust and dust or solutions of calcium hydroxide
can cause severe chemical burns, especially of the eyes but also of skin and mucous
membranes. The critical effects of exposure to calcium oxide and calcium hydroxide
are reduced nasal clearance and irritation of the respiratory passages. Calcium oxide
is the more irritating of the two substances. No conclusions can be drawn regarding
the carcinogenic effects of either substance.
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Consensus Report for Cyclohexanone
February 24, 1999
This report is based on two documents previously published here (4, 54) and on
research published since 1987. It contains some supplementary information from
older literature.
Chemical and physical data. Uses
CAS No.: 108-94-1
Synonyms: cyclohexylketone, ketohexamethylene,
pimelin ketone
Formula: C6H10O
Structure:
O
Molecular weight: 98.14
Density
      liquid: 0.95 (20 ° C)
      vapor: 3.4 (air = 1)
Boiling point: 155.6 ° C
Melting point: - 32.1 ° C
Flash point
     open cup: 44 ° C
     closed cup: 54 ° C
Vapor pressure: 0.69 kPa (25 ° C)
Distribution coefficients
     olive oil/air: 3.83 (30 ° C) (1)
     olive oil/water: 0.79 – 1.23
Conversion factors: 1 ppm = 4 mg/m3 (25 ° C, 101.3 kPa)
1 mg/m3 = 0.249 ppm (25 ° C, 101.3 kPa)
Odor threshold: 0.88 ppm (2)
Cyclohexanone is an alicyclic ketone which at room temperature is a colorless, oily
liquid. It has an odor reminiscent of peppermint and acetone. Cyclohexanone is
used in the production of polyamide (nylon) and as a solvent for paint, enamel,
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printing ink, rubber, wax, various kinds of resin (vinyl, cellulose acetate, nitro-
cellulose), glue, insecticides and polyvinyl chloride (PVC). PVC is widely used in
medical equipment and supplies, and there is a risk that residual amounts of cyclo-
hexanone can escape from the polymer. Small amounts of cyclohexanone have
been identified in intravenous solutions stored in bags made of PVC plastic (30,
57, 62), and leaching from dialysis tubes has also been reported (58). The use of
cyclohexanone as a solvent in the production of audio and video tapes has increased
in recent years. Cyclohexanone has been identified as an emission product in the
thermal breakdown of PVC at 170 ° C, and it is therefore possible that electro-
magnetic welding of PVC produces emissions of cyclohexanone (3). Cyclo-
hexanone is also used as a monomer in the production of cyclohexanone resin.
Uptake, biotransformation, excretion
Uptake
It has been demonstrated in animal experiments that cyclohexanone is taken up by
the lungs, digestive tract and skin. The blood/air distribution coefficient is 2150,
implying high uptake via respiratory passages (26). This was confirmed in an
inhalation study with human subjects, which reports a relative uptake during rest of
57 – 59% (40). Skin uptake of liquid cyclohexanone by persons (n = 3) who held
one hand immersed up to the wrist in pure solvent for 30 minutes was estimated to
be 1 – 2% of the dose absorbed by inhalation during 8 hours of exposure to a
cyclohexanone concentration of 200 mg/m3 (50 ppm) (40).
Biotransformation and excretion
In inhalation studies in which eight human subjects were exposed to 100 –
400 mg/m3 cyclohexanone for 8 hours, 1,2- and 1,4-cyclohexanediol in urine
accounted for 56 – 62% of the amount of uptake, and only 1% was excreted as
cyclohexanol (40). Similar results were obtained when three volunteers were
exposed to 415 mg/m3 for 8 hours. Cyclohexanol and 1,2-cyclohexanediol were
excreted primarily as glucuronides, whereas the 1,4-diol was excreted only in
unconjugated form. The study also indicated that cyclohexanediol in urine occurs
almost entirely as trans isomer (12). Repeated exposure to cyclohexanone vapor
(200 mg/m3, 8 hours/day, 5 days) resulted in a gradually increasing excretion rate
for cyclohexanediol, at least for the first few days (40).
The urine of newborn babies that had been given intravenous nutrient solutions
contaminated with cyclohexanone contained mostly unconjugated trans-1,2-cyclo-
hexanediol, with small amounts of the 1,3- and 1,4-isomers. The cis form of 1,2-
cyclohexanediol was also detected in a few samples (38).
In contrast to the studies described above, large amounts of glucuronidized
cyclohexanol were seen in a case of acute poisoning. The half time for cyclo-
hexanol in the patient’s plasma was 4.75 hours (50). Cyclohexanol has also been
identified in the urine of workers occupationally exposed to cyclohexanone (43,
44).
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It has been proposed that the primary metabolic pathway in man is initial
reduction to cyclohexanol by alcohol dehydrogenase, followed by cytochrome
P-450 mediated hydroxylation to cyclohexanediol, which is excreted in urine (38).
Available data do not indicate whether the glucuronide of the 1,2-diol is formed
exclusively by glucuronidation of the diol or if oxidation of glucuronidized
cyclohexanol occurs as well.
In laboratory animals, cyclohexanone is reduced to cyclohexanol, which conju-
gates with glucuronic acid and is excreted in urine. Rabbits excreted 66% of an oral
dose as glucuronides, mostly of cyclohexanol (11). In beagles, the total excretion
of cyclohexanol accounted for 74 – 100% of the given dose, and most of it (60% of
the dose) was glucuronide. Less than 1% of the dose was excreted in urine as
unconjugated cyclohexanone and cyclohexanol. Repeated exposure to cyclo-
hexanone had no effect on the fraction of the dose that was transformed to cyclo-
hexanol (34). When Wistar and Gunn rats were given an intravenous infusion of
50 mg/kg, conjugates of cyclohexanol accounted for 15 – 20% (Wistar) and 19 –
29% (Gunn) of the dose. After infusions of 100 mg/kg the conjugates accounted
for 17 – 25% and 24 – 34% respectively (17). After oral administration of cyclo-
hexanone to rabbits (1.9 mmol/kg) and rats (2.5 mmol/kg), trace amounts of cis-2-
hydroxycyclohexyl mercapturic acid were found in their urine (28).
When beagles were given bolus doses of cyclohexanone by intravenous infusion
(284 mg/kg/day, 18 days), cyclohexanone in plasma followed a two-compartment
model with half times of 6.6 minutes and 81 minutes (31).
Since alcohol dehydrogenase catalyzes both the reduction of cyclohexanone to
cyclohexanol and the oxidation of ethanol to acetaldehyde, interaction between
ethanol and cyclohexanone can be expected. A man who drank 720 ml sake (10%
ethanol w/v), mixed with about 40 g cyclohexanone and some acetone and methyl
ethyl ketone, showed unusually rapid elimination of the ethanol and low levels of
cyclohexanone in plasma (50). Rabbits that were given cyclohexanone and ethanol
(4.8 mmol/kg) either separately or together showed accelerated metabolism of both
substances when they were given simultaneously (51). This is probably because
metabolism of one of the substances generates the right oxidation state of the
cofactor NAD+ / NADH for metabolism of the other substance.
Cyclohexanone induces the cytochrome P-450 system and has been shown to
potentiate the hepatotoxicity of other chemicals (5).
Toxic effects
Human data
About ten people, both men and women, were exposed to cyclohexanone vapor for
3 to 5 minutes and asked to assess the degree of eye, nose and throat irritation and
say whether they believed they could work in that atmosphere for 8 hours. The
results were reported as the concentrations that a majority of the subjects considered
irritating/acceptable. Irritation of eyes, nose and throat was reported after exposure
to 75 ppm. Exposure to 50 ppm “was not tolerable,” mostly because of the
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resulting throat irritation. The highest concentration judged acceptable for the
proposed 8-hour exposure was 25 ppm (42).
Allergic contact eczema has been reported after exposure to paint containing
cyclohexanone resin, but cyclohexanone alone showed no sensitizing ability when
tested on guinea pigs (6). A later case report, however, describes allergic contact
eczema caused by cyclohexanone (53).
Two cases of poisoning have been reported. The first was a man who drank
720 ml sake (10% alcohol) mixed with 100 ml of a liquid cement for PVC
containing 39% cyclohexanone, 18% acetone and 28% methyl ethyl ketone. The
man lost consciousness and was found to have metabolic acidosis and low blood
oxygen. During the following days the man’s blood-sugar level rose – probably
caused by the acetone – and later he also had elevated serum levels of transaminases
(liver enzymes). The kinetics of the three solvents and the time the man was
unconscious indicate that cyclohexanol was the probable reason for the loss of
consciousness. Whether the man recovered or not is not mentioned (50).
A 15-year-old boy who drank cyclohexanone became mentally affected and went
into shock, with metabolic acidosis, chemical hepatitis, renal insufficiency and
muscular degeneration (pain, elevated serum levels of creatine phosphokinase,
myoglobulinuria) (63).
Workers (n = 75) in a furniture factory who coated wood with cyclohexanone
reported symptoms such as mood swings, irritability, forgetfulness, insomnia and
headaches more often than controls (n = 85). Irritation of eyes, upper respiratory
passages and skin were also more common among the exposed workers than
among controls, as were aching joints, muscles and bones. The statistical analysis
of the symptom data (if one was made) is not given. Significant effects on both the
central and peripheral nervous system were found. Reduced conductivity was
observed in all three studied nerves (medianus, ulnaris and peroneus). Latency time
and amplitude were also affected. As to CNS function, there were delayed reaction
times to both visual and auditory stimuli. The average exposure time was 14 –  3 (–
SD) years (39). According to the authors, exposure measurements were made at the
beginning, middle and end of twelve consecutive 8-hour shifts and in different
places where cyclohexanone was used: the measured air concentrations ranged
from 162 to 368 mg/m3 (40 – 92 ppm). There may have been exposure to other
substances. The control group was matched for socioeconomic factors, workload
and shift (39).
Workers (n = 23) who had been exposed for 4 years to cyclohexanone (150 –
630 mg/m3 or 37 – 158 ppm; unclear what the interval refers to), methyl ethyl
ketone and minor amounts of toluene and acetone, showed declines in alertness and
verbal memory on tests of cognitive performance (37).
A case report describes a 58-year-old man with lifelong exposure to solvents,
mostly cyclohexanone, white spirit and isopropanol. For nearly 30 years the man
had had repeated seizures resembling epilepsy, with reduced consciousness and
occasionally a total loss of consciousness. There were never any convulsions. The
man’s exposure to solvents stopped, and the seizures stopped within a year. Four
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years later the man was again exposed to high solvent levels (not further described)
for three days and had a seizure resembling those he had had earlier (27).
Anosmia (loss of the sense of smell), irritation of mucous membranes, loss of
appetite, headaches, dizziness, concentration difficulty and alcohol intolerance were
reported in a man who had been exposed for 20 years to dichloromethane,
tetrahydrofuran, methyl ethyl ketone, cyclohexanone and small amounts of
dimethylformamide. The inability to discern odors lingered for 15 months after
exposure was terminated (41).
Animal data
The acute toxicity of cyclohexanone is low or moderate. Reported LD50 values are
in the range 0.9 – 2.2 g/kg (20, 29, 61), depending on species and method of
administration. When rats were exposed to 4000 ppm for 4 hours, all of them died
(n = 6) (56). In a later study with rats, 4000 ppm was reported to be the level at
which mortality was first observed (“approximate lethal concentration”) (29).
Simultaneous administration of oxime (not specified) increased the toxicity of
cyclohexanone, measured as LD50, for female rats (23). Oxime occurs together
with cyclohexanone in the production of caprolactam, which is transformed to
polyamide fiber by heating.
Female guinea pigs (n = 10) exposed to 4000 ppm for 6 hours showed effects on
respiration and declining rectal temperature, and after about 1.5 hours of exposure
declining pulse rate also (59).
When cyclohexanone was given to dogs in intravenous infusions (284 mg/kg/day,
18 – 21 days) it affected respiration, caused “vocalization,” stimulated urine
production, and caused salivation, watering of the eyes and ataxia (loss of muscular
coordination). The effects intensified with increased concentration and infusion rate.
Despite the indications of CNS effects, no damage to the brain could be detected
histologically. The dogs given the dose as a 6% solution, 75 ml/minute, had to be
killed after 18 days. Examination of these animals revealed metabolic acidosis,
elevated absolute and relative liver weights with depletion of glycogen in the liver,
plasma cell infiltrate around hepatic veins, hemosiderin deposits (accumulation of
iron outside the blood) in the liver, spleen and lymph nodes, as well as mild
extramedulary blood formation and bone marrow hyperplasia. An increase in the
number of white blood cells, reduction in the number of erythrocytes and reduced
hemoglobin contents were also observed, and in some cases elevated concentrations
of hemoglobin in plasma. These findings, taken together with the enlarged and
thickened epithelial cells and the protein droplets in the kidneys, indicate hemolysis.
There were no pathological findings in the liver, kidneys or spleen in the groups of
dogs given the same daily dose in a more diluted solution (0.75%) (31).
High doses of cyclohexanone (1000 – 1600 mg/kg) given orally to rabbits
caused pronounced damage to lungs, heart muscle, liver, spleen and kidneys.
Repeated skin application of high doses of cyclohexanone caused a pronounced
drop in rectal temperature, convulsions and narcosis (61).
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Slight narcosis, effects on respiration, ataxia and increased salivation were
observed in rabbits exposed to 3000 ppm cyclohexanone vapor 6 hours/day,
5 days/week for 3 weeks. Eye irritation was observed at 300 ppm, but not at
190 ppm (10 weeks). After exposure to 190 ppm, low-grade degenerative changes
were observed in liver and kidneys. There was no observed effect on hemoglobin
levels or on number of red or white blood cells at any dose level (60).
Mice exposed to 19,000 mg/m3 cyclohexanone vapor (4730 ppm) for up to 2
hours developed edema and local hemorrhages in the lungs, respiratory effects and
CNS depression. Average survival time was about 100 minutes. The mice that
survived the exposure were sacrificed 7 days later: histological examination
revealed hyperplasia in the white pulp of the spleen. The same study reports a
concentration-dependent weakening of contraction ability in isolated perfused rabbit
heart after exposure to 1.93 – 19.3 mM (perfusate, 30 minutes). Cyclohexanone in
oil instilled in one eye (5 – 40%) or applied to the skin under occlusion (12.4 –
99%) resulted in concentration-dependent irritation (rabbits) (20).
Groups of 10 newborn rats were given repeated intravenous injections of
cyclohexanone (1, 10, or 25 mg/kg/day, 18 days): there were no observed histo-
pathological changes in brain, heart, lungs, liver, spleen, kidneys, eyes, stomach,
caecum or duodenum that could be related to the cyclohexanone. Nor were there
any observed effects on clinical chemical or hematological parameters (16).
Male rats (Wistar and Gunn) were given cyclohexanone (0, 50 or
100 mg/kg/day) by repeated intravenous infusion for 28 days: no effects were
noted on weight gain, hematological or clinical chemical parameters, other than
significantly lower levels of serum calcium. No macroscopic (heart, lungs, liver,
spleen and kidneys) or histopathological (spleen, skeletal muscles, kidneys, lungs,
liver, stomach, duodenum, pancreas, bladder, brain and eyes) changes were
reported. Nor were there any observed effects on the lens of the eye (17).
In another study, however, lens clouding was reported in 3 of 12 guinea pigs
after repeated application of cyclohexanone directly to the skin. No such effects
were noted in the controls (49). This result, however, could not be confirmed in a
later study with rabbits and guinea pigs (18). The latter study reports changes in the
lens after intravenous (0.5 or 5 mg/kg) and percutaneous (0.5 ml) administration (3
times a week for 3 weeks) of cyclohexanone in all guinea pig groups including the
controls. There were no changes in exposed rabbits. The authors conclude that the
changes observed in the guinea pigs are natural to the species and make guinea pigs
unsuitable experimental animals in this context.
No damage to the peripheral nervous system could be demonstrated in experi-
mental animals given cyclohexanone intraperitoneally in doses of 200 mg/kg, twice
a day, 5 days/week for 13 weeks (46).
The duration of an electrically stimulated muscle contraction in male rats after
4 hours of exposure to cyclohexanone vapor was compared with an unexposed
control group, and the air concentration that shortened the duration by 30% was
determined to be 440 ppm. Female mice were exposed for 2 hours and the time to
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maximum contraction after electrical stimulation was measured. Exposure to
490 ppm reduced the speed to contraction by 30%, i.e. latency time increased (13).
The mechanism behind cyclohexanone’s neurotoxicity was investigated by
studying its ability to induce or prevent convulsions. Intraperitoneal administration
of cyclohexanone did not cause convulsions in female mice – it had an anti-
convulsive action. Cyclohexanone impeded both chemically and electrically induced
convulsions. The doses that had effect in 50 % of animals (ED50). were 238 mg/kg
(chemical induction) and 397 mg/kg (electrical induction). Cyclohexanone also
acted as a competitive inhibitor for a ligand specific for picrotoxin receptors, which
suggests that cyclohexanone has its effect via this mechanism (24).
Adult male rats exposed to 8 ppm cyclohexanone constantly for 10 weeks (45)
and young rats exposed to 2 ppm constantly for 3 weeks (48) developed morpho-
logical changes in cells in their olfactory bulbs. Exposure to completely odorless air
caused similar changes in adult animals, though not so pronounced. The result
should be regarded as an adaptation to a restricted olfactory environment.
Cyclohexanone (0.01 M) reduced the uptake of 3H-thymidine by human lympho-
cytes in vitro (47) and was cytotoxic to mouse fibroblasts in vitro (20). A
concentration of 0.02 M in the culture medium reduced cell growth by 50%.
Mice exposed for 4 hours to cyclohexanone vapor (184, 255, 282, 334 or
577 ppm) showed changed behavior in swimming tests immediately following the
exposures. The effect was dose-dependent and reversible (9). This performance
measure does not differentiate between effects on the central nervous system and
those on other organs.
Teratogenicity mutagenicity, carcinogenicity
Teratogenicity
Cyclohexanone given intraperitoneally to female mice (50 mg/kg/day, 28 days) had
no observable effect on their fertility (21).
Sprague-Dawley rats were exposed to 100, 250 or 500 ppm cyclohexanone
vapor 7 hours/day on days 5 to 20 of gestation: birth weight, sex distribution,
resorptions and fetal deaths were not significantly different from controls. No
significant increase in the frequency of aberrations was noted, although there was a
weak increase in the proportion of rudimentary ribs per litter in the groups exposed
to 250 and 500 ppm. In the absence of conventional indications of embryotoxicity,
the small number of deformities noted in the cyclohexanone group was judged to be
unrelated to the exposure (52).
Cyclohexanone given orally to pregnant mice in doses of 800 mg/kg/day on days
8 –12 of gestation had no effect on litter size or weight of pups on days 1 and 3 (7),
nor on their performance in a maze on days 21, 58 and 200 (15). Cyclohexanone
given orally to pregnant mice in doses of 2200 mg/kg/day on days 8 –12 of
gestation caused significantly lower birth weights in a screening test with pregnant
mice (n = 28). The treatment was lethal for 6 of the 28 mice (55).
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Development of fertile chicken eggs exposed to an unspecified concentration of
cyclohexanone vapor was retarded, and the neuromotor ability of the chicks was
worse than that of controls (19).
When female mice were given 1% cyclohexanone in food during gestation and
lactation, their pups were smaller and mortality was higher (14).
Mutagenicity, carcinogenicity
Cyclohexanone was not mutagenic in tests with Salmonella typhimurium (22) or in
the L5178Y tk+ / tk- mouse lymphoma cell forward mutation assay, either with or
without addition of metabolic systems (36). In another study, however, cyclo-
hexanone was positive in Ames tests with Salmonella typhimurium. The number of
forward mutations in Bacillus subtilis was also elevated (35). This study has been
criticized on several points: the frequency of spontaneous mutations was elevated,
the number of controls small and the procedures done only once (10).
Cyclohexanone (0.1 – 10 mM) has induced chromosome aberrations in human
leukocytes in vitro (8, 32).
In a 2-year study with rats and mice, elevated incidence of some cancer forms
was reported in exposed animals. Since the expected dose-response relationship did
not appear, the evidence of carcinogenicity was judged to be minimal and the effect
weak to nonexistent (33).
In 1989 the IARC stated in its assessment that cyclohexanone was “not classi-
fiable as to its carcinogenicity to humans” (Group 3). Evidence of carcinogenicity
to experimental animals was judged to be inadequate. There were no human data
(25). No subsequent studies were found in the literature.
Dose-response/dose-effect relationships
Dose-response and dose-effect relationships observed in experimental animals
exposed to cyclohexanone (inhalation and other means of administration) are
summarized in Tables 1 and 2.
Occupationally exposed persons experience effects on the nervous system and
eye, nose and throat irritation at air concentrations of 40 to 92 ppm. A majority of
subjects exposed to cyclohexanone vapor for 3 to 5 minutes reported throat
irritation at 50 ppm, and at 75 ppm irritation of eyes and nose as well. The highest
concentration the majority of them judged tolerable for a hypothetical 8-hour
working day was 25 ppm.
Rats showed no effects at 100 mg/kg. In a study of rabbits, marginal liver and
kidney effects were observed at 190 ppm (760 mg/m3) and eye irritation at
300 ppm (1200 mg/m3).
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Table 1. Dose-effect and dose-response relationships observed in experimental
animals exposed to cyclohexanone by inhalation.
Species Exposure
(ppm)
Exposure time Effects Ref.
Mouse 4730 104 min. 2 of 5 animals died  20
Mouse 4730  78 min CNS effects, irritation, respiratory effects,
pulmonary edema
 20
Guinea pig 4000 6 hours Depressed respiration, pulse and rectal
temperature; 3 of 10 died after 4 days.
 59
Rat 4000 4 hours All 6 animals died   56
Rat 2000 4 hours 1 of 6 died   56
Rabbit 3000 90 hours
(6 h/d, 5 d/w, 3 w)
2 of 4 animals died; slight narcosis,
depressed respiration, ataxia, salivation,
irritation and blood vessel dilation in
conjunctiva, weight loss
  60
Rabbit 1400 300 hours
(6 h/d, 5 d/w, 10 w)
Slight lethargy, conjunctivitis as above   60
Rabbit   760 300 hours
(6 h/d, 5 d/w, 10 w)
Somewhat increased salivation, slight
conjunctivitis
  60
Monkey   600 300 hours
(6 h/d, 5 d/w, 10 w)
Slight conjunctivitis   60
Rabbit   300 300 hours
(6 h/d, 5 d/w, 10 w)
Very slight dilation of blood vessels in
conjunctiva
  60
Rabbit   190 300 hours
(6 h/d, 5 d/w, 10 w)
Barely discernible degenerative changes in
liver and kidneys
  60
Mouse 184-575 4 hours Effects on performance in swimming test    9
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Table 2. Dose-effect and dose-response relationships observed in experimental
animals exposed to cyclohexanone by means other than inhalation.
Species Dose
(mg/kg/d)
Administration
method
Effects Ref.
Rabbit 1600-1900 oral Narcosis 61
Mouse 2200 oral 6/28 pregnant mice died. Pups had low
birth weights
55
Mouse 800 oral No effect on locomotor activity of pups 15
Mouse 800 oral, days 8-12
of gestation
No effect on litter size or weight of pups 7
Rat 200 i.p.
5 d/w, 13 weeks
No effect on neural conductivity in
peripheral nerves
46
Dog 284 i.v. 18-21 days
6% solution
75 ml/minute
CNS effects that increased with concentra-
tion and rate of administration; respiratory
effects, elevated liver and adrenal weight,
metabolic acidosis
31
Dog 284 i.v. 18-21 days
0.75% solution
5 ml/minute
Lethargy, dilated pupils 31
Rat 0, 50, 100 i.v.
28 days
No histopathological changes in brain,
no effects on clinical/chemical parameters
17
Rat 1, 10, 25 i.v., 18 days No effects on hematology, chemistry,
histopathology or organ weights
16
Rabbit 12.4-99% epidermal Concentration-dependent skin irritation,
from mild to very severe
20
Rabbit 5-40% instillation in eyes Concentration-dependent irritation, mild
to severe
20
Rabbit 2.5% instillation in eyes No eye irritation 20
Conclusions
The critical effect of occupational exposure to cyclohexanone is judged to be its
effect on the nervous system. Occupationally exposed persons (40 – 92 ppm)
report symptoms including CNS effects and irritation. Throat irritation was
observed in volunteers exposed to 50 ppm for a few minutes.
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Consensus Report for Some Lactate
Esters
June 2, 1999
This report is based primarily on a criteria document compiled jointly by the Nordic
Expert Group and the Dutch Expert Committee (9). That document, in turn, is
based on two recently published survey articles (5, 6). The Criteria Group
published an earlier consensus report for lactate esters in 1995 (8). The present
report takes up the following lactate esters: methyl lactate, ethyl lactate, isopropyl
lactate, isobutyl lactate, n-butyl lactate, 2-ethylhexyl lactate, myristyl lactate and
cetyl lactate. Some information on a few of the other lactate esters is given in the
criteria document (9).
Lactates occur in two enantiomorphous (mirror image) forms, D (dextro) and L
(levo). The forms often occur together: the DL (dextrolevo) form. 2-Ethylhexyl
lactate also has diastereoisomeric forms.
Chemical and physical data. Uses
methyl lactate
CAS No.: 547-64-8 (DL form)
27871-49-4 (L form)
Formula: C4H8O3
CH3CH(OH)COOCH3
Molecular weight: 104.1
Melting point: - 66 ° C
Boiling point: 144 ° C
Flash point: 57 ° C
Density: 1.092 g/ml (20 ° C)
Vapor pressure: 0.34 kPa (20 ° C)
23 kPa (100 ° C)
Saturation concentration: 3302 ppm (20 ° C)
Distribution coefficient: log Po/w = - 0.53
Conversion factors: 1 ppm = 4.3 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.23 ppm (20 ° C, 101.3 kPa)
Methyl lactate is a colorless, transparent liquid. It mixes with water at room
temperature, and is also soluble in alcohol and ether. It is used as a solvent for
cellulose acetate.
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ethyl lactate
CAS No.: 97-64-3 (DL form)
687-47-8 (L form)
Formula: C5H10O3
CH3CH(OH)COOCH2CH3
Molecular weight: 118.1
Melting point: - 25 ° C
Boiling point: 153 ° C
Flash point: 61 ° C
Density: 1.033 g/ml (20 ° C)
Vapor pressure: 0.22 kPa (20 ° C)
17 kPa (100 ° C)
Distribution coefficient: log Po/w = 0.06
Conversion factors: 1 ppm = 4.9 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.20 ppm (20 ° C, 101.3 kPa)
Ethyl lactate at room temperature is a colorless liquid with a mild, characteristic
odor. The reported odor threshold is 0.89 mg/m3, and the odor becomes irritating at
65 mg/m3 (5). Ethyl lactate mixes with water, alcohols, ketones, esters, hydro-
carbons and ethers. It occurs naturally, most notably in several different kinds of
fruit. It is used as a solvent for nitrocellulose, cellulose acetate and many cellulose
ethers. It is an ingredient in enamels, paints, polishes and various cosmetic
products. It is used as a replacement for trichloroethylene in de-greasing and
cleaning (9). An air concentration of 0.6 ppm was measured at a Swedish company
that used ethyl lactate for de-greasing metal. There were peaks of 10 ppm around
some operations, and an 8-hour average was calculated to be 4.2 ppm (4).
isopropyl lactate
CAS No.: 617-51-6 (DL form)
63697-00-7 (L form)
Formula: C6H12O3
CH3CH(OH)COOCH(CH3)2
Molecular weight: 132.2
Boiling point: 157 ° C
Flash point: 60 ° C
Density: 0.991 g/ml (20 ° C)
Vapor pressure: 0.17 kPa (20 ° C)
15 kPa (100 ° C)
Distribution coefficient: log Po/w = 0.39
Conversion factors: 1 ppm = 5.5 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.18 ppm (20 ° C, 101.3 kPa)
Isopropyl lactate is soluble in water, alcohol, ether and benzene.
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isobutyl lactate
CAS No.: 585-24-0 (DL form)
702-84-0 (L form)
Formula: C7H14O3
CH3CH(OH)COOCH2CH(CH3)2
Molecular weight: 146.2
Boiling point: 182 ° C
Flash point: 76 ° C
Density: 0.979 g/ml (20 ° C)
Vapor pressure: 0.05 kPa (20 ° C)
Distribution coefficient: log Po/w = 1.10
Conversion factors: 1 ppm = 6.1 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.165 ppm (20 ° C, 101.3 kPa)
Isobutyl lactate is soluble in water: 5.1 g/100 ml at 20 ° C.
n-butyl lactate
CAS No.: 138-22-7 (DL form)
34451-19-9 (L form)
Formula: C7H14O3
CH3CH(OH)COO(CH2)3CH3
Molecular weight: 146.2
Melting point: - 43 ° C
Boiling point: 187 ° C
Flash point: 79 ° C
Density: 0.984 g/ml (20 ° C)
Vapor pressure: 0.03 kPa (20 ° C)
4.7 kPa (100 ° C)
Distribution coefficient: log Po/w = 1.10
Conversion factors: 1 ppm = 6.1 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.165 ppm (20 ° C, 101.3 kPa)
At room temperature, n-butyl lactate is a watery liquid with a mild odor. It mixes
with water (4.5 g/100 ml), alcohol, ether and many solvents. In acids and alkalis it
is hydrolyzed to lactic acid and butyl alcohol. The odor threshold is reported in one
source (5) to be 0.095 mg/m3, and in another (2) to be 7 ppm (42.6 mg/m3). The
reported irritation threshold for the odor is 9 mg/m3. Butyl lactate has been used as a
solvent for synthetic polymers, enamels, paints etc. It occurs in low concentrations
(< 0.03%) in cosmetic products (9).
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2-ethylhexyl lactate
CAS No.: 6283-86-9 (DL form)
186817-80-1 (L form)
Formula: C11H22O3
CH3CH(OH)COOCH2CH(C2H5)(CH2)3CH3
Molecular weight: 202.3
Boiling point: 246 ° C
Flash point: 113 ° C
Density: 0.940 g/ml (20 ° C)
Vapor pressure: 0.002 kPa (20 ° C)
0.6 kPa (100 ° C)
Distribution coefficient: log Po/w = 3.17
Conversion factors: 1 ppm = 8.4 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.12 ppm (20 ° C, 101.3 kPa)
For 2-ethylhexyl lactate, the reported solubility in water is 30 mg/100 ml. The
reported odor threshold is 0.45 mg/m3 and the reported discomfort threshold is 40
mg/m3 (5). Ethylhexyl lactate has been used as a degreaser.
myristyl lactate
CAS No.: 1323-03-1 (DL form)
Formula: C17H34O3
CH3CH(OH)COO(CH2)13CH3
Molecular weight: 286.5
Density: 0.892 – 0.904 (25 ° C)
Conversion factors: 1 ppm = 11.9 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.08 ppm (20 ° C, 101.3 kPa)
Myristyl lactate occurs as a white to yellowish liquid or a soft solid. The substance
dissolves in ethanol and propylene glycol but is insoluble in water and glycerin.
Myristyl lactate is used as a softener in several cosmetic products, usually in
concentrations of 5 to 10% (6).
cetyl lactate
CAS No.: 35274-05-6 (DL form)
Formula: C19H38O3
CH3CH(OH)COO(CH2)15CH3
Molecular weight: 314.4
Melting point: 23 – 41 ° C
Boiling point: 170 ° C (at 2 x 10-3 kPa)
Density: 0.893 – 0.905 (25 ° C)
Conversion factors: 1 ppm = 13.05 mg/m3 (20 ° C, 101.3 kPa)
1 mg/m3 = 0.077 ppm (20 ° C, 101.3 kPa)
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Cetyl lactate is a white to yellow, soft, waxy substance with a faint, pleasant and
easily recognizable aroma. It is soluble in ethanol and propylene glycol. Cetyl
lactate is used as a non-ionic softener in pharmaceuticals and cosmetics, usually in
concentrations of 1 to 5% (9).
Uptake, biotransformation, excretion
There are no quantitative data on uptake of lactate esters. Twenty-four hours after
14C-labeled ethyl lactate was applied to the skin of rats, the radioactivity was seen in
sebaceous glands, hair follicles, epidermis and dermis (11).
Hydrolysis of lactate esters to lactic acid and alcohol has been reported to occur
after both skin application and oral administration (3). Lactic acid is a naturally
occurring metabolite, and its toxicity is mostly a result of its acidity. Concentrated
lactic acid is irritating to skin and eyes. In in vitro studies, 80% of ethyl lactate in rat
plasma was hydrolyzed within 60 minutes. Similar results have been demonstrated
in homogenates of nasal mucosa, liver and skin from rats (5).
There are no quantitative data on excretion of lactate esters. Since hydrolysis of
lactate esters is fairly rapid, elimination pathways are probably the same as those for
lactic acid and alcohol.
Toxic effects
Human data
One case of allergic contact dermatitis has been reported. An acne medication (gel)
containing 10% ethyl lactate caused acute erythema (skin reddening). Tests six
weeks later yielded a positive response to the gel and to 1% ethyl lactate in
petroleum jelly (10).
Unpublished reports on n-butyl lactate, cited in the ACGIH document, state that
occupational exposure to 43 mg/m3 (about 7 ppm) with brief peaks of about 67
mg/m3 (11 ppm) caused headache, coughing and irritation of mucous membranes.
Some symptoms also occurred with exposure to 24 mg/m3 (4 ppm), whereas no
symptoms resulted from exposures below 8 mg/m3 (1.4 ppm). A later report, also
unpublished, states that 7 ppm had a definitely unpleasant odor but caused no harm
and was judged acceptable (1).
Animal data
Lactate esters dropped into the eyes of rabbits caused eye irritation. Tested esters
that yielded a positive response were ethyl, n-propyl, n-butyl, lauryl, and myristyl
lactate. Methyl lactate, however, was classified as non-irritating (5, 6, 7, 12).
A 50% solution of ethyl lactate caused no irritation when applied to the skin of
rabbits, but undiluted butyl lactate caused mild to moderate reddening. Mild skin
irritation can be caused by cosmetics containing up to 12% lauryl lactate or myristyl
lactate (5).
The calculated RD50 for mice is 750 – 800 mg/m3 for ethyl lactate and butyl lactate
(5). (RD50 is the dose that causes a 50% reduction in respiratory rate.)
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Cosmetics containing small amounts of lauryl lactate or cetyl lactate were tested
on the skin of guinea pigs (the Magnusson-Kligman test). Both substances were
judged to be non-sensitizing (6).
In inhalation studies, groups of rats (both sexes) were exposed 6 hours/day,
5 days/week for 28 days. Exposure levels for ethyl lactate were 0, 25, 75, 150,
200, 600 or 2500 mg/m3. In the two highest dose groups there were degenerative
changes in olfactory epithelia with hyperplasia in goblet cells. Similar effects were
observed at high doses when the animals were exposed to isobutyl lactate or n-butyl
lactate. The NOAEL for these three lactates is 200 mg/m3. Further information is
presented in Table 1 (9).
At the same laboratory, rats exposed by inhalation to 2-ethylhexyl lactate showed
the same effects even at 75 mg/m3, the lowest tested dose. The effects were the
same whether the ester was in gas or aerosol phase. See also Table 1 (9).
Groups of rats (both sexes) were given myristyl lactate in oral doses of 0, 0.5,
2.5 or 5.0 mg/kg body weight, 5 days/week for 13 weeks. Elevated relative liver
weights and enlargement and thickening of the walls of the stomach and duodenum
were seen in rats in the two higher dose groups. Histological examination revealed
diffuse hyperplasia in the mucous membranes of the duodenum. These changes
were not observed at the lowest dose (6).
Mutagenicity, carcinogenicity, teratogenicity
Ethyl lactate has been tested on several different strains of Salmonella typhimurium,
both with and without metabolizing systems. No mutagenic activity was observed.
No mutagenic activity was observed when 2-ethylhexyl lactate was tested on
Salmonella and E. coli (5).
No carcinogenicity studies were found on any of these lactate esters.
Ethyl lactate (doses of 0, 517, 1551 or 3619 mg/kg body weight/day) was
applied to the skin of rats on days 6 – 15 of gestation. There was slight reddening at
the site of application, but no clinical effects were seen in the mothers and there
were no observed effects on the young (5).
Pregnant rats were exposed to an aerosol of 2-ethylhexyl lactate (0, 200, or 600
mg/m3) 6 hours/day on days 6 to 15 of gestation. Animals in the high-dose group
had lower food intake, but showed no toxic effects. Retarded ossification was noted
in pups in both dose groups, but was attributed to stress rather than the toxicity of
the exposure (5).
Dose-response/dose effect relationships
For most of the lactate esters, there are no data from which to derive a dose-effect or
dose-response relationship. Data on human exposures are particularly sparse.
Data from inhalation exposure studies with rats are presented in Table 1.
Myristyl lactate given orally to rats increased liver weights at a daily dose of 2.5
mg/kg body weight or higher. The NOAEL in this study was 0.5 mg/kg body
weight (6).
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Table 1. Effects of some lactate esters on rats exposed 6 hours/day, 5 days/week for
28 days (from References 5 and 9).
Lactate            Exposure Effect
     mg/m3    ppm
ethyl
(gas)
2500 500 Reduced growth, lower absolute liver weights, reduced
food intake, elevated blood glucose, degenerative changes
in olfactory epithelium, hyperplasia in goblet cells.
600 120 Degenerative changes in olfactory epithelium, hyperplasia
in goblet cells.
200 40 NOAEL
n-butyl 600 99 Slight focal hyperplasia in nasal epithelium.
(gas) 200 33 NOAEL
i sobutyl
(gas)
800 132 “Disarrangement” of olfactory epithelium, hyperplasia in
respiratory epithelium in nose.
400 66 Hyperplasia in respiratory epithelium in nose.
200 33 NOAEL
2-ethylhexyl
(aerosol)
1800 216 Histopathological changes in nose, larynx, trachea and
lungs; peroxisome proliferation.
600 72 Histopathological changes in respiratory passages.
200 24 Histopathological changes in respiratory passages.
75 9 Histopathological changes in nasal cavity; LOAEL.
(gas) 75 9 Focal hyperplasia in respiratory epithelium in nose;
LOAEL
Conclusions
The critical effect of occupational exposure to lactate esters is judged to be irritation
of mucous membranes. The similarities in responses to the different esters implies
that lactic acid is probably the underlying reason for the effects. For rats, the
NOAEL for several tested lactate esters is 200 mg/m3. For 2-ethylhexyl lactate,
effects can be observed at an exposure as low as 75 mg/m3. According to
unpublished data on human subjects exposed to n-butyl lactate, effects appear at
exposure to 7 ppm (43 mg/m3) or higher.
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Consensus Report for Ethylene Glycol
Methylether and Ethylene Glycol
Methylether Acetate
June 2, 1999
This report is based on a criteria document published in Arbete och Hälsa (22).
Chemical and physical characteristics. Uses
Ethylene glycol methylether (EGME)
CAS No.: 109-86-4
Synonyms: glycol methylether, 2-methoxyethanol,
methyl glycol
Formula: CH3–O–CH2–CH2–OH
Molecular weight: 76.09
Density: 0.96 (20 ° C)
Boiling point: 124 ° C
Melting point: - 85.1 ° C
Vapor pressure: 1.3 kPa (9.7 mm Hg) (20 ° C)
Evaporation rate: 0.5 (butyl acetate = 1)
Saturation concentration: 12,800 ppm (25 ° C)
Relative density: 2.6 (air = 1)
Conversion factors: 1 ppm = 3.11 mg/m3 (20 ° C)
1 mg/m3 = 0.322 ppm (20 ° C)
Ethylene glycol methylether acetate (EGMEA)
CAS No.: 110-49-6
Synonyms: ethylene glycol monomethylether acetate
2-methoxyethyl acetate,  methyl glycol acetate
Formula: CH3–O–CH2–CH2–O–CO–CH3
Molecular weight: 118.13
Density: 1.005 (20 ° C)
Boiling point: 145 ° C
Melting point: - 65 ° C
Flash point: 55.6 ° C (open cup)
Vapor pressure: 0.27 – 0.50 kPa (2.0 – 3.7 mm Hg) (20 ° C)
Evaporation rate: 0.3 (butyl acetate = 1)
Saturation concentration: 3100 – 6000 ppm (25 ° C)
Relative density: 4.07 (air = 1)
Conversion factors: 1 ppm = 4.90 mg/m3 (20 ° C)
1 mg/m3 = 0.200 ppm (20 ° C)
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EGME and EGMEA at room temperature are flammable, volatile, clear liquids with
a weak, sweetish odor and bitter taste. Both substances dissolve readily and
completely in water as well as polar and non-polar solvents.
EGME is produced by a reaction between methanol and ethylene oxide. EGMEA
is produced from EGME by conventional estrification. Known impurities in EGME
are reported to be < 0.1% methanol, < 0.1% diethylene glycol methylether and
< 0.02% ethylene glycol (22).
EGME and EGMEA do not occur in nature. World-wide reported uses for the
two glycol ethers are in paints and enamels; printer’s ink; plastic packaging for
foodstuffs; pigments for silk-screen printing; photographic and photolithographic
processes (including the production of offset plates); CDs, circuit boards and
integrated circuits; cleaners for household and industrial use; and antifreeze in
hydraulic fluids and airplane fuel. In 1993 there were 23 Swedish chemical
products containing EGME, and total annual use was about 260 tons of the pure
substance. EGMEA was not listed in the product register. EGME was used
primarily as a solvent, but it was also an ingredient in paints and enamels. In 1997
there were 27 Swedish products containing EGME, and annual use was 19 tons,
most of which was used as photoresist in the telecommunications industry.
EGMEA was a listed ingredient in 3 products, with an annual use of less than
0.1 ton. In 1994 EGME and EGMEA were classified by the EU as toxic to
reproduction and their use in consumer products was prohibited (22).
Reported average exposure levels are in the range <0.1 to 23 mg/m3 for EGME,
and from <0.1 to 143 mg/m3 for EGMEA. Exposure has been reported from semi-
conductor and circuit board manufacture, printing, painting (especially automobile
and ship painting), furniture finishing, paint production and automobile repair (22).
No data were found on exposures in Swedish workplaces.
Uptake, biotransformation, excretion
As suggested by the chemical structure and the ready solubility of EGME and
EGMEA, both substances are efficiently absorbed via all paths of uptake and
rapidly distributed throughout the body. Uptake via respiratory passages has been
measured at 76% of the amount inhaled (22).
Uptake of EGME by frozen and thawed human epidermis in vitro was
2.8 mg/cm2/hour (12). An average absorption rate of 2.9 mg/cm2/hour, with large
inter-individual variations, was measured for liquid EGME in an in vivo study with
volunteers. Exposure of hands and lower arms to EGME in liquid form was calcu-
lated to yield an absorption rate 100 times that of exposure to 5 ppm in the air. The
authors also calculated that, with whole-body exposure to EGME vapor, 55% of
total uptake occurs via the skin (24).
EGME is distributed fairly evenly between blood and other tissues, with the
exception of low solubility in adipose tissue. Methoxyacetic acid (MAA) also has
relatively even distribution in body tissues (22).
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EGMEA is efficiently hydrolyzed to EGME by the carboxylesterases in nasal
mucosa, liver, kidneys, lungs and blood. The most important metabolic pathway
for EGME is oxidation via methoxyacetaldehyde (MALD) to MAA. This meta-
bolism can be inhibited by ethanol, and the importance of alcohol dehydrogenase is
illustrated by the fact that metabolism of EGME is almost completely suppressed in
rats that have been pre-treated with pyrazol. When men were exposed to 5 ppm
EGME for 4 hours (resting), an estimated 86% of the inhaled amount of EGME
was excreted in urine as MAA. The reported half time for MAA in human urine is
77 hours. The half time for MAA in serum and plasma has been reported to be
about 6 hours for mice and 20 hours for monkeys (22).
In addition to MAA, methoxyethyl glucuronide, methoxyethyl sulfate, ethylene
glycol, glycolic acid, glycine, methoxyacetyl glucuronide, methoxyacetyl glycine,
methoxycitrate and methoxybutenic acid were identified in nucleomagnetic
resonance spectrometry (NMR) analysis of urine samples from mice and rats given
doses of 13C -labeled EGME. Simultaneous administration of acetate, an
endogenously formed substance and a precursor in the Krebs cycle, increased the
proportion of EGME-related metabolites and reduced the proportion of MAA-related
metabolites. These results show that ether cleavage can occur, and also that EGME
after oxidation can form methoxyacetyl-coenzyme A. It has been suggested that this
“false substrate” in the Krebs cycle may be related EGME’s toxic effects on
reproduction (22).
Mechanism studies
EGME had no effect when incubated with human erythrocytes, whereas 0.5 mM of
MAA increased their osmotic fragility. When human erythrocyte membranes
(ghosts) were incubated with MAA or EGME, membrane-bound acetyl-
cholinesterase (IC50 = 5.5 mM) and ATPase (IC50 = 1.4 mM) were inhibited by
MAA but not by EGME (26).
Simultaneous administration of a number of other substances (formate, acetate,
glycine, glucose, serine, sarcosine) involved in the formation of pyridine and purine
– which in turn are needed for synthesis of DNA and RNA – reduces or completely
eliminates the malformed sperm and disruption of spermatogenesis caused by
EGME in experimental animals (22).
Addition of 10 m M MAA, but not 1 m M, reduced the proliferative capacity of fetal
mouse liver cells in vitro, observed as reduced incorporation of tritium-labeled
thymidine. No effect on survival of the cells was observed, however (20).
Toxic effects
Animal data
EGME and EGMEA have moderate acute toxicity. The reported LD50 values for
EGME range from 0.9 to 3.4 g/kg body weight, depending on species and method
of administration. The reported LC50 for inhalation is 4600 mg/m3 (1480 ppm).
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Four hours of exposure to 1000 ppm resulted in atrophied sperm in male rats, and
625 ppm produced damaged spermatids within 24 hours. The reported LD50 values
for EGMEA range from 1.3 to 5.6 g/kg. The reported LD50 for MAA with oral
administration (in water) is 1 to 1.5 g/kg (22).
Short-term exposures via gavage, skin application, feed and inhalation have
similar effects in several species, including reduced thymus, spleen and testes
weights, lower counts of white and red blood cells and platelets, lower hematocrit,
hemoglobin levels and bone marrow cellularity, higher numbers of immature
granulocytes and disturbance of spermatogenesis. Spermatogenesis is disrupted at a
particular phase, the late pachytene, and the effect shows up later in lower sperm
counts or aspermia. Toxicity is about the same regardless of the method of exposure
– gavage, drinking water, skin application or inhalation (22).
After tests with rabbits, EGME and EGMEA were classed according to EEC
criteria as non-irritating to skin, and EGME as non-irritating to eyes (22).
Human data
Older studies report that repeated occupational exposure to products containing
EGME can cause headaches, weakness, dizziness, ataxia, toxic encephalopathy and
dampened reflexes (22). Further case reports are summarized in Table 1.
In a cross-sectional study of 65 workers who produced and packaged EGME,
measured concentrations in workplace air were 4 to 20 ppm and personal monitors
indicated 5.4 to 8.5 ppm (time-weighted averages). Trends (not significant) to
lower leukocyte counts and lower Hb were seen in the 40 exposed workers when
they were compared with the 25 unexposed workers. Closer study of a sub-group
of 6 exposed and 9 unexposed workers showed tendencies to reduced leukocyte
counts, lower hemoglobin, reduced testicle size, lower sperm counts, elevated
levels of luteinizing hormone (LH) and lower levels of testosterone and follicle-
stimulating hormone (FSH) in serum, none of which was statistically significant
(7).
Of 73 painters at a shipyard, 10% had anemia and 5% had granulocytopenia,
compared with 0% in an unexposed control group. No other hematologic differ-
ences between the groups were observed. Measured exposure levels were 0 – 5.6
(mean 0.8, median 0.4) ppm for EGME and 0 – 21.5 (mean 2.6) ppm for ethylene
glycol ethylether (EGEE). A review of patient journals revealed that the conditions
had arisen during employment as painters. The authors listed about 60 substances
that painters at a shipyard might be exposed to, and of these lead, benzene and
glycol ethers were identified as potentially harmful to blood-forming organs. All
blood-lead levels were below 40 m g/dl and most of them were below 20 m g/dl. Air
monitoring and product reviews indicated negligible exposure to benzene, and the
authors concluded that the observed hematologic effects could not be explained by
exposure to lead or benzene (33).
No reports on skin irritation, eye irritation or sensitization were found in the
literature.
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Mutagenicity
With the exception of the studies reviewed below, EGME and its metabolite MAA
have been negative in all genotoxicity studies, including Ames tests, in all tested
Salmonella strains, both with and without addition of metabolizing systems (for a
survey see Reference 25).
EGME caused mutations in the gpt gene in a cell line from Chinese hamsters, but
no mutations in the hprt gene in another cell line. The metabolite MALD was weakly
mutagenic in Salmonella (TA97a) and gave rise to an increased number of muta-
tions, sister chromatid exchanges and chromosome aberrations in Chinese hamster
cells in vitro, in the concentration interval 5 – 40 mM. Chromosome damage from
MALD was also seen in human lymphocytes after 1 hour at 40 mM and after 24
hours at 2.5 mM. No chromosome damage was observed in mice that had been
given up to 1000 mg/kg MALD or up to 2500 mg/kg EGME by gavage (22).
EGME and its metabolites were tested for genotoxicity and epigenetic effects in
different test systems. Increased numbers of micronuclei and mitotic irregularities
were seen in vitro at 65 mM EGME, 0.12 mM MALD and 3.2 mM MAA. With
MALD, an elevated frequency of mutations was seen at 1 – 10 mM, of sister
chromatid exchanges and chromosome aberrations at 0.1 – 1 mM, and of
morphological transformations at 0.1 – 0.3 mM. The authors regard the results as
weakly positive for EGME and MAA and clearly positive for MALD (13).
EGMEA was tested with a number of Salmonella strains, both with and without
metabolic activation, in two different laboratories. One judged it to be weakly muta-
genic, and the other judged it to be possibly mutagenic (36).
Carcinogenicity
There are no reports of animal studies on the carcinogenicity of EGME or EGMEA.
In McGregor’s assessment, aside from a few positive results in Ames tests (see
Mutagenicity), there is no experimental evidence that either of the substances is
carcinogenic (25).
A review of 198 cases of acute myelotic leukemia (AML) was made in a French
case-control study. Blind estimates of exposure to different types of glycol ethers
and potential exposure levels were made by an expert panel. No relationship
between AML and glycol ethers was seen (21).
Reproduction toxicity
Animal data
A large number of animal studies have provided a clear and unambiguous picture of
the toxic effects on reproduction in both sexes. Males given low doses have reduced
testes weights, histological changes in testes and low sperm counts; higher doses
cause testicular atrophy and aspermia. The effects are temporary. Females have
lower fertility and higher numbers of dead and resorbed fetuses. Young have lower
post-natal survival rates and higher frequencies of skeletal anomalies, malformed
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extremities and severe deformities. Effects on fetuses appear at doses too low to
have visible effects on the mothers. At higher doses there is 100% fetal mortality.
The degree of fetal damage is extremely sensitive to the time of exposure. These
effects have been demonstrated for all administration methods and in several
different species (22). A few of the more recent studies are summarized below.
Rabbits were given EGME in drinking water, 12.5 – 50 mg/kg/day, 5 days/week
for 12 weeks: there were dose-dependent declines in several parameters of sperm
quality. The effects were significant at 37.5 and 50 mg/kg, and the most marked
effect was reduced number of sperm per ejaculate. Histologically, spermatogenesis
(number of round spermatids per Sertoli’s cell) was somewhat reduced at 25 and
severely disrupted at 37.5 mg/kg. At 50 mg/kg spermatogenesis ceased almost
completely in 5 of 7 rabbits. No effects were seen on the libido or fertility of the
rabbits that still had functional sperm production, and no other pathological or
histopathological effects were observed. The authors concluded that spermato-
genesis in rabbits is about 10 times more sensitive to EGME than that in rats or
mice (4, 16).
EGME given to female rats in doses of 300 mg/kg/day completely eliminated the
estrus cycle: inhibition of ovulation, luteal body hypertrophy, permanently elevated
progesterone levels and permanently low levels of estradiol, follicle-stimulating
hormone (FSH), luteinizing hormone (LH) and prolactin. Addition of MAA to
luteal cells in vitro resulted in elevated progesterone levels in the cultivation medium
at all levels; 1 mM was the lowest tested concentration (9). MAA was also tested in
an in vitro system with luteinized granulosa cells from humans. Incubation with
0 – 5 mM of MAA for 6 to 48 hours yielded a duration- and concentration-
dependent increase of progesterone. The effect was significant at 1 mM, but the
tendency was also apparent at 0.1 and 0.5 mM. The authors associate these
observations with the effects on menstrual cycle and ovarian function in humans
(1).
Pregnant monkeys (Macaca fascicularis) were given EGME by gavage in doses
of 12, 24, or 36 mg/kg/day on days 20 to 45 of gestation (during organogenesis).
Effects on the mothers (moderate to extreme loss of appetite, weight loss) were
observed at all dose levels. Most of the animals in the two higher dose groups were
therefore given nourishment and/or electrolytes by gavage. Caesarean sections were
performed after 100 days: all 8 fetuses in the high-dose group were dead or
resorbed, as were 3 of 11 in the middle group and 4 of 14 in the low-dose group.
This can be compared with 0 of 6 in the untreated control group and 0 of 3 in a
control group treated with ethanol (0.47 mmol/kg/day). The authors noted that the
dead fetuses looked different from those seen in spontaneous, drug-induced or
ethanol-induced fetal deaths, and drew the conclusion that the effect was not
secondary to the maternal toxicity but a direct effect of the EGME. One of the dead
fetuses in the highest dose group had no digits on the forelimbs. Deformities of this
type had not previously been seen in monkeys, but had been observed earlier in
mice and rabbits given EGME. Other deformities were also observed, but the
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possibility that these were secondary to the death of the fetus could not be ruled out.
No deformities were seen in the living fetuses (31).
Human data
In examination of sperm quality in painters at a shipyard, it was found that they had
oligospermia (10/79 compared to 0/40) and azoospermia (4/79 compared to 0/40)
more often than controls, as well as a tendency to a lower number of sperm per
ejaculate. Average exposures of the painters were 0.8 ppm for EGME and 2.6 ppm
for EGEE. Urine analyses for ethoxyacetic acid indicated considerable skin
exposure (34).
A women whose job during two pregnancies was to rinse laboratory glassware in
EGMEA had in both cases boys with genital defects (hypospadia, micropenis, bifid
type of scrotum). The authors could find no other factors in the work environment,
the home environment or heredity that could explain them (5).
There is a report on 44 patients in Matamoros, Mexico, who had a syndrome with
characteristic facial distortions and mental retardation. All of them were born in
1971 – 1977 and were children of mothers who during their pregnancies had
worked at a factory making condensers. There are no quantitative data on exposure,
but during work the women had dipped their hands into a solution consisting
mainly of EGME and ethylene glycol. There was no ventilation, and workers used
no protective gloves or face masks. Indications of acute poisoning, with fatigue,
dizziness, nausea and vomiting, had occurred during work. A closer examination of
28 of the cases revealed that all of them also had musculoskeletal defects and that
about half of them had eye and ear defects as well. There was no familial relation-
ship between the cases and birth defects of this nature had not occurred previously
in any of the affected families (30).
An elevated frequency of spontaneous abortions (compared with unexposed
controls) was noted in women in the semiconductor industry, and was associated
particularly with diffusion/dipping and photolithography. (For a brief description of
the production of integrated circuits, see e.g. Britannica Online (6)). Exposure to
glycol ethers, xylene, toluene and hexamethyl disilazane was reported to occur
during photolithographic work, and to arsine, phosphine and diborane during
diffusion work. No exposure measurements were made (27). This report served to
initiate several further epidemiological studies in the semiconductor industry.
In a cohort study of 6088 women employed in 14 semiconductor factories, 904
pregnancies and 113 miscarriages were examined. After control for age, smoking
habits, ethnic background, education, income, date of pregnancy and stress levels,
there was a tendency for women in production work to have a higher proportion of
miscarriages than other employees. A significantly higher frequency was seen
among women who worked with masking. In this group, the highest risk of
miscarriage was associated with etching (3). In a sub-study, the outcomes of 891
pregnancies were sorted according to exposure during the first trimester. Women
working with photolithography, who were exposed to ethylene glycol ethers
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(EGME, EGEE and their acetates), fluorides and other substances, had a signifi-
cantly higher risk of miscarriage (32).
In a prospective study made at the same companies, 403 women were followed
for 6 months by analysis of chorionic gonadotropin in urine. After control for
possibility of conceiving, use of contraceptives and age, there was significantly
lower fertility in the women working in dipping and the same tendency in those
exposed to glycol ethers (14). In addition, female production workers had a signifi-
cantly higher risk of spontaneous abortions than those who held other types of jobs.
All three pregnancies among the women who were exposed to ethylene glycol
ethers terminated in miscarriages (14). The same group of women also kept diaries
on their menstruations. Prolonged menstrual cycles were seen in women who
worked with dipping, and shortened cycles and a greater number of irregular
menstruations were seen in the photolithography group (17).
In exposure assessments made in the workplaces at the same time, it is stated that
15 – 20% of the factories used photochemicals (negative photoresist), usually
containing 3% EGME. All personal monitors registered EGME levels below
10 ppb, average exposure to ethylene glycol ethylether acetate (EGEEA) was
22 ppb, and exposure to 1-methoxypropyl acetate was 8 ppb (18). Exposures to
glycol ethers were strongly correlated to exposures to xylene and n-butyl acetate
(19).
In a study of 454 pregnancies among 1368 women employed in the semi-
conductor industry, risk of spontaneous abortion tended to be higher for those who
worked in chip production, and those with chemical exposure outside of chip
production, than for unexposed subjects. The proportion of stillbirths also tended to
be higher in the two exposed groups. The authors report that chip production
involves exposure to glycol ethers and a number of other solvents, which they
listed, but exposures were not measured (29).
Another study in the semiconductor industry covered both female employees
(561 pregnancies) and the wives of male employees (589 pregnancies). For the
female employees, those with the highest likelihood of exposure to ethylene glycol
ethers had significantly reduced fertility and elevated risk of spontaneous abortion.
No increased risk of miscarriage was found among the wives of employed men, but
there was a tendency to lower fertility. No personal monitoring measurements were
taken, and only general information on exposures is given. A few measurements
yielded glycol ether levels below 0.2 ppm in the highest exposure group. The glycol
ethers named in the study are diethylene glycol dimethylether (DEGDME) and
ethylene glycol ethylether acetate (EGEEA); EGME was not mentioned. Simul-
taneous exposure to glycol ethers and hexamethyl disilazane occurred. No increase
in frequency of the studied effects was noted with exposure to n-butyl acetate, N-
methyl-2-pyrrolidone or xylene, unless there was simultaneous exposure to glycol
ether (8).
None of the epidemiological studies made in the semiconductor industry contains
detailed information on exposure levels. About 400 air samples were analyzed in a
separate study, and average levels of 0.1 ppm EGME and 0.01 ppm EGMEA were
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found (28). The studies are also alike in that the authors claim there was exposure to
no factors, other than glycol ethers, known to have toxic effects on reproduction.
Immunotoxicity
Animal data
All clinical, morphological and histological indications of leukemia disappeared in male
rats that had been given subcutaneous injections of human leukemia cells when they
were given drinking water containing 2.5 mg/ml EGME. Addition of 0.25 mg/ml,
equivalent to a daily dose of 15 mg/kg, halved the leukemia response. EGEE also
retarded the leukemia response, but was ten times less potent than EGME. Seven other
tested glycols and glycol ethers had no effect. In vitro tests with the same cell line
showed a concentration-dependent reduction in number of cells in the dose interval
1 – 100 m M EGME. The metabolite MAA was about half as effective, which the
authors regard as an indication that the mitosis-inhibiting effect of EGME is not due to
a cytotoxic mechanism alone (11).
Mice given EGME by gavage in doses of 500 or 100 mg/kg/day for 5 to 10 days
developed atrophy and decline in mature thymocytes in the thymal cortex, but the
medulla was unaffected (23).
Female rats were exposed to EGME in drinking water, 2000 or 6000 mg/liter
(equivalent to 161 or 486 mg/kg/day), for 21 days: the treatment resulted in a dose-
dependent reduction of thymus weight, increased activity of killer cells, reduced
antibody production and a lower number of cells in the spleen. At 6000 mg/l there
was also reduced production of gamma interferon. Male rats exposed to 1600 or
4800 ppm in drinking water (200 or 531 mg/kg/day) showed all these effects as
well as reduced testes weights at both dose levels. Thymus atrophy and reduced
interleukin-2 production were also seen at the higher dose (15).
Single oral doses of 125 or 500 mg/kg caused a 3 or 8 times higher apoptosis
index (programmed cell death) in the thymus, compared with unexposed rats. There
was a parallel increase in the liver’s capacity to metabolize MALD to MAA. Pre-
treatment with phenobarbital suppressed this effect almost completely (2).
Immune response was studied in rats and mice that had been given EGME,
EGMEA, MALD or MAA in oral doses of 50 to 400 mg/kg/day for 10 days. In the
rats, the four substances yielded similar immunosuppression, expressed as reduced
thymus and spleen weights and reduced antibody plaque-forming cell (PFC)
response. The effects were significant at the lowest dose level, and equimolar doses
of the four substances produced equivalent immunosuppression. Pre-treatment with
4-methylpyrazole caused these effects to disappear, which indicates that metabolic
activation is necessary. This immunosuppression was observed in all of the rat
strains but in none of the mouse strains. Nor did MAA in subcutaneous doses of up
to 1920 mg/kg/day produce immunosuppression in the mice, which indicates that
the difference between the species can not be explained by differences in
bioavailability or metabolic rate (22).
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Atrophy, dose-dependent reduction in cellularity, and changes in thymocyte
patterns indicating disturbances in thymocyte maturation were observed in thymus
glands from the young of mice given EGME in doses of 100 – 200 mg/kg/day on
days 10 to 17 of gestation (20).
There are a number of other animal studies that support these findings on the
immunotoxic effects of EGME (22).
Human data
Effects on several kinds of leukocytes were observed in 9 floorlayers when they
were compared with an unexposed, matched control group. The changes comprised
reduced numbers of eosinophils and segmented neutrophils and increased numbers
of rod neutrophils and lymphocytes. Among the lymphocytes there were lower
numbers of T cells and helper cells, but higher numbers of NK and B cells.
According to the authors, this lymphocyte pattern resembles the one seen in
immune-deficiency diseases. Tendencies to lower hemoglobin values and lower
numbers of erythrocytes were also observed. The floorlayers were exposed to a
number of solvents, including EGME (mean 6.1, maximum 150 mg/m3), EGEE,
EGBE, butanol, isobutanol, toluene, xylene, methyl ethyl ketone and methyl
isobutyl ketone. Solvent levels in blood indicated that EGME was the predominant
exposure (10).
Dose-effect/dose-response relationships
The addition of 10 m M MAA reduced mitosis in fetal liver cells in vitro (20).
According to a toxicokinetic model, this level is equivalent to 8 hours of inhalation
exposure to 1 ppm EGME (35).
Increased fetal death was observed in monkeys given EGME in oral doses of
12 mg/kg/day during gestation (31). At 25 mg/kg/day there were effects on testes
and sperm in rabbits (4, 16), and in rats prolonged gestation, smaller litters and
deformed pups. Doses of 50 mg/kg/day affect the thymus, suppress the immune
response, are toxic and teratogenic to fetuses of rodents and completely eliminate
spermatogenesis in rabbits. At doses around 100 mg/kg/day these effects are
considerably stronger, and bone marrow depression, disturbances in hematopoiesis
and reduced fertility are also seen. Inhalation exposure to 50 ppm has fetotoxic
effects on rodents, producing skeletal aberrations and deformities. It is noteworthy
that most of these effects are seen in all species and with all methods of administra-
tion, although the necessary exposure level varies. These variations can probably be
partly explained by differences in study design. It is therefore difficult to give a
single critical effect. Immunological effects of inhalation exposure have not been
studied with modern methods.
Relationships between occupational exposure and effects are given in Table 1.
Because the exposure situations are not fully known – particularly with regard to
skin exposure – it is difficult to draw quantitative conclusions on a dose-effect or
dose-response relationship from the existing data on human exposures.
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Table 1. Effects on human health associated with occupational exposure to EGME.
Level
 ppm
Exposure
situation
Number of
persons
Observed effects Ref.
mean 0.8
median 0.4
Shipyard painters; high
skin exposure,
including EGEE (mean
2.6 ppm)
73 men 10% had anemia and 5% had
granulocytopenia
(0% in controls).
Low sperm counts.
33, 34
mean 2
peak 48
Floorlayers; also
exposed to EGEE and
other solvents
9 men Higher numbers of rod neutrophils,
lymphocytes, NK and B cells.
Lower numbers of eosinophils,
segmented neutrophils, T cells and
helper cells. Tendencies to lower Hb
values and erythrocyte counts.
10
5 – 9 Production and
packaging of EGME
65 men Tendencies to lower white blood
cell counts, Hb values, testicle size,
sperm counts and testosterone and
FSH levels in serum. Tendency to
elevated serum level of leuteinizing
hormone (studied in different sub-
groups).
 7
about 8 Manual cleaning, skin
exposure
2 men Bone-marrow depression, pancyto-
penia
22
18 – 58 Production and
cleaning of microfilm
1 man Apathy, fatigue, increased need for
sleep, low counts of red and white
blood cells and platelets, low Hb
and hematocrit.
22
60 – 4000
(reconstruc-
tion)
Printshop cleaning;
large surfaces, skin
exposure
6 men Symptoms of poisoning, CNS
effects. Hypocellular bone marrow
(examined in only one of the men)
22
Effects on blood composition, immune system, testes and spermatogenesis have
been seen with occupational exposure to EGME at air levels of 0.4 to 10 ppm,
combined with unknown, but probably quite high, skin exposure. These
observations are in good agreement with the results of animal experiments, and
should be attributed to EGME even though other agents can not be unequivocally
ruled out.
Two case reports (5, 30) contain descriptions of 44 and 2 children with birth
defects born to mothers who were massively exposed to EGME during their
pregnancies, and where there seems to be no other explanation for the deformities.
Effects on the menstrual cycle, reduced fertility and higher frequencies of sponta-
neous abortions have been seen among women production workers in the semicon-
ductor industry. These observations are also in accordance with the effects of
EGME observed in laboratory animals, and ethylene glycol ethers are presented by
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the authors as the only plausible agents that could be identified. The importance of
EGME relative to that of other glycol ethers is unclear. To the extent that exposure
to EGME occurs, the air levels in this context should be below 1 ppm.
Conclusions
Judging from both animal data and experience of occupational exposures, the
critical effects of ethylene glycol methylether (EGME) are its toxic effects on
reproduction and blood formation.
EGME and its acetate ester EGMEA are efficiently absorbed via both inhalation
and skin exposure. Skin penetration can account for a large portion of the total
uptake if the skin is exposed to liquids or vapors containing EGME or EGMEA.
EGMEA is rapidly transformed to EGME in the body, and in animal experiments
the two substances are equally toxic. The health hazards of EGMEA should
therefore be regarded as equivalent to those of EGME.
Effects on blood composition, testes and spermatogenesis have been observed in
men occupationally exposed to EGME at air levels of 0.4 to 10 ppm, probably
combined with considerable skin exposure. Severe birth defects and disturbances in
hematopoiesis have been associated with occupational exposure to EGME and
EGMEA at unknown, but probably high levels. Daily oral doses of 12 mg/kg body
weight caused fetal death in monkeys, and 25 mg/kg/day reduced spermatogenesis
in rabbits.
Several studies report elevated incidences of miscarriage, menstrual irregularities
and low fertility among women in the semiconductor industry. The importance of
EGME in relation to other agents is not clear.
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Consensus Report for Thiourea
June 2, 1999
This report is an update of the Consensus Report published in 1988 (3).
Chemical and physical data
CAS No.: 62-56-6
Synonym: thiocarbamide
Formula: H2N-CS-NH2
Molecular weight: 76.12
Melting point: 176 – 178 ° C
Boiling point: disintegrates below boiling point
Density: 1.405 g/cm3 (20 ° C)
Solubility
     in water: 136 g/liter (20 ° C)
     in ethanol: 37 g/liter (20 ° C)
Volatility: does not evaporate from an aqueous solution (10)
Thiourea at room temperature is a white, crystalline powder. The compound occurs
in two tautomeric forms, i.e. the molecule has three different reactive groups:
amino, imino and sulfhydryl.
C S
H2N
H2N
C SH
H2N
HN
Occurrence and use
Thiourea is used as a catalyst in the production of fumaric acid, as an intermediate in
the production of chemicals such as the dioxide of thiourea (formamidine sulfinic
acid, FASA), thiouracil, thiobarbiturates and thiazol dyes, in metal refining, and as
an antioxidant in photosensitive paper (diazo paper). Some metal polishes contain
thiourea. Thiourea was once used medicinally as a treatment for hyperthyroidism
(10).
Thiourea has been found to occur naturally in laburnum (14).
World production of thiourea in 1994 was about 10,000 tons, and Germany,
Japan and China were the major producers (10).
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Air monitoring during the years 1988-1991 at German workplaces where thiourea
was used showed levels ranging from below the detection limit (not specified) to
0.32 mg/m3, with an average of 0.085 mg/m3 (10).
Uptake, distribution, excretion
Thiourea is taken up rapidly and completely from the digestive tracts of both
animals and man (84). A peak concentration in blood was measured in human
subjects 30 minutes after oral intake of 200 g thiourea, and at that point thiourea
could also be found in urine.
Studies of skin uptake (rabbits) showed that 4% was absorbed if the thiourea
(2.0 g/kg) was dissolved in water, whereas only 0.1% was absorbed if it was
applied to the skin in solid form (10). Thiourea dissolved in acetone was applied to
the lower arms of human subjects (4 m g/cm2; total exposed surface was 13 cm2 )
and they were instructed not to wash for 24 hours. Uptake was measured by
determination of excretion in urine within the following 5 days: less than 1% was
absorbed (20). In an in vivo study on hairless rats the flow of thiourea through the
stratum corneum was determined to be 3.5 nmol/cm2/hour (66). A Russian study
with rats reports systemic effects on the thyroid after single exposures to 500 mg
thiourea/kg body weight, applied to the back in the form of a 3% aqueous solution.
The amount of uptake was not determined (45).
Thiourea is rapidly spread throughout the body. A whole-body autoradiography
study with mice (14C-thiourea, i.v.) showed that radioactivity began to accumulate
in the thyroid after only 5 minutes, and remained higher in this tissue than in any
other organ during the entire 4-day observation period. Elevated concentrations
were also seen in the walls of the larger blood vessels, the adrenal cortex and
mammary tissue, as well as liver, lungs and kidneys. Thiourea passes the placental
barrier and also accumulates in the thyroid of the fetus (74). Red blood cells (25)
and lungs (33, 34) contain proteins with high affinity for thiourea. Thiourea also
seems to accumulate in melanomas in mice during the process of melanin synthesis
(52). In an older study with rats, about 2% of an injected (i.p.) dose of 35S-labeled
thiourea was deposited in the thyroid mostly in the form of sulfate (56%) and bound
to proteins (13%) (36).
In an experiment in which rats were given thiourea (100 mg/kg) by intraperitoneal
injection, the half time in plasma was calculated to be 3.3 hours (25).
Thiourea is excreted primarily via the kidneys: when rats were given 35S-labeled
thiourea (1 mg, i.p.), 98% of the radioactivity was excreted in urine within 48
hours. Most of it was unchanged, but 6% was in the form of inorganic sulfate and
another 6% in the form of ether sulfate (68). When rats were injected with 14C-
labeled thiourea (0.6 mg/kg, i.p.), 80 to 90% of the radioactivity was recovered in
urine within 24 hours (35). When 12 healthy volunteers were given 500 mg
thiourea intravenously, about a third of the dose was recovered in urine within 24
hours. Only a few percent were excreted during the following 24-hour period, and
none thereafter (84).
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Thiourea has been found in the urine of workers exposed to carbon disulfide
(58).
Biotransformation
As mentioned previously, most thiourea is excreted unchanged, but some metabolic
transformation may occur (see Figure 1). The microsomal flavin-containing mono-
oxygenase (FMO) catalyzes an NADPH and O2-dependent S-oxidation of thiourea
to formamidine sulfinic acid (FASA) with the corresponding sulfenic acid as an
intermediate product (60). This means that a more toxic product is formed (86, 88).
Thiourea can also undergo autooxidiation to FASA (88). The oxidation of thiourea
can also increase the formation of oxidized glutathione (GSSG) in the cells, since
reduced glutathione (GSH) can reduce the sulfenic acid back to thiourea (46).
Cyanamide and urea are other possible metabolites of thiourea (86). FMO occurs as
multiple iso–enzymes in mammals. Five different isoenzymes of FMO have been
identified in humans: FMO3 and FMO5 are expressed in the liver, and FMO1 in
kidneys. It is not clear which isoenzymes oxidize thiourea. FMO1 from rats (37)
and mice (38) has been shown in vitro to use thiourea as substrate. Inhibition
experiments have shown that thiourea is probably the substrate for FMO3 from both
mice and humans (18).
Thiourea functions as an antioxidant and has the ability to capture hydroxyl and
superoxide radicals as well as hydrogen peroxide (42) and peroxynitrite (83).
Experiments with yeast suggest that thiourea can also generate oxygen radicals (9).
Figure 1. Metabolism of thiourea
Toxic effects
Human data
Of 525 patients given thiourea in initial doses of up to 2 – 3 g/day as a treatment for
hyperthyroidism (antithyroid), 9% developed side effects in the form of fever,
digestive upsets etc. (78). A maintenance dose in treatment of hyperthyroidism was
25 – 70 mg/day, whereas 10 – 15 mg/day had no effect (cited in Reference 15).
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A pronounced drop in thrombocyte and granulocyte levels was seen in a woman
who was treated with a total of 83 g thiourea over a period of 5 weeks. The toxic
effect on bone marrow was reversible (54).
Indications of reduced thyroid function were observed in a Russian study of
workers employed in thiourea manufacture. The study covered 45 exposed workers
and 20 unexposed controls. Reported air concentrations of thiourea were in the
range 0.6 to 12 mg/m3. In the middle of the production hall the air concentration
was 3.9 –  1.0 mg/m3, and concentrations around loading and cleaning were higher
(9.0 –  0.9 mg/m3). The workers had been exposed for 9.5 –  1.1 years, 73% had
been exposed for at least 5 years, and 54.5% of them were over 40 years of age.
The concentrations of thyroid hormones T4 and T3 were significantly lower in the
exposed workers than in the controls (T4: 78.0 –  5.2 vs 109.4 –  2.0 nmol /l,
p < 0.05; T3: 1.2 –  0.1 vs 3.8 –  0.1 nmol/l, p < 0.001). Thyroid hyperplasia was
observed in 17 of the 45 exposed workers. Concentrations of T4 and T3 in this sub-
group were 80.6 –  1.8 and 0.9 –  0.1 nmol/l respectively (76).
An elevated prevalence of hypothyroidism was observed, especially among men,
in a study of workers in an English textile factory where thiourea (as well as
resorcinol, which can also inhibit thyroid function) was used. The study was
initiated because four cases of clinical hypothyroidism, three of which were men in
their 40s, had been diagnosed among the factory workers within a period of 6
years. In a follow-up survey of 189 men and 48 women (44% of the employees:
115 production workers and 122 from offices, management and laboratories)
12 new cases of hypothyroidism of varying degrees of severity were discovered
(classification according to Evered). Most of these cases were in the group
considered to be unexposed. The air concentration of thiourea in the production hall
was measured in the vicinity of the exhaust fans, and was reported to be about
5 m g/m3, i.e. extremely low. The resorcinol concentration was also low: 20 m g/m3.
The authors suggest the possibility of exposure to chemicals outside the production
facilities (63). The proportion of participants was low, the exposure situation was
unclear, and no dose-response relationship was seen.
There are number of case reports of contact allergies from contact with photocopy
paper containing thiourea (diazo paper), sometimes in combination with light
(photoallergy) (16, 24, 41, 55). One case of contact and photoallergy after exposure
to thiourea in silver polish has also been described (17). The number of reported
cases of contact allergy to thiourea is low, considering how much of it is used (29,
39).
Exposure to thiourea in silver polish was recently suggested as a possible cause
of a case of hepatitis (11).
Animal data
The LD50 for thiourea ranges from 125 to 10,000 mg/kg with oral exposure
(mouse, rat, rabbit), and from 4 to 1340 mg/kg with intraperitoneal administration
to various strains of rats (15). This indicates a wide variation in sensitivity between
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different species and strains. The LC50 for rats (4 hours of inhalation) is above
170 mg/m3 (10, 14).
Thiourea does not seem to be particularly irritating to eyes or skin (14).
Studies of lung damage have sometimes used chemicals including a thiourea
group. Rats given 1.25 mg/kg thiourea by intraperitoneal injection (the LD50 for
thiourea in this experiment was 3.55 mg/kg) developed pulmonary edema,
probably because of effects on the endothelium that increased its permeability (26).
Several studies of the mechanism behind this effect have shown that young rats are
less sensitive, and that tolerance develops if the animals are first treated with a lower
dose of thiourea (35). Toxicity to the lungs is correlated to the amount of thiourea
that forms covalent bonds to proteins in the alveolar walls (35, 69) and to the
histamine content of plasma (27, 28).
Repeated exposure to thiourea inhibits thyroid function in laboratory animals.
Secondary effects are enlargement of the pituitary and atrophy of ovaries, uterus
and prostate. Toxic effects on blood-forming organs have also been reported. Mice
seem to be less sensitive than rats (15).
Young female rats (21 – 30 days old) were exposed for 10 days to various
amounts of thiourea in drinking water (2 to 4 animals per dose). Inhibition of
thyroid activity was registered in the form of induced compensatory thyroid
hyperplasia. Animals exposed to 0.1% thiourea in drinking water (equivalent to
131 mg/kg body weight/day) developed greatly enlarged thyroids (hyperplasia).
Exposure to 1% in drinking water (1.17 g/kg/day) had the same effect on the
thyroid. A weak effect was observed at 21 mg/kg, and 12 mg/kg had no observed
effect (5).
In a study with Sprague-Dawley rats, thiourea was given in drinking water
(0.02 – 2.5 ppm) for 13 weeks. No clinical or histopathological effects were
observed (reviewed in Reference 10).
Long-term exposure (3 to 63 weeks) of 11-month old female mice (0.25 –
0.375% thiourea in feed) caused changes in the adrenals, pituitary, ovaries, uterus
and blood vessels, in addition to the effects on the thyroid (13).
Genotoxicity, mutagenicity
The results of a large number of experiments in which thiourea was tested for
genotoxic/mutagenic activity have recently been summarized in a German report (4).
The report concludes that thiourea is either not genotoxic or is only weakly so.
There are no data from bacterial test systems that clearly indicate genotoxicity (53,
85). Thiourea was not genotoxic in tests with Aspergillus nidulans (12). A weak
mutagenic effect was observed in V79 cells (87) and in a host-mediated test system
(72). Thiourea, without metabolic activation, was positive in a DNA repair test with
E. coli (31) and in an in vitro micronucleus test (22). A cell transformation test with
hamster embryo cells was considered negative, since a positive effect was seen only
at the lowest dose (59). The results of various tests for DNA damage and repair in
rat hepatocytes have been contradictory (1, 19, 47, 73, 87). Weak positive or
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positive results (inter- and intrachromosomal recombinations), sometimes at toxic
concentrations, have been observed in yeasts (23, 67). Formation of free radicals
seems to be involved in the recombination effect in yeast (9). Some in vivo studies
of genotoxicity with Drosophila have had positive results (8, 81) while others have
been negative (6, 7, 64). Thiourea was not clastogenic in an in vivo micronucleus
test with rats (study reviewed in Reference 4). Results of mouse lymphoma tests (in
vivo) have been inconsistent (48, 51, 82).
It is not clear just how thiourea exercises its genotoxicity, but metabolism to a
more reactive substance is probably necessary. Formamidine sulfinic acid, or FASA
(see Biotransformation) is a conceivable candidate. FASA has been shown to be
genotoxic in several in vitro tests (88). Chemical oxidation of 14C-labeled thiourea
with H2O2 in the presence of calf thymus DNA caused the formation of FASA,
cyanamide and urea, as well as covalent bonding of the radioactivity to DNA (88).
Carcinogenicity
Thiourea has been tested for carcinogenic activity in several older studies. The
results of these studies have been well summarized by the IARC (36) and the
German working group for MAK values (15). The IARC has placed thiourea in
Group 2B: “possibly carcinogenic to humans.” The EU has made a similar
assessment, and placed thiourea in Category 3 (“substances that may be carcino-
genic to humans”) in accordance with Directive 67/548/EEC. There are no reported
studies in which thiourea was tested according to present praxis for cancer tests on
animals (See Table 1).
Oral administration of thiourea to rats has caused tumors in the thyroid (61), liver
(21), ear canal (Zymbal’s gland), and eyelid (Meibom’s gland) (65). These different
tumor locations have usually been observed in different studies. In a 2-year study
with rats in which thiourea was mixed in feed (80 ppm), no increase of tumor
frequency was observed (62).
Thiourea’s ability to cause tumors in the thyroid is attributed to hormonal distur-
bances. Rats are regarded as a sensitive species in this respect. Thiourea inhibits the
enzyme thyroid peroxidase, causing a drop of thyroid hormones T3 and T4 in
serum. This in turn stimulates the hypothalamus and pituitary to produce more
thyroid-stimulating hormone (TSH). TSH stimulates thyroid growth, and
chronically elevated levels of TSH in serum can result in thyroid hyperplasia, which
may eventually develop into tumors (2, 30, 32).
A medium-term study, in which rats were exposed to 0.25% thiourea in drinking
water (which would be about 200 mg/kg/day) for up to 26 weeks, showed that
thiourea had a promotive effect on the formation of thyroid tumors in animals
previously initiated with a nitrosamine. The hormonal changes were greater in the
initiated animals than in those receiving thiourea alone (40). Elevated TSH levels
seem to be most important during the earliest stages of tumor development (57, 71).
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Table 1. Cancer studies with rats
Strain Number Exposure Location Response
(animals with tumors)
Ref.
Local albino
(R. norw.)
males, females,
Wistar males
3 x 10 0.25% in drinking
water, 5 to 24
months.
No controls
Thyroid < 12 months: 0/5
> 12 months:22/25
61
Albino 8 x 18 up to 2 years:
0
0.01% in diet
0.025%
0.05
0.1
0.25
0.5
1%
Liver Controls: 0/18 Surviving 2
years:14/29 (not dose-
dependent)
3/5
4/8
2/8
5/8
£ 0.25%: all animals died
within 17 months (1 liver
tumor)
21, 36
Albino
(Hebrew
university)
males
12 controls
16 (a)
19 (b)
(a) 4 ml 10%
solution i.p.
3 times/week,
6 months; thereafter
0.2% in drinking
water, up to 26
months (b) 0.2% in
drinking water, up to
26 months
Nasal
epithelium,
eyelid
(Meibom’s
gland), ear
Controls: 0/12
(a) 2-11 months: 0/4 died
>12 months:10/12
(b) 18/19
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Osborne-
Mendel, males
and females
4 x 30 24 months:
0 ppm
80 ppm in diet
Several
different
Males:3 malignant/30 (1
lung, 2 subcutaneous)
Females: 6 malignant (liver,
lung, intestine, mammary,
adrenal, lymph node
metastasis) + 6 benign
(mammary)/30
Males: 1 benign (testis +
subcutaneous)/30
Females:1 malignant (lung +
mammary) + 10 benign (9
mammary + 1 adrenal)/30
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In a similar promotion study (initiation with a nitrosamine, followed by 0.2%
thiourea in drinking water for 19 weeks) it was shown that simultaneous exposure
to massive amounts of vitamin A enhanced the effect of the thiourea on the levels of
T3, T4 and TSH in serum (49). A possible explanation for this may be induction of
glucuronyltransferase, an enzyme that collaborates in the metabolism of thyroid
hormone (32), which was observed in the livers of the animals treated with both
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thiourea and vitamin A. Thiourea (0.2%) in drinking water, either with or without
vitamin A, also increased the level of CYP2E1 in the liver (75).
Thiourea showed no initiating or promoting ability in a liver foci test with rats.
Instead, treatment with 0.05 – 0.2% thiourea in drinking water for 51 to 70 days
reduced both the number and the volume of foci (which lacked ATPase) in diethyl-
nitrosamine-initiated male and female Sprague-Dawley rats (56). In another study
with rats (F-344 males, initiation with another nitrosamine) thiourea (0.1% in
drinking water for 19 weeks) increased the number of GSTP-positive foci. This
treatment also resulted in nodules and neoplasias in thyroids. Thiourea and
phenobarbital were observed to have a slight synergistic effect on liver foci (70).
Thyroid tumors have not been observed in mice after exposure to thiourea. In one
study with mice in which thiourea was given orally (5 g/kg in diet), benign bone
tumors were observed in the skull. According to the authors, the bone tumors were
probably a side-effect of a direct toxic effect on the pituitary (50). In an older study
with C3H mice it was found that high doses of thiourea inhibited the occurrence of
spontaneous mammary tumors in surviving animals – probably because of
thiourea’s toxic effect on ovaries in this strain of mice and the consequent reduction
in estrogen production (79).
No significant elevation in risk of bladder cancer was found in an epidemiological
case-control study (relative risk 1.2; 95% confidence interval 0.4 – 3.3) in which
exposure to thiourea was estimated from job or business sector (80).
Teratogenicity
High doses of thiourea given orally to pregnant rats (1 or 2 g/kg, day 12) and mice
(1 g/kg, day 10) were fetotoxic, causing an increased number of resorbed
embryos. No weight reductions and no deformities were observed in surviving
fetuses (77).
When pregnant rats were exposed to thiourea (0.2% in drinking water) during the
third or the second and third week of gestation, there were effects on the thyroids of
the fetuses (day 20), the newborn pups and the mothers. The treatment had no
effect on the body weights of the mothers. Exposure during the entire period of
gestation was altogether too toxic for the fetuses. Increased thyroid weights and
reduced iodine content were also observed in the young when the females were
exposed to the same dose of thiourea during the nursing period. The effects on the
thyroid were reversible (44). In another study by the same research group, female
rats were given 0.2% thiourea in drinking water during the first 14 days of
gestation. The exposure caused deformities in the bones and nervous systems of the
young. General hemorrhaging was also observed (43).
Dose-effect/dose-response relationships
It was found in one study that occupational exposure to thiourea inhibited thyroid
function, measured as lower levels of the thyroid hormones T3 and T4. Measured air
concentrations in the factory were reported to be between 0.6 and 12 mg/m3.
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Thyroid hyperplasia was observed in 17 of 45 workers (76). If it is assumed that
the workers weighed 70 kg and inhaled 1 m3 per hour for 8 hours/day, and that
uptake was complete, this air concentration is equivalent to a dose of 0.07 to 1.4 mg
thiourea/kg body weight/day. Data from therapeutic use of thiourea indicate clearly
that a daily oral dose of 10 to 15 mg/day (about 0.1 - 0.2 mg/kg/day) has no effect
on the thyroid, and that doses of 25 to 70 mg/day (about 0.4 - 1.0 mg/kg/day) do
have an effect (15).
The Dutch expert group has reported a NOEL of 4 mg/kg (80 ppm in diet,
Osborne-Mendel rats) for the tumorigenic effect on rats with oral exposure (14, 62).
An LD50 of about the same size, 3.55 mg/kg, has been reported for Sprague-
Dawley rats after intraperitoneal injection of thiourea (26).
For rats, The NOEL for thiourea in drinking water (13-week study) was
determined to be > 2.5 ppm (10), equivalent to a dose of about > 0.25 mg/kg/day.
Conclusions
The critical effect of thiourea is inhibition of thyroid function, and this has been
reported with occupational exposure. Thiourea causes tumors in experimental
animals. In addition to thyroid tumors, which are probably caused by hormonal
disturbances to which the test animals are particularly sensitive, tumors in other
locations – notably liver, ear canal and eyelid – have been observed. Documentation
of this carcinogenic activity is weak, however. The results of tests for genotoxicity
are inconsistent. Skin contact with thiourea can cause contact allergy and
photoallergy. Thiourea can cross the placental barrier.
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Critical evaluation of those scientific data which are relevant as a background for
discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life between July, 1998 and June, 1999.
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Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XX. Arbete
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Sammanställningar baserade på kritisk genomgång och värdering av de
vetenskapliga fakta, vilka är relevanta som underlag för fastställande av hygieniskt
gränsvärde. Volymen omfattar de underlag som avgivits från Kriteriegruppen för
hygieniska gränsvärden under perioden juli 1998 - juni 1999.
Nyckelord: Cyanamid, Cyklohexanon, Dimetyladipat, Dimetylglutarat,
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APPENDIX
Consensus reports in this and previous volumes
Substance Consensus Volume in Arbete
date och Hälsa (No.)
Acetaldehyde February 17, 1987 1987:39 (VIII)
Acetamide December 11, 1991 1992:47 (XIII)
Acetic acid June15, 1988 1988:32 (IX)
Acetone October 20, 1987 1988:32 (IX)
Acetonitrile September 12, 1989 1991:8 (XI)
Acrylamide April 17, 1991 1992:6 (XII)
Acrylates December 9, 1984 1985:32 (VI)
Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983:36 (IV)
Aliphatic monoketons September 5, 1990 1992:6 (XII)
Allyl alcohol September 9, 1986 1987:39 (VIII)
Allylamine August 25, 1982 1983:36 (IV)
Allyl chloride June 6, 1989 1989:32 (X)
Aluminum April 21, 1982 1982:24 (III)
revised September 14, 1994 1995:19 (XVI)
p-Aminoazobenzene February 29, 1980 1981:21 (I)
Ammonia April 28, 1987 1987:39 (VIII)
Amylacetate March 23, 1983 1983:36 (IV)
Aniline October 26, 1988 1989:32 (X)
Anthraquinone November 26,1987 1988:32 (IX)
Arsenic, inorganic December 9, 1980 1982:9 (II)
revised February 15, 1984 1984:44 (V)
Arsine October 20, 1987 1988:32 (IX)
Asbestos October 21, 1981 1982:24 (III)
Barium June 16, 1987 1987:39 (VIII)
revised January 26, 1994 1994:30 (XV)
Benzene March 4, 1981 1982:9 (II)
revised February 24, 1988 1988:32 (IX)
Benzoyl peroxide February 13, 1985 1985:32 (VI)
Beryllium April 25, 1984 1984:44 (V)
Borax October 6, 1982 1983:36 (IV)
Boric acid October 6, 1982 1983:36 (IV)
Boron Nitride January 27 1993 1993:37 (XIV)
Butadiene October 23, 1985 1986:35 (VII)
1-Butanol June 17, 1981 1982:24 (III)
Butanols June 6, 1984 1984:44 (V)
Butyl acetate June 6, 1984 1984:44 (V)
Butyl acetates February 11, 1998 1998:25 (XIX)
Butylamine August 25, 1982 1983:36 (IV)
Butyl glycol October 6, 1982 1983:36 (IV)
Cadmium January 18, 1980 1981:21 (I)
revised February 15, 1984 1984:44 (V)
revised May 13, 1992 1992:47 (XIII)
Calcium hydroxide February 24, 1999 1999:26 (XX)
Calcium nitride January 27, 1993 1993:37 (XIV)
Calcium oxide February 24, 1999 1999:26 (XX)
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Caprolactam October 31, 1989 1991:8 (XI)
Carbon monoxide December 9, 1981 1982:24 (III)
Cathecol September 4, 1991 1992:47 (XIII)
Chlorine December 9, 1980 1982:9 (II)
Chlorine dioxide December 9, 1980 1982:9 (II)
o-Chlorobenzylidene malononitrile June 1, 1994 1994:30 (XV)
Chlorocresol December 12, 1990 1992:6 (XII)
Chlorodifluoromethane June 2, 1982 1982: 24 (III)
Chlorophenols September 4, 1985 1986:35 (VII)
Chloroprene April 16, 1986 1986:35 (VII)
Chromium December 14, 1979 1981:21 (I)
revised May 26, 1993 1993:37 (XIV)
Coal dust September 9, 1986 1987:39 (VIII)
Cobalt October 27, 1982 1983:36 (IV)
Copper October 21, 1981 1982:24 (III)
Cotton dust February14, 1986 1986:35 (VII)
Creosote October 26, 1988 1989:32 (X)
Cresols February 11, 1998 1998:25 (XIX)
Cumene June 2, 1982 1982:24 (III)
Cyanamid September 30, 1998 1999:26 (XX)
Cyanoacrylates March 5, 1997 1997:25 (XVIII)
Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
revised January 25, 1995 1995:19 (XVI)
Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
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Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate April 8, 1981 1982:9 (II)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate April 8, 1981 1982:9 (II)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
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Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formare December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
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Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
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Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 !989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
Sent for publication December 1999
